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Abstract
Due to the advancement of microarray technology over the last decade, it is feasible to
monitor the gene expression dynamics not only over a set of replicates but also either a
set of time points or doses of chemical substances. In such three dimensional datasets,
variations in the expression profiles can not only be observed across the time points or
doses of the chemical substances but also across the replicates due to either abnormalities
in the experimental protocol or the physiological variations. Thus, it is important to mine
such three dimensional datasets in order to extract biologically meaningful information.
In this work, I have proposed a novel triclustering algorithm δ-TRIMAX by introducing a
mean squared residue (MSR) score as a coherence measure of the resultant triclusters. The
application of this algorithm has been shown in the context of breast cancer progression
in order to reveal potential biological processes driving breast cancer invasion. Moreover,
I have proposed an improved version of δ-TRIMAX, the EMOA-δ-TRIMAX algorithm
which effectively deals with the pitfalls of the former one. One artificial dataset and three
real-life datasets have been used to compare the performance of the proposed algorithms
with that of other existing algorithms. Besides, the improved version has been applied to
one dataset monitoring expression profiles of genes during breast cancer progression for
unveiling regulatory mechanisms. Furthermore, the application of the EMOA-δ-TRIMAX
algorithm has been demonstrated in investigating the potential biological processes and
transcriptional regulatory mechanisms involved in the adolescence of cardiomyocytes. Ad-
ditionally, I have applied EMOA-δ-TRIMAX algorithm to four real-life datasets in order to
provide hints on the pathways perturbed by different toxicants in different tissues. Overall,
I could demonstrate that the results of the proposed algorithms for each of the real-life
datasets and the artificial ones are promising and provide new insights into the context of




1.1 Central Dogma of Molecular Biology
1.1.1 DNA
Figure 1.1 shows the central dogma of molecular biology.
Figure 1.1: The central dogma of molecular biology. Transcription is the processes of mak-
ing RNA from DNA, whereas RNA is translated into Protein.
Deoxyribonucleic acid (DNA) is a molecule which comprises two biopolymer strands
coiled around each other to shape a double helix and encodes the genetic instructions
required for the development of all living organisms. The information in DNA is stored
as sequence of four bases i.e. adenine(A), cytosine(C), guanine(G) and thymine(T). The
double helix of DNA basically comprises two strands which form the helical structure as
shown in Figure 1.2. Each of these two strands has two ends which are called 5’ and 3’
where the 5’ and 3’ carbon atoms of the deoxyribose are exhibited, respectively. In a DNA
double helix, each type of nucleobase located on one strand bonds with just another type of
nucleobase on another strand. For instance, adenine bonds with thymine in two hydrogen
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bonds, whereas cytosine bonds with guanine in three hydrogen bonds and the arrangement
of two nucleotides binding together is called a base pair.
Figure 1.2: The helical structure of DNA. The figure has been taken from [2].
1.1.2 RNA
Ribonucleic acid (RNA) is a large biological constituent which is found in all living organ-
isms and involved in regulation and expression of genes. RNA differs from DNA in terms
of base pairing, stability and propagation. For instance, instead of the bonds between
adenine and thymine in DNA, adenine bonds with uracil (U) in RNA. Because of the C-H
bonds, deoxyribose sugar in DNA is less reactive, whereas ribose sugar in RNA is more
reactive because of the hydroxyl group in the 2 position. Besides, DNA is known to be
self-replicating, whereas RNA is synthesized from DNA. Messenger RNA (mRNA) plays
instrumental roles to transfer genetic information from DNA to ribosome where the syn-
thesis of polypeptides encoded by mRNA occurs, whereas transfer RNA (tRNA) delivers
amino acids to the ribosomes and ribosomal RNA (rRNA) forms proteins by linking the
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amino acids together. Another type of RNA is a small non-coding RNA also called micro
RNA (miRNA). miRNA plays crucial roles in RNA silencing and the post transcriptional
regulation of gene expression.
1.1.3 Protein
Proteins are also polymeric molecules consisting of one or more amino acid chains. Pro-
teins are polymers built of 20 different amino acids. The linear sequence of amino acids are
referred as primary structure of the proteins. Alpha helix and beta pleated-sheets are the
most common types of secondary structure of proteins. The patterns of hydrogen bonds
located between the main-chain peptide groups delineate these secondary structures. More-
over, the three dimensional folding of a protein is referred as the tertiary protein structure,
whereas the association of two or more identical or different polypeptides forms the qua-
ternary protein structure. Proteins play essential roles in any biological process including
proper development of tissues and organs in the body, maintaining the metabolism of cells,
mediating the communication between cells, etc.
1.1.4 Transcription
Transcription is the process of producing RNA from DNA. Transcription is usually accom-
plished by the steps described as follows. First a number of proteins called transcription
factors (TFs) bind to specific DNA sequences. This facilitates the assembly of general
transcription factors around TATA box and transcription start site (TSS) and the recruit-
ment of RNA polymerase. Subsequently, RNA is produced from the transcribed region of
a gene. Other proteins such as coactivators, corepressors also assist TFs in the regulation
of a gene product either by enhancing or diminishing the rate of transcription, respectively.
The region around the TSS, the TATA box and comprising all the nearby TF binding sites
(TFBSs) constitute the promoter of a gene. Up to several mega bases away, either up-
stream or downstream, are additional control regions such as enhancers. They also consist
of arrays of TFBSs and influence the efficiency of the promoter.
During transcription of the synthesis of the RNA occurs in the direction of 5’ to the 3’ as
shown in Figure 1.3 [1] using the template strand of DNA for arranging the proper sequence
of ribonucleotides according to the principles of base pairing. The coding strand of DNA
is the complementary copy of the template strand and used to represent the sequence of a
gene.
7
Figure 1.3: Orientation of transcription. The figure has been taken from [1].
1.1.5 Translation
In case of protein-coding genes, the transcript is an mRNA molecule.
RNA Splicing
The process of modifying the pre-messenger RNA (pre-mRNA) transcript through the
deletion of introns and the joining of exons is referred as RNA splicing. This process is
essential for the mRNA prior to its translation into a protein.
Attaching to Ribosomes
First, RNA from the nucleus enters the ribosome and attaches to the ribosomes in order
to produce protein.
Polypeptide Synthesis
The process of producing long peptides or proteins is called protein biosynthesis.
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1.2 Microarray Technology
Microarray technology is used to monitor the changes in the expression profiles of mRNA
across a variety of experimental conditions. A microarray is a 2D array which consists of
a solid substrate and the probes are attached in fixed positions. Based on the ways how
probes are placed on the solid substrate, microarray can be of two different types.
1.2.1 cDNA Microarray
In case of a cDNA microarray (Figure 1.4), complementary DNA copies of mRNA tran-
scripts are used and labeled with fluorescent dyes of two different colors, namely red and
green. The red colored fluorescent dye is used to label the treated libraries, whereas the
green colored dye is used to label the control or untreated ones. Once the hybridization of
these two libraries is finished, the fluorescent dye is excited by a dual channel laser. The
fluorescent intensity is used to represent the degree of hybridization occurred. Then the
ratio of two fluorescent wavelengths is computed to measure the gene expression.
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Figure 1.4: The workflow of cDNA microarray to measure gene expression. The figure has
been taken from [3].
1.2.2 Oligonucleotide Microarray
These chips are manufactured by companies like Affymetrix, Illumina, Agilent etc. Fig-
ure 1.5 shows the workflow of an Affymetrix microarray experiment to monitor gene ex-
pression profiles. Oligonucleotide refers to the process of creating short sequences that
are complementary to parts of a gene. Thus a gene can be represented by one or several
probes. Here the oligonucleotides are synthesized by a photolithographic process. Once
the sample has been hybridized to a chip, an Affymetrix scanner is used to quantify the
fluorescence intensity at each spot. Evaluation of the readings is done by Affymetrix soft-
ware which usually produces several files of different extensions such as EXP, DAT, CEL,
CDF, CHP. An ”.EXP” file contains information about the experiment. ”.DAT” file stores
the raw image of the scanned array and pixel values of the image are read to compute the
intensities which are stored in the ”.CEL” file. The content of the ”.CHP” file is the gene
expression levels, estimated by the Affymetrix software. ”.CDF” file contains information
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needed for mapping between features, probe-sets, genes.
Figure 1.5: The workflow of an Affymetrix microarray experiment. The figure has been
taken from [4].
1.3 Computational Analysis of Microarray Gene Expression Data
1.3.1 Differential Expression Analysis
Differential expression analysis is performed in order to identify genes which are up- or
down-regulated between two experimental conditions such as untreated vs treated. Sta-
tistical methods such as ordinary t-test, Bayesian methods, rank-sum statistics, moderate
t-test (used in linear models for microarray (limma) package available in R) are used to
extract the groups of differentially expressed genes [5]. The ordinary t-test is able to con-
sider only one gene or probe to test the differential expression, whereas limma can take
all genes/ probes into consideration at each condition at a time. In case of each gene
expression profile, limma fits a linear model, coefficients of which represent the differences
between the sources of RNA hybridized to the arrays.
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1.3.2 Machine Learning in Mining Microarray Gene Expression Data
In machine learning, the main task of supervised learning technique is to train a classifier
using a set of training examples categories of which is known for inferring a function which
can later be used to classify new examples properly. To evaluate the accuracy of the
classifier K-fold cross validation is usually performed where the examples are divided into
K subsets and during each iteration one subset is used as test, whereas (K-1) subsets of
examples are used as training set [6]. One of the application of supervised learning in the
field of bioinformatics is to assign genes into proper classes for instance, different tumor
stages.
In contrast with the supervised learning technique, unsupervised learning refers to finding
the proper categories of examples without having any prior knowledge about the categories
of any one of the examples [6]. One of the applications of unsupervised learning in mining
the microarray gene expression data is to find the associations between a set of genes which
in turns may provide insights into the biological processes in which the groups of associated
genes play major roles. In other words, unsupervised learning may facilitate to identify
groups of co-expressed genes.
Role of Co-expression Analysis in the Field of Biology
Developmental Biology
Elucidating the biological processes that play crucial roles in the development of organs
or tissues for instance, differentiation of a stem cell into cardiomyocytes, is the purpose
of studying developmental biology. Disruption of these biological processes may lead to
the developmental disorders which in turn cause disease like cardiac disorders etc. Either
a single gene or a set of genes interacting with each other can act as driver genes which
participate in the developmental processes. Moreover, revealing the genes that drive phe-
notypic changes during the development may also provide hints on potential therapeutic
targets. Co-expression analysis thus may play major roles in unraveling the interactions
between such driver genes in the context of a particular experimental study of interest [7–9].
Disease Biology
Co-expression analysis may also be beneficial in unraveling the interaction between key
genes which mediate the potential biological processes that trigger the progression of dis-
eases such as breast cancer etc. [10–12]. Any disease may be considered as a specific cellular
state, alternative to the normal state of a cell (or a whole organ). Thus, having the full
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gene activity profiles of a normal and a disease state available may enable us to characterize
these states, identify the transition between them and to give hints on how to interfere with
the transition and to prevent the development of a disease. These characterizations can be
done by simply comparing gene activity lists or, more sophisticated, by constructing and
analyzing the underlying regulatory networks.
Inference of Gene Regulatory Network
A gene regulatory network can be viewed as a mixed graph G={V , U , D}, where V
denotes a set of vertices each of which represents a gene, whereas U and D represent sets of
undirected and directed edges, respectively. An undirected edge may refer to the association
between genes in terms of their expression similarity. Each directed edge may refer to
the causal relationship between two nodes which is a regulatory relationship between a
transcription factor and a target gene [13]. Co-expression analysis facilitates in deducing
the undirected edges, whereas the transcription factor binding site (TFBS) information
may help us in inferring the directed edges in gene regulatory network. Thus integrating
both TFBS and microarray gene expression data may assist in inferring the gene regulatory
network where the co-expressed genes are co-regulated by a set of transcription factor as
shown in Figure 1.6.
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Figure 1.6: Co-regulation of co-expressed genes by a set of transcription factors. The figure
has been taken from [14].
1.3.3 Co-expression and Cluster Analysis
To carry out this exploratory analysis, several clustering algorithms have been proposed
to identify the groups of genes that have similar expression profiles over all experimental
conditions or replicates based on some similarity or dissimilarity metrics. Bayesian Net-
work (BN) and Dynamic Bayesian Network (DBN) are also used to perform this kind of
exploratory analysis on microarray gene expression data [6]. By estimating the conditional
dependencies among the genes, it can provide insightful knowledge about the gene inter-
action networks. In spite of having their own merit in mining 2D gene expression data,
the clustering algorithms are not capable of grouping genes and experimental conditions/
replicates simultaneously. To cope with the problem, biclustering algorithms are used.
Several biclustering algorithms have been propounded over the last decade. The advances
in microarray technology over the past decade facilitate to monitor the expression pro-
files of thousands of genes not only over a set of replicates but also across a set of time
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points or substances. These replicates may either be technical or biological. For instance,
if the expression profiles of thousands of genes are measured from one source for a certain
number of times, then the replicates are said to be technical, whereas if the expression
profiles of thousands of genes are measured from different sources such as, patients etc.
then the replicates are treated as biological ones. It is quite obvious that the variations
in the expression profiles of genes over different biological replicates are present in such
3D gene expression data. However, the expression profiles of genes may also vary over the
technical replicates in such datasets. Hence, it is required to mine all these three dimen-
sions in order to extract potential biologically meaningful information from such datasets.
To accomplish this goal, triclustering algorithms are used. A triclustering algorithm is
capable of grouping genes, replicates and time points/ substances simultaneously. Zhao et
al. proposed the TRICLUSTER algorithm to retrieve groups of genes that have similar
expression profiles over a subset of replicates and across a subset of time points [15]. In a
recent work, Tchagang et al. proposed a triclustering algorithm (OPTricluster) in order to
mine short time series gene expression datasets. OPTricluster effectively mines time series
gene expression data that have approximately 3-8 time points and 2-5 replicates. Accord-
ing to their definition of a tricluster, genes belonging to a tricluster must have constant,
coherent or order preserving expression patterns over a subset of replicates during a subset
of time points. In case of an order-preserving tricluster, there must be a permutation of the
time points such that expression levels of genes form a monotonic function [16]. However,
the OPTricluster algorithm is not computationally efficient to mine the long time series
gene expression datasets. Furthermore, as the OPTricluster algorithm yields triclusters
each of which always comprises all the time points, this algorithms is not applicable to
the datasets which provide the expression profiles of genes measured during the exposure
of a cell to the different doses of chemical substances. During my PhD studies, we have
proposed a triclustering algorithm δ-TRIMAX and an improved version of δ-TRIMAX
namely, EMOA-δ-TRIMAX (Evolutionary Multiobjective Optimization Algorithm for δ-
TRIMAX) and both of these two algorithms use a novel coherence measure namely, mean
squared residue (MSR) in order to mine three dimensional gene expression dataset.
1.4 Structure of the Thesis
The thesis has been structured in the following way.
Chapter 2 provides the mathematical background, definition of the mean squared residue
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(MSR) and the steps of δ-TRIMAX triclustering algorithm. Moreover, it provides an ap-
plication of the δ-TRIMAX algorithm in elucidating the biological processes involved in
the progression of breast cancer.
In Chapter 3, we describe the pitfalls of δ-TRIMAX algorithm and provided the details of
its improved version, the EMOA-δ-TRIMAX algorithm. Furthermore, this chapter shows
an application of EMOA-δ-TRIMAX algorithm in investigating the biological processes
and the corresponding key genes involved in the phenotypic divergence during stem cell
differentiation into cardiomyocytes.
Being motivated by the biological processes of development obtained in the previous chap-
ter, in Chapter 4, we have applied the EMOA-δ-TRIMAX algorithm to the same dataset
in order to investigate the transcriptional regulatory mechanisms during the adolescence
of cardiomyocytes.
Being inspired by the promising results in the context of revealing transcriptional regula-
tory mechanisms, in Chapter 5, we have used EMOA-δ-TRIMAX in order to unveil the
transcriptional regulatory mechanisms governing the progression of a breast cancer cell
exposed to estrogen.
To show the capability of EMOA-δ-TRIMAX algorithm in mining other types gene expres-
sion dataset, Chapter 6 emphasizes an application of EMOA-δ-TRIMAX in the context
of toxicology i.e. we have applied the algorithm to four different datasets which comprise
expression profiles of genes measured during the exposure of different tissues to different
doses of chemical substances in order to reveal the lists of perturbed signaling pathways.
Chapter 7 emphasizes the importance of clustering replicates in three dimensional gene
expression datasets.
Finally, Chapter 8 summarizes the conclusions of the individual applications.
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2 A New Triclustering Approach for
Unveiling Biological Processes of Disease
Progression from Gene Expression Profiles
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2.1 Introduction
Estrogen a chemical messenger, plays an instrumental role in the development of many
tissues such as breast, uterus etc. through binding to the estrogen receptor. In the context
of breast cancer originates in the breast tissue, the abnormal cells grow and divide i.e.
cell proliferation is observed. Estrogen enhances the risk of breast cancer by triggering
cellular proliferation. Moreover, cellular proliferation is also controlled by nutrients. Thus
oncogenes which play crucial roles in promoting cellular proliferation may also be involved
in metabolic alteration. Hence, understanding the metabolic and signaling pathways nay
facilitate the development of novel therapeutic strategies for the breast cancer treatment.
In this chapter, we have applied our proposed triclustering algorithm to a dataset in which
the expression profiles of genes were measured during different stages of estrogen’s effects on
a MCF-7 breast cancer cell. Our results not only provide novel insights into the metabolic
pathways most of which are already known to be associated with breast cancer but also
elucidate the regulatory roles of several transcription factors in estrogen induced breast
cancer cell.
2.2 Materials and Methods
2.2.1 Materials
Artificial dataset: We have used one simulated dataset of size 2000 × 30 × 30. At first
we have inserted three perfect shifting triclusters of size 100 × 6 × 6, 80 × 6 × 6 and 60 ×
5 × 5 into the simulated dataset and then implanted three noisy shifting triclusters having
the same size and different levels of noise i.e. standard deviations (σ = 0.1, 0.3, 0.5, 0.7,
0.9, 1.1, 1.3, 1.5, 1.7) into the dataset [1, 2].
Real-life dataset: This publicly available gene expression data (dataset id- GSE 11324)
contains 54675 affymetrix probe-set ids, 3 biological replicates and 4 time points. In this
experiment, MCF7 cells were stimulated with 100 nm estrogen during 0, 3, 6 and 12 hours
and the expression values are measured in triplicate. The experiment aims at discovering
the cis-regulatory sites in previously uninvestigated regions and cooperating transcription




Definition 1 (Time Series Microarray Gene Expression Dataset) A time series gene
expression data can be considered as a G × C × T matrix, each element of which (dijk)
represents the expression value of the gene i over the jth sample/experimental condition
across the time point k and i ∈ (g1,g2,...,gG), j ∈ (c1,c2,...,cC), k ∈ (t1,t2,...,tT ) [1, 2].
Definition 2 (Tricluster) A tricluster can be delineated as a sub-matrix M(I,J,K) =
[mijk], where i ∈ I, j ∈ J and k ∈ K. The sub-matrix M corresponds to a subset of genes
(I) that are co-expressed over a subset of conditions (J) across a subset of time points
(K) [1, 2].
Definition 3 (Perfect Shifting Tricluster) A Tricluster M(I,J,K) = [mijk], where i ∈
I, j ∈ J and k ∈ K, is a perfect shifting tricluster if each element of the sub-matrix M
can be formulated as: mijk = Γ + αi + βj + ηk, where Γ corresponds to a constant
value for the tricluster, αi, βj and ηk represent shifting factors of the ith gene, the jth
samples/experimental condition and the kth time point, respectively [1, 2].
But in case of a noisy microarray gene expression dataset, the deviation from actual value
and expected value of each element is usually observed. This deviation may prevent re-
trieving a perfect shifting tricluster from a gene expression dataset.
In this work, we present a novel definition of Mean Squared Residue (MSR) score for 3D
microarray gene expression datasets. The MSR score we defined here, is a generalization
of the one proposed by Cheng and Church [4, 5]. The MSR of a perfect shifting tricluster
becomes zero, where each element, mijk = Γ + αi + βj + ηk. To delineate the MSR score
for 3D gene expression datasets, at first we need to define the residue score as follows:
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i∈I,j∈J,k∈K mijk. Now the mean of the tricluster can
be considered as the value of constant i.e. Γ = mIJK . We can define the shifting factor for
the ith gene (αi) as the difference between miJK and mIJK i.e. αi = miJK −mIJK [1, 2].
Similarly, we can define shifting factor for the jth condition (βj) as βj = mIjK−mIJK and
shifting factor for the kth time point (ηk) can be defined as ηk = mIJk −mIJK . Hence,
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we can define each element of a perfect shifting tricluster as mijk = Γ + αi + βj + ηk =
mIJK+(miJK−mIJK)+(mIjK−mIJK)+(mIJk−mIJK) = (miJK+mIjK+mIJk−2mIJK).
As noise is discernible in microarray gene expression dataset, we need to compute the
difference between the actual value of an element (mijk) and its expected value, obtained
from the above equation. This deviation can be termed as “residue” [5]. Thus, the residue
of a tricluster (rijk) can be formulated as follows: rijk = mijk − (miJK + mIjK + mIJk −
2mIJK) = (mijk −miJK −mIjK −mIJk + 2mIJK).
Definition 4 (Mean Squared Residue) We delineate the Mean Squared Residue MSR(I,J,K)
of a tricluster M(I,J,K) to measure the quality of a tricluster i.e. the level of coherence












(mijk −miJK −mIjK −mIJk + 2mIJK)2 (2.1)
Lower residue score represents larger coherence and better quality of a tricluster.
Theoretical Background of the Proposed Mean Squared Residue Score
Table 2.1 shows the numbers of transactions in each month. Now, no straight line will pass
exactly through the four blue colored points shown in Figure 2.1. However, there are many
straight lines that will pass close to the four blue colored points. For instance one of them
is represented by the red colored line and the values are P = {62, 70, 78, 86}. In a linear
regression model, we could consider the set P as predicted values. So the better choice of
line would be the one which is closer to the observed values (minimize the value of r).
As real-life gene expression datasets are noisy, it is hard to find the perfect additive tri-
cluster. So we defined a novel MSR score that aims to minimize the deviation between
observed value (noisy) and the computed value (perfect additive tricluster). Note that
MSR does not use any distance measure directly. It only computes the deviation of a
detected tricluster from a ideal tricluster and we try to minimize this deviation.
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(r = O−P )
January 68 62 6
February 72 70 2
March 80 78 2
April 83 86 -3
Figure 2.1: Number of transactions in each month. Blue colored points and red colored line
represent the observed and predicted numbers of transactions, respectively.
Proposed Method
δ-TRIMAX aims at finding the largest and maximal triclusters in a 3D microarray gene
expression dataset [1, 2]. It is a generalization of the biclustering algorithm proposed by
Cheng and Church [4] that copes with 2-D microarray datasets. In contrast, our algorithm
is capable to mine 3D gene expression dataset. There is always a sub-matrix in an ex-
pression dataset that has a perfect MSR(I,J,K) = 0 and this sub-matrix is each element of
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the dataset [1,2]. But as mentioned above, our algorithm finds maximal triclusters having
MSR score under a threshold δ, hence we have used a greedy heuristic approach to find
triclusters. Our algorithm therefore starts with the entire dataset containing all genes, all
samples/experimental conditions and all time points.
Algorithm I (δ-TRIMAX):
Input. D, a matrix that represents 3D microarray gene expression dataset, λ > 1, an
input parameter for multiple node deletion algorithm, δ ≥ 0, maximum allowable MSR
score.
Output. All possible δ-triclusters.
Initialization. Missing elements in D ← random numbers, D’ ← D
Repeat a. D’1 ← Results of Algorithm II on D’ using delta and λ. If the no. of genes
(conditions/samples and/or no. of time points) is 50 (This value can be choosen exper-
imentally. Large value increases the execution time of the algorithm as it then executes
more number of iterations.), then do not apply Algorithm II on genes (conditions/samples
and/or time points).
b. D’2 ← Results of Algorithm III on D’1 using δ.
c. D’3 ← Results of Algorithm IV on D’2.
d. Return D’3 and replace the elements that exist in D’ and D’3 with random numbers.
Until(No gene is found for δ-tricluster)
Initially, our algorithm removes genes or conditions or time points from the dataset to
effectuate largest diminishing of the MSR score; this step is described in the following
section in which a node represents a gene or an experimental condition or a time point in
the 3D microarray gene expression dataset.
Algorithm II (Multiple node deletion):
Input. D, a matrix of real numbers that represents 3D microarray gene expression dataset;
δ ≥ 0, maximum allowable MSR threshold, λ > 1, threshold for multiple node deletion.
The value of λ has been set experimentally to optimize the speed and performance (to
avoid falling into local optimum) of the algorithm.
Output. MIJK , a δ-tricluster, consisting of a subset(I) of genes, a subset(J) of samples/
experimental conditions and a subset of time points, having MSR score less than or equal
to δ.
Initialization. I ← {set of all genes}, J ← {set of all experimental conditions/ samples}
and K ← {set of all time points} and to M(I,J,K) ← D
Repeat Calculate miJK , ∀ i ∈ I; mIjK , ∀ j ∈ J; mIJk, ∀ k ∈ K; mIJK and MSR.
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If MSR ≤ δ return M(I,J,K)
Else Delete genes i ∈ I that satisfy the following inequality
1
|J ||K|
Σj∈J,k∈K(mijk −miJK −mIjK −mIJk + 2mIJK)2>λMSR
Recalculate miJK , ∀ i ∈ I; mIjK , ∀ j ∈ J; mIJk, ∀ k ∈ K; mIJK and MSR Delete sam-
ples/experimental conditions j ∈ J that satisfy the following inequality
1
|I||K|
Σi∈I,k∈K(mijk −miJK −mIjK −mIJk + 2mIJK)2>λMSR
Recalculate miJK , ∀ i ∈ I; mIjK , ∀ j ∈ J; mIJk, ∀ k ∈ K; mIJK and MSR Delete time
points k ∈ K that satisfy the following inequality
1
|I||J |
Σi∈I,j∈J(mijk −miJK −mIjK −mIJk + 2mIJK)2>λMSR
End if
Until(There is no change in I, J and/or K)
In the second step, we delete one node at each iteration from the resultant sub-matrix,
produced by Algorithm II, until the score MSR of the resultant sub-matrix is less than or
equal to δ. This step yields a δ-tricluster.
Algorithm III (Single node deletion):
Input. D, a matrix of real numbers that represents 3D microarray gene expression dataset;
δ ≥ 0, maximum allowable MSR threshold.
Output. MIJK , a δ-tricluster, consisting of a subset(I) of genes, a subset(J) of sam-
ples/experimental conditions and a subset of time points, having MSR score less than or
equal to δ.
Initialization. I ← {set of all genes in D}, J ← {set of experimental conditions/samples
in D} and K ← {set of time points in D} and to M(I,J,K) ← D
Calculate miJK , ∀ i ∈ I; mIjK , ∀ j ∈ J; mIJk, ∀ k ∈ K; mIJK and MSR.




Σj∈J,k∈K(mijk −miJK −mIjK −mIJk + 2mIJK)2
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Σi∈I,k∈K(mijk −miJK −mIjK −mIJk + 2mIJK)2




Σi∈I,j∈J(mijk −miJK −mIjK −mIJk + 2mIJK)2
Delete gene or sample/experimental condition or time point that has highest µ score and




As the goal of our algorithm is to find the maximal triclusters, having MSR score below
the threshold δ, the resultant tricluster M(I,J,K) may not be the largest one. That means
some genes and/or experimental conditions/samples and/or time points may be included
in the resultant tricluster T produced by the node deletion algorithm, so that the MSR
score of new tricluster T ′ produced after node addition does not exceed the MSR score of
T .
Now the third step of our algorithm is described below.
Algorithm IV (Node addition):
Input. D, a matrix of real numbers that represents δ-tricluster, having a subset of genes
(I), a subset of experimental conditions/samples (J) and a subset of time points (K).
Output. MI′J ′K′ , a δ-tricluster, consisting of a subset of genes (I’) , a subset of sam-
ples/experimental conditions (J’) and a subset of time points (K’), such that I ⊂ I’, J ⊂
J’, K ⊂ K’ and MSR(I’,J’,K’) ≤ MSR of D.
Initialization. M(I,J,K) ← D
Repeat Calculate miJK , ∀ i; mIjK , ∀ j; mIJk, ∀ k; mIJK and MSR. Add genes i 6∈ I that
satisfy the following inequality
1
|J ||K|
Σj∈J,k∈K(mijk −miJK −mIjK −mIJk + 2mIJK)2 ≤MSR
Recalculate mIjK , ∀ j; mIJk, ∀; mIJK and MSR Add samples/experimental conditions j 6∈
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J that satisfy the following inequality
1
|I||K|
Σi∈I,k∈K(mijk −miJK −mIjK −mIJk + 2mIJK)2 ≤MSR




Σi∈I,j∈J(mijk −miJK −mIjK −mIJk + 2mIJK)2 ≤MSR
Add genes i 6∈ I that satisfy the following inequality
1
|J ||K|
Σj∈J,k∈K(−mijk + miJK − mIjK − mIJk + 2mIJK)2 ≤ MSR
Until(There is no change in I, J and/or K)
I’ ← I, J’← J, K’ ← K
Return I’, J’, K’
Complexity of the Proposed Algorithm
The complexity of Algorithm II is O(max(m,n,p)), where m, n and p correspond to the
number of genes, samples and time points in the 3D microarray dataset. The complexity
of first and second steps of Algorithm III is O(mnp) as those will iterate (m+n+p) times.
The complexity of selection of best genes, samples and time points is O(log m + log n +
log p). So it is recommended to use the Algorithm II before Algorithm III. The complexity
of Algorithm IV is O(mnp) as each step iterates (m+n+p) times [1, 2].
Tricluster Eigen-gene
We applied singular value decomposition method (SVD) on the expression data of each
tricluster to find the tricluster eigen-gene [6]. For instance, Xig×(c∗t) corresponds to the
expression matrix of ith tricluster, where g, c and t represent the number of genes, samples
and time points of ith tricluster. Now we apply SVD on the data matrix (normalized to
mean=0 and variance=1) and the SVD of ith tricluster can be computed as,
Xi = UDV T , (2.2)
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where U and V are the orthogonal matrices. U i is a g ∗ (c ∗ t) matrix with orthonormal
columns, V i is a (c ∗ t) × (c ∗ t) orthogonal matrix and Di is (c ∗ t) × (c ∗ t) diagonal
matrix of singular values.
Assuming that singular values of matrix Di are arranged in non-decreasing order, we
can represent eigen-gene of the ith tricluster by the first column of matrix V i, i.e.
Ei = V i1 , (2.3)
2.3 Results and Discussion
2.3.1 Results on Simulated Dataset
To measure the degree of similarity between the implanted and produced triclusters, we
delineate the affirmation score in the same way as Prelic et. al. defined for two sets
of biclusters [5, 7]. Suppose, we have two sets of triclusters Tim and Tres where Tim is
the set of implanted triclusters and Tres corresponds to the set of triclusters retrieved by
any triclustering algorithm. So, overall average affirmation score of Tim with respect to
Tres is as follows [1, 2], where (SM
∗
G(Tim, Tres)) is the average gene affirmation score,
(SM∗C(Tim, Tres)) is the average sample affirmation score and (SM
∗
K(Tim, Tres)) is the
average time point affirmation score of Tim with respect to Tres:
SM∗(Tim, Tres) =
√
(SM∗G(Tim, Tres)× SM∗C(Tim, Tres)× SM∗T (Tim, Tres)) (2.4)
Hence, SM∗(Tim, Tres) denotes how well the triclustering algorithm finds the implanted
triclusters from the dataset. This score ranges from 0 to 1 (if Tim = Tres). To compute the
value of δ, we have first clustered the genes over all time points and then the time points
over the subset of genes for each gene cluster in each sample plane using the K-means
algorithm. Then we have measured the MSR of the sub-matrix, considering a randomly
selected sample plane, gene and time-point cluster for 100 times. Then we have taken the
lowest value as the value of δ [1, 2]. For the dataset containing perfect shifting triclusters,
the parameters δ and λ are set to 0.35 and 1.0005, respectively whereas in case of the noisy
datasets, we have assigned 3.75 and 1.004 to the parameters δ and λ, respectively [1, 2].
Figure 2.2 shows the comparison between the performance of our algorithm with that of
the TRICLUSTER algorithm [8] in terms of affirmation score using the artificial dataset.
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Our δ-TRIMAX algorithm outperforms TRICLUSTER algorithm for the noisy dataset
used in this chapter.
Figure 2.2: Comparison in terms of Affirmation Scores. a. Comparison of Affirmation
scores produced by δ-TRIMAX and TRICLUSTER algorithm. b. Comparison
of running time of δ-TRIMAX and TRICLUSTER algorithm on the synthetic
dataset. The figure has been taken from [1,2].
2.3.2 Results on Real-life Dataset
We assigned 0.012382 and 1.2 to the parameters δ and λ, respectively [1, 2] and our algo-
rithm yields 115 triclusters. To collate the performance of our proposed algorithm with
TRICLUSER algorithm on the real-life dataset, we have used three validation indexes.
Coverage
Coverage for any triclustering algorithm can be delineated as
Coverage = (
galg × calg × talg
G× C × T
)× 100, (2.5)
where galg, calg and talg represent the total number of genes, experimental samples and
time points retrieved by the triclustering algorithm. G, C and T denote the number of all
genes, experimental samples and time points in the dataset.
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Triclustering Diffusion (TD) Score





where MSRi and V olumei correspond to the mean-squared residue and volume of the ith
tricluster. Lower TD score represents better quality of tricluster.
Statistical Difference from Background (SDB)
Here we have introduced another quality measurement, called as Statistical Differences












where n is the total number of triclusters extracted by the algorithm. MSRi represents
mean squared residue of ith tricluster retrieved by the algorithm and RMSRj represents
mean squared residue of jth random tricluster having the same number of genes, experi-
mental samples and time points as that of ith resultant tricluster. Here a lower value of the
denominator denotes better quality of the resultant tricluster. Hence, a higher SDB score
signifies better performance of the algorithm. Table 2.2 shows the comparison between
proposed δ-TRIMAX algorithm and TRICLUSTER algorithm in terms of coverage, SDB
and TQI score.
Table 2.2: Comparison between δ-TRIMAX and TRICLUSTER algorithm using coverage,
Statistical Difference of from Background (SDB) and Triclustering Quality Index
(TQI). The contents of this table have been taken from [2].
Algorithm Coverage SDB Average
TD
δ-TRIMAX 93.7412 2.140935 3.082684e-
05




To establish the biological significance of genes belonging to each resultant tricluster, we
have carried out the following: (a) Gene Ontology (GO) and KEGG pathway enrichment
analysis, (b) identifying key genes of each tricluster and the corresponding enriched KEGG
pathway terms and (c) Transcription Factor Binding Site (TFBS) enrichment analysis.
GO and KEGG Pathway Enrichment Analysis
GOStats package [10] in R has been used to perform GO and KEGG pathway enrich-
ment analysis for establishing biological significance of genes belonging to each tricluster.
Adjustment of the p-values has been done using FDR method proposed by Benjamini-
Hochberg [11]. The terms having a p-value below a threshold of 0.05 are considered as
significant ones. We have found statistically enriched GO terms for genes belonging to
each tricluster. Moreover, we have collated the performance of our proposed δ-TRIMAX
algorithm with that of TRICLUSTER algorithm on the real-life dataset used in this chap-
ter. To compare the performances, we have considered GO Biological Processes (GOBP)
and KEGG pathway terms that have already been reported to play an important role in
estrogen induced breast cancer cell. Table 2.3 shows the comparison between δ-TRIMAX
and TRICLUSTER algorithm in terms corrected p-values of GOBP and KEGG pathway
terms cell adhesion and Wnt signaling pathway that have already been inferred to play a
crucial role in estrogen induced breast cancer [12,13], respectively.
Table 2.3: Comparison between δ-TRIMAX and TRICLUSTER algorithm in terms of p-
values of GOBP and KEGG pathway term enrichment analysis. The contents
of this table have been taken from [1,2].
Algorithm GOBP term KEGG pathway terms








Identifying Key Genes and Their Corresponding Pathways During Early, Middle and
Late Stages of Estrogen Treatment
The Pearson correlation coefficients between the expression profiles of genes over the clus-
tered time points, samples and the tricluster eigen gene vector have been computed to
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identify the key genes of each of the resultant triclusters. The genes having the Pearson
correlation coefficient closed to 1 or -1 can be considered as tricluster key genes. We have
considered the gene symbols of the 10 topmost probe-ids as key genes of each tricluster.
From Figure 2.3, we can see that the identified tricluster key genes are highly correlated
with the corresponding eigene-gene vector. Moreover, we have performed KEGG pathway
enrichment analysis on the sets of identified key genes to reveal the potential pathways
during different stages of estrogen treatment. Through our analysis we have found sev-
eral pathways such as Huntington’s disease, lysosome, oxidative phosphorylation, phago-
some, MAPK signaling pathway, endometrial cancer, non-small cell lung cancer, ether lipid
metabolism, adherens junction, natural killer cell mediated cytotoxicity, chemokine signal-
ing pathway, adipocytokine signaling pathway, steroid hormone biosynthesis, Hepatitis C,
chronic myeloid leukemia, toll-like receptor signaling pathway, toxoplasmosis, Jak-STAT
signaling pathway, rheumatoid arthritis, leukocyte transendothelial migration, cell adhe-
sion molecules (CAMs), glioma, arginine and proline metabolism, N-Glycan biosynthesis,
mTOR signaling pathway, tight junction, osteoclast differentiation, leishmaniasis, ErbB
signaling pathway, GnRH signaling pathway, circadian rhythm, viral myocarditis, arrhyth-
mogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM),
dilated cardiomyopathy, mucin type O-Glycan biosynthesis, D-glutamine and D-glutamate
metabolism, etc. that are already known to be used for breast cancer therapeutics [14–68].
Figures 2.4-2.5 show all the pathways found to be enriched for the triclusters key genes.
Though it is astonishing to us to find the cardiac disorders related pathways such as dilated
cardiomyopathy, hypertrophic cardiomyopathy etc. as the enriched ones for tricluster 4 key
genes (Figure 2.4) in the context of breast cancer, the association between cardiovascular
diseases and cancer therapy was inferred by a previous study [63].
33
Figure 2.3: The Pearson correlation coefficient between tricluster eigen-gene vector and the
tricluster key genes
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Figure 2.4: Enriched KEGG pathway terms for the key genes of different triclusters during
cellular response to estrogen at different time points
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Figure 2.5: Enriched KEGG pathway terms for the key genes of different triclusters during
cellular response to estrogen at different time points
TFBS Enrichment Analysis
The transcription factor binding site (TFBS) enrichment analysis using the TRANSFAC
library (version 2009.4) has been performed to establish the potential co-regulation of the
genes belonging to each of the resultant triclusters [69]. Here we used 42,544,964 TFBS
predictions that have high affinity scores and are conserved between human, mouse, dog
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and cow [70]. Out of these 42 million conserved TFBSs, we have chosen the best 1% for each
TRANSFAC matrix individually to identify the most specific transcription factor - target
interactions. We have applied the hyper-geometric test [71] and Benjamini Yekutieli-FDR
method [72] for p-value correction to find over-represented binding sites (p-value ≤ 0.05) in
the upstream regions of genes belonging to each tricluster. Table 2.4 shows the list of tri-
clusters where we have found statistically enriched TFBSs. From Table 2.4, we can observe
that the genes in tricluster 26 are enriched with helix-turn-helix, zinc-coordinating DNA-
binding and basic domain transcription factors. The helix-turn-helix domain transcription
factor E2F1, to which TRANSFAC matrix V$E2F Q2 is associated acts as a regulator of
cell proliferation in estrogen-induced breast cancer cell [73]. The zinc finger transcription
factors Sp1 and Sp4, associated with matrix V$SP1 Q6 01 have already been reported to
play an instrumental role in estrogen-induced MCF-7 breast cancer cell line [74, 75]. In
tricluster 17, the basic domain transcription factor CREB (matrix V$CREB 01) is im-
portant for malignancy in breast cancer cell. ATF1, ATF2, ATF3, ATF4, ATF5 (matrix
V$CREBATF Q6) likewise play a crucial role in breast cancer cell [76]. Moreover,we have
observed the enrichment for matrix V$NFAT1 Q6 and the corresponding transcription
factor (NFATC1) has been inferred to be associated with clinical characteristics in breast
cancer cell [77]. In tricluster 4 POU2F1, the TF associated with matrix V$OCT1 03 is a
helix-turn-helix domain transcription factor (Oct-1) and has been reported to be estrogen-
responsive in a previous study [78].
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Table 2.4: TRANSFAC Matrices for Triclusters, having statistically enriched TFBS for










Tricluster 3 (875) V$NCX 02, V$MSX1 02,
V$PAX4 02, V$POU3F2 01,
V$TBP 01, V$BRN3C 01,
V$BARX2 01, V$HB24 02,
V$HOXD10 01, V$BARX1 01,
V$DBX1 01, V$HMBOX1 01,
V$HDX 01, V$BSX 01,
V$NKX52 01, V$HMX3 02,
V$LBX2 01, V$HOXD13 01,
V$NFAT1 Q6, V$HOXD8 01
4.29e-08
Tricluster 1 (4477) V$NCX 02, V$HDX 01,
V$BCL6 01, V$ZNF333 01,
V$DLX2 01, V$DLX7 01,
V$DLX5 01, V$SRY 02,
V$BARX1 01, V$SOX4 01,
V$NKX24 01, V$HOXD3 01,
V$LBX2 01, V$LHX61 02,
V$SRY 01, V$TST1 01,
V$DLX3 01, V$XVENT1 01,
V$EVX1 01, V$BARX2 01
1.27e-05





Tricluster 4 (3482) V$BCL6 01, V$HOXA10 01,
V$SRY 01, V$NKX23 01,
V$WT1 Q6, V$HOXB9 01,
V$ISL2 01, V$HOXD10 01,
V$HOXD8 01, V$NCX 02,
V$MSX1 02, V$PAX4 04,
V$BARHL2 01, V$DLX1 01,
V$SRY 02, V$OCT1 03,
V$DLX5 01, V$LHX9 01,
V$DBX2 01, V$HMGIY Q6
9.51e-05
Tricluster 2 (2186) V$CHCH 01, V$MOVOB 01,
V$MAZ Q6, V$PAX4 03,
V$CACD 01, V$GEN INI3B B,













Tricluster 12 (476) V$SRY 02, V$NCX 02,
V$BCL6 01, V$HB24 01,
V$HOXA10 01, V$NKX25 02,
V$SRY 01, V$PBX1 02,
V$HOXD10 01
0.002
Tricluster 17 (999) V$CREB 01,V$CREBATF Q6,
V$SP1 Q6 01,V$ATF3 Q6,
V$CREBP1CJUN 01
0.004
Tricluster 50 (182) V$ETF Q6 0.006
Tricluster 18 (260) V$STAT1STAT1 Q3 0.042
Tricluster 31 (2465) V$SP1 Q6 01 0.046
2.4 Conclusion
In this chapter, we have applied our proposed triclustering algorithm δ-TRIMAX to a time-
series gene expression data which contains expression values of genes during adaptation
of a MCF-7 breast cancer cell to possession of estrogen receptor alpha. The proposed
algorithm not only outperforms an existing triclustering algorithm in case of both artificial
and real-life datasets but also provides propitious results in terms of both co-expression and
co-regulation. Further analysis of the groups of co-expressed genes yielded by δ-TRIMAX
algorithm provides insights into several metabolic, biosynthetic processes which can be
used as therapeutic targets for the treatment of breast cancer.
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3 Enhanced Multi-objective Triclustering
Based on a Genetic Algorithm and Its




In this chapter, we have leveraged the proven benefits of Genetic Algorithm (GA) to con-
quer the disadvantages of the proposed triclustering algorithm δ-TRIMAX and described
an improved version of it, namely Evolutionary Multi-objective Optimization Algorithm for
δ-TRIMAX (EMOA-δ-TRIMAX). Here we have used one artificial dataset by implanting
different levels of noise and three real-life datasets to compare the performance of EMOA-
δ-TRIMAX with that of the existing triclustering algorithms. Capability of a stem cell to
differentiate into a specific tissue has been emerged by several studies such as cardiac my-
ocytes, neural progenitors etc. Development of cardiomyocytes from a stem cell is attained
by several steps such as epithelial to mesenchymal transition, mesoderm differentiation, car-
diac specification, differentiation and maturation [1]. Several metabolic processes, signaling
pathways are found to be instrumental in driving the phenotypic changes of the adolescent
cell [2]. Moreover, unveiling the signaling pathways involved in such differentiation may
provide insightful knowledge into the therapeutic targets for the treatment of cardiac disor-
ders [3,4]. In this chapter, we have applied the improved version of δ-TRIMAX algorithm
to a time-series gene expression dataset obtained during the adolescence of cardiomyocytes
from human induced pluripotent stem cells (hiPSCs) in order to reveal potential key genes,
biological processes and signaling pathways which may play instrumental roles during dif-
ferent stages of cardiomyocytes development.
3.2 Summary of δ-TRIMAX
3.2.1 Aim of δ-TRIMAX
The proposed algorithm δ-TRIMAX aims at finding maximal triclusters having mean
squared residue (MSR) score delineated in the previous chapter below a threshold δ [5, 6].
Thus δ-TRIMAX deals with two conflicting objectives i.e. minimization of MSR score of
the resultant triclusters and enhancement of the size of the triclusters.
3.2.2 Pitfalls of δ-TRIMAX
Though the proposed triclustering algorithm δ-TRIMAX algorithm described in the pre-
vious chapter has some advantages, it has few drawbacks such as (a) because of using
a greedy search heuristic, it often plunges into local optima and (b) it can not retrieve
overlapping triclusters which is an important aspect from biological point of view. For
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instance, in case of a time-series gene expression dataset same set of genes may be involved
in two different biological processes with some other genes over two overlapping subsets of
time points and replicates.
3.3 Materials and Methods
3.3.1 Materials
Artificial Dataset
We have used an artificial dataset having 1000 genes, 5 replicates and 4 time points. First
we have implanted 3 perfect shifting triclusters (standard deviation (σ) = 0) of size 100
× 4 × 4, 80 × 4 × 4 and 60 × 4 × 4 into the dataset. In the next step, we have added
different levels of noise to the implanted triclusters (σ = 0.1, 0.3, 0.5, 0.7, 0.9) [7].
Real-life Datasets
Dataset 1: The description of this dataset was given in the previous chapter (GSE11324)
[8].
Dataset 2: The aim of the experiment was to provide new insights into the regulation of
gene expression during the differentiation of a pluripotent stem cell into cardiomyocytes.
This dataset contains 48803 Illumina HumanWG-6 v3.0 probe ids, 3 technical replicates
and 12 time points (days 0, 3, 7, 10, 14, 20, 28, 35, 45, 60, 90 and 120) (GSE35671) [9]. A
detailed description of the time points is shown in Figure 3.1.
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Figure 3.1: Descriptions of the time points of Dataset 2
Dataset 3: To monitor the dynamics of expression profiles of 54675 Affymetrix human
genome U133 plus 2.0 probe ids in response to IFN-beta-1b treatment across four time
points over 6 patients, the experiment was carried out (GSE46280) [10]. Figure 3.2 provides
details of the different time points used in this experiment.
Figure 3.2: Descriptions of the time points of Dataset 3
53
Figure 3.3: Workflow used in this chapter. The figure has been taken from [7].
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Figure 3.4: Steps of EMOA-δ-TRIMAX. The figure has been taken from [7].
3.3.2 EMOA-δ-TRIMAX
Figure 3.3 represents the workflow applied in this chapter, whereas Figure 3.4 shows the
steps of the EMOA-δ-TRIMAX algorithm [7].
Multi-objective Optimization Problem
It refers to the problem of optimizing multiple conflicting objectives where a set of al-
ternative solutions having identical calibre exists instead of one single optimal solution.






of decision variables that meets a number of quality and inequality constraints by opti-
mizing the vector function f̄(x̄) = [f1(x̄), f2(x̄), ..., fr(x̄)]
T subject to some constraints.
Here constraints denote the possible region F which holds all acceptable solutions and x̄∗
represents an optimal solution. In case of a minimization problem, a decision vector x̄∗ is
called Pareto optimal if and only if there is no x̄ such that ∀i ∈ {1, 2, .., r}, fi(x̄) ≤ fi(x̄∗)
and ∃i ∈ {1, 2, ..., r}, fi(x̄)<fi(x̄∗). In words, x̄∗ is referred to as Pareto optimal if there
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exists no feasible vector x̄ that causes the curtailment of some criterion without a simulta-
neous increase of one other criterion [11,12]. In this chapter, we have used non-dominated
sorting genetic algorithm II (NSGA-II) [11] as a multi-objective optimization method to
develop an improved version of δ-TRIMAX algorithm, named evolutionary multi-objective
optimization for δ-TRIMAX (EMOA-δ-TRIMAX) which copes with the disadvantages of
δ-TRIMAX algorithm.
Genetic Algorithm
Genetic algorithm is a search heuristic which follows the process of Darwin evolution [11,12].
Here the parameters of the search space are encoded by a set of randomly initialized chro-
mosomes which composes the population. The goodness of each chromosome in the popu-
lation is measured by a fitness function also called an objective function. Genetic operators
such as selection, crossover and mutation are used to evolve the succeeding generations. If
certain criterion is satisfied or the maximum number of generation is reached, the algorithm
stops its execution.
Encoding Chromosome
In this work, we used a binary string to represent each chromosome in the population and
each of these chromosomes denotes one possible tricluster. Suppose, a time series gene
expression data contains G, C and T number of genes, replicates and time points, respec-
tively. Hence, each string consists of (G + C + T) number of bits and each bit has either
a value 1 or 0. A value 1 represents the presence of the corresponding gene/ sample/ time
point in the triclusters. For example, in case of a time series gene expression data having 15
genes, 3 replicates and 10 time points, the binary string 1001010011000100110100100110
denotes that genes {g1, g4, g6, g9, g10, g14}, replicates {c2, c3} and time points {t2, t5, t8, t9}
are the members of the corresponding tricluster. As the initial population is generated ran-
domly, some genes and/ or replicates and/or time points may be implanted to the initial
population inspite of being far away from the feature space. To overcome this problem, we
have used the proposed triclustering algorithm δ-TRIMAX as a local search heuristic.
Fitness Functions
In the next step, the goodness of each individual of the population is measured by com-






where MSR is the mean squared residue score of the resultant tricluster. Hence, obj1 needs
to be minimized.
The second objective function is
obj2 =
|I| ∗ |J | ∗ |K|
|G| ∗ |C| ∗ |T |
, (3.2)
where (|I| ∗ |J | ∗ |K|) is the volume of the resultant tricluster and (|G| ∗ |C| ∗ |T |) is the
volume of the dataset. Here we aim at maximizing the value of obj2.
Finally, the third objective function is
obj3 =
∣∣∣∣1− 6∑ d2in(n2 − 1)
∣∣∣∣ , (3.3)
where di is the difference between the ranks of average expression values (sorted either in
ascending or descending order) over a subset of samples at ith time point of each pair of
genes in one tricluster and n is the number of time points in that tricluster. Here the goal
is to increase the non-parametric Spearman correlation coefficient (obj3) of the resultant
triclusters [13].
Motivation of Fitness Functions
Optimizing the first two objective functions obj1 and obj2 (equation (3.1)-(3.2)), accom-
plishes the goals of the δ-TRIMAX algorithm i.e. maximization of size of the tricluster and
minimization of the MSR score of the resultant tricluster. The third objective function
obj3 (equation (3.3)) aims at assuring the monotonic changes in the expression profiles of
the co-expressed genes over a subset of clustered replicates and time points. Moreover,
the absolute value of the correlation coefficient has been considered due to the fact that
co-regulated genes can be both up- and down-regulated by the transcription factors across
a subset of time points.
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Genetic Operators
Selection Operator: In this work, we have applied crowded binary tournament selection
in which the binary tournament selection operator is performed based on the crowding
distance [11]. Suppose, two solutions sol1 and sol2 are being compared and the solution
sol1 wins the tournament if and only if either of the following two is satisfied:
(a) The rank of sol1 is better (less) than that of sol2.
and (b) If the solutions sol1 and sol2 belong to the same non-dominated front and sol1 has
the higher crowding distance than that of sol2. In other words, the solution located in the
less crowded region will be selected.
Crossover: A previous study reports crossover as a generalization of several mutations
performed at once. Being motivated by this fact, we did not use crossover operator [14].
Mutation: The bit string mutation has been used with a higher mutation probabil-
ity. Suppose, we are performing mutation operator on a bit string {1000011100} using a
probability 0.8. For each bit of the string we first generates a random number ranges from
0 to 1. Suppose, the generated random numbers are {0.85, 0.5, 0.7, 0.9. 0.6, 0.95, 0.55,
0.84, 0.3, 0.65}. Now in case of a particular bit of the string if the random number is less
than or equal to the mutation probability, then the bit will flip from 1 to 0 or 0 to 1. For
this particular example, the offspring will be 1110110111. After performing the mutation
operator on each individual of the population, some genes / samples / time points may be
inserted into the population that lies far away from the feature space. To deal with that
problem δ-TRIMAX algorithm has been applied as a local search heuristic.
Elitism
Elitism has been performed to keep track of the non-dominated Pareto optimal solutions
after each generation and carry over to the next generation [11].
3.3.3 Convergence of Solutions
In order to check whether solutions converge towards the Pareto optimal front around
its center region, we have calculated minSum values in each generation as follows (equa-




(f1(x) + (1− f2(x)) + (1− f3(x))), (3.4)
where Ψ corresponds to the current population and k denotes the number of given
objectives. We have observed the convergence of solutions towards the Pareto optimal
front (Figure 3.6).
3.4 Results and Discussions
3.4.1 Artificial Dataset
To estimate the performance of the proposed algorithm EMOA-δ-TRIMAX for the artificial
dataset used in this work, we have used the affirmation score defined in the previous
chapter [5, 6]. Moreover, we used the same metric to compare the performance of the
proposed algorithm (EMOA-δ-TRIMAX) with that of the other existing algorithms. The
value of δ has been computed in the same way as described in the previous chapter, whereas
the value of λ was set experimentally to optimize the speed and performance (to avoid
falling into a local optima) of the proposed algorithm. Table 3.1 shows the values of two
input parameters λ and δ for different levels of noise. From Figure 3.5 we can observe that
the proposed algorithm performs better than the other triclustering algorithms and one
biclustering algorithm proposed by Cheng and Church [16].
Table 3.1: Values of input parameters of EMOA-δ-TRIMAX namely, λ and δ for different
levels of noise in case of the artificial dataset. The contents of the table have
been taken from [7].








Figure 3.5: Comparison between EMOA-δ-TRIMAX, δ-TRIMAX, TRICLUSTER, OPTri-
cluster and the biclustering algorithm proposed by Cheng and Church in terms
of affirmation score for artificial dataset. The figure has been taken from [7].
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3.4.2 Real-life Datasets
Figure 3.6: Convergence of solutions towards the Pareto optimal front. minSum values
are plotted for dataset 1 (a), dataset 2 (b) and dataset 3 (c). The figure has
been taken from [7].
Table 3.2 enlists the values of input parameters and Table 3.3 shows the number of resultant
triclusters and the percentage of probe-ids, samples, time points for the aforementioned
real-life datasets.
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Table 3.2: Values of the input parameters in case of real-life datasets. The contents of the
table have been taken from [7].
Dataset Dataset 1 Dataset 2 Dataset 3
Values of λ 1.2 1.2 1.2
Values of δ 0.012382 0.008 0.008754
number of generations 100 100 100
population size 100 100 100
mutation probability 0.9 0.9 0.9
Table 3.3: Number of resultant triclusters, percentage of probe-ids, replicates and time
points covered by the resultant triclusters for each of the real-life datasets. The
contents of the table have been taken from [7].
Dataset Dataset 1 Dataset 2 Dataset 3
Number of resultant triclusters 100 100 32
Probe-id coverage 99.02 88.14 93
Replicates Coverage 100 100 100
Time point coverage 100 100 100
3.4.3 Performance Comparison
To compare the performance of the proposed triclustering algorithm EMOA-δ-TRIMAX
with that of the previously published ones for the real-life datasets we have used the
following three metrics.
Tricluster Diffusion (TD) Score
The definition of this metric has been given in the previous chapter. From Figures 3.7-3.9,
we can see that EMOA-δ-TRIMAX yields triclusters with a lower TD score compared to
the other algorithms for each of the real-life datasets used here.
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Figure 3.7: Tricluster Diffusion scores for Dataset 1. Performance comparison between
EMOA-δ-TRIMAX, δ-TRIMAX, TRICLUSTER and OPTricluster in terms of
TD (in log scale) score for Dataset 1. The figure has been taken from [7].
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Figure 3.8: Tricluster Diffusion scores for Dataset 2. Performance comparison between
EMOA-δ-TRIMAX, δ-TRIMAX and TRICLUSTER in terms of TD score (in
log scale) for Dataset 2. The figure has been taken from [7].
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Figure 3.9: Tricluster Diffusion scores for Dataset 3. Performance comparison between
EMOA-δ-TRIMAX, δ-TRIMAX, TRICLUSTER and OPTricluster in terms of
TD score (in log scale) for Dataset 3. The figure has been taken from [7].
Statistical Difference from Background (SDB)
This metric has been delineated in the previous chapter. From Tables 3.4-3.9, we can
observe that EMOA-δ-TRIMAX results in triclusters with a higher SDB score compared
to the other existing algorithms for each of the real-life datasets.
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Table 3.4: Performance comparison between EMOA-δ-TRIMAX, δ-TRIMAX, TRICLUS-
TER and OPTricluster in terms of SDB score for Dataset 1. The contents of






Table 3.5: Performance comparison between EMOA-δ-TRIMAX, δ-TRIMAX and TRI-
CLUSTER in terms of SDB score for Dataset 2. The contents of the table





Table 3.6: Performance comparison between EMOA-δ-TRIMAX, δ-TRIMAX, TRICLUS-
TER and OPTricluster in terms of SDB score for Dataset 3. The contents of






Hit Score Using KEGG Pathway and TFBS Enrichment Analysis
To establish the biological relevance of the groups of co-expressed genes, first we have done
KEGG pathway enrichment analysis using GOStats package in R using a FDR-corrected
p-value cutoff 0.05 [17, 18]. Using the results of KEGG pathway enrichment analysis, we
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have computed hit score [19] (equation (3.5)) for each of the resultant triclusters [7].
Hit(K) =
max{
∣∣N1T ∣∣ , ∣∣N2T ∣∣ , ..., |NnT |}
|T |
, (3.5)
where N iT corresponds to the intersection gene set of tricluster T and its enriched KEGG
pathway term i; |T | is the total number of genes in tricluster T . A higher hit score means
more genes in T participate in a canonical pathway.
In the next step, we have carried out TFBS enrichment analysis on the groups of co-
expressed genes to establish their potential co-regulation using the TRANSFAC library
(version 2012.2) [20]. A hypergeometric test has been used to detect the over-represented
binding sites in the upstream regions of the groups of co-expressed genes [21, 22]. Here
we have used 52 million TFBS predictions having high affinity scores and are conserved
between four species, namely human, mouse, dog and cow [23]. Out of these 52 million
conserved TFBSs, we have then selected the highest-scoring 1% for each TRANSFAC
matrix to identify the most specific transcription factor and target interactions. We have
then measured the hit score (equation (3.6)) in the same way that we did in case of the
KEGG pathway enrichment analysis [7].
Hit(TF ) =
max{
∣∣P 1T ∣∣ , ∣∣P 2T ∣∣ , ..., |PnT |}
|T |
, (3.6)
where P iT represents the intersection gene set of tricluster T and its enriched TRANSFAC
matrix i; |T | corresponds to the total number of genes in tricluster T . A higher hit score
signifies that more genes in T are regulated by a common transcription factor.
At first we have computed the hit scores (Hit (K) and Hit(TF)) for each resultant tricluster
using KEGG pathway and TFBS enrichment results. Then we generated 100 random gene
lists having the same size of that of the each resultant tricluster (T). The Hit scores for each
randomly generated gene list were computed using KEGG pathway and TFBS enrichment
results. As a final step we have applied the non-parametric Mann-Whitney-Wilcoxon
test [24] to measure the significance between these two sets of hit scores in terms of p-
values. From Figures 3.10-3.15, we can deduce the fact that EMOA-δ-TRIMAX results in
the groups of co-expressed genes which show better potential co-regulation than that of
the others yielded by the other existing triclustering algorithms.
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Figure 3.10: Hit scores using KEGG pathway enrichment for Dataset 1. Performance com-
parison between EMOA-δ-TRIMAX, δ-TRIMAX, TRICLUSTER and OPTri-
cluster in terms of Hit scores for Dataset 1. The figure has been taken from [7].
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Figure 3.11: Hit scores using KEGG pathway enrichment for Dataset 2. Performance com-
parison between EMOA-δ-TRIMAX, δ-TRIMAX and TRICLUSTER in terms
of Hit scores for Dataset 2. The figure has been taken from [7].
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Figure 3.12: Hit scores using KEGG pathway enrichment for Dataset 3. Performance com-
parison between EMOA-δ-TRIMAX, δ-TRIMAX, TRICLUSTER and OPTri-
cluster in terms of Hit scores for Dataset 3. The figure has been taken from [7].
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Figure 3.13: Hit scores using TFBS enrichment for Dataset 1. Performance comparison
between EMOA-δ-TRIMAX, δ-TRIMAX, TRICLUSTER and OPTricluster
in terms of Hit scores for Dataset 1. The figure has been taken from [7].
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Figure 3.14: Hit scores using TFBS enrichment for Dataset 2. Performance comparison
between EMOA-δ-TRIMAX, δ-TRIMAX and TRICLUSTER in terms of Hit
scores for Dataset 2. The figure has been taken from [7].
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Figure 3.15: Hit scores using TFBS enrichment for Dataset 3. Performance comparison
between EMOA-δ-TRIMAX, δ-TRIMAX, TRICLUSTER and OPTricluster
in terms of Hit scores for Dataset 3. The figure has been taken from [7].
3.4.4 Identifying Key Genes of Triclusters and Analyzing Their Roles During
hiPSC Differentiation into Cardiomyocytes
To validate the proposed triclustering algorithm EMOA-δ-TRIMAX, we have also identi-
fied the key genes of each resultant tricluster in the same way that we did in the previous
chapter i.e. first we computed the eigen-gene vector for each tricluster using the expression
profiles of clustered probe-ids, replicates and time points. In the next step, we ranked the
probe-ids in the descending order of the Pearson correlation coefficient between the eigen-
gene vector and the expression profiles of probe-ids. Then, we considered the genes of 10
topmost probe-ids of each tricluster as key genes and performed the gene ontology biolog-
ical process enrichment analysis to detect the specific biological processes. Understanding
the specific biological processes might facilitate to gain knowledge about the differentia-
tion of a stem cell into cardiomyocytes. Moreover, the clustered time points may provide
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insights into the different stages of differentiation during which the processes remain ac-
tive. From Figure 3.16, we can deduce that the identified key genes exhibit strong positive
correlation with eigen-gene vector of the corresponding tricluster. Furthermore, we have
summarized the lists of biological processes and signaling pathways in Figure 3.17 across
different time points and most of these identified processes such as lipoprotein, naphtha-
lene, S-adenosylhomocysteine, serotonin, fucose, putrescine, ketone, prostanoid, fatty acid,
carbohydrate, spermidine etc. and amine, putrescine, folate biosynthetic processes, canon-
ical Wnt receptor signaling pathway, histone H3 acetylation, the hippo signaling, processes
associated with smooth, cardiac and skeletal muscle cell development, etc. are inferred to
be associated with the cardiac development in previous studies [25–41].
Figure 3.16: Average Pearson correlation coefficient between 10 top-most probe-ids of tri-
clusters and the corresponding eigen-gene vectors during different phases of
cardiomyocyte differentiation. The figure has been taken from [7].
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Figure 3.17: Summarization of enriched GOBPs and metabolic pathways during hiPSC
differentiation to cardiomyocytes. Green, red, blue and black colored boxes
represent the time points Days 0 to 35, Days 35 to 120, Days 14 to 120 and
Days 0 to 120, respectively. The figure has been taken from [7].
3.5 Conclusion
In this work, we have presented an improved version (Evolutionary Multiobjective Op-
timization Algorithm for δ-TRIMAX) of our previously proposed triclustering algorithm
δ-TRIMAX and showed that EMOA-δ-TRIMAX outperforms the existing triclustering al-
gorithms in case of one artificial dataset and three real life datasets. Furthermore, we have
applied our proposed algorithm to one of the aforementioned real life datasets monitor-
ing the expression profiles of genes during stem cell differentiation into cardiomyocytes in
order to unveil the key genes and potential biological processes and/ or KEGG pathways
involved at different stages of the differentiation. Through our analysis, we have observed
that most of the identified biological processes are known to play instrumental roles in the
context of cardiomyocytes development. Furthermore, the roles of most of the identified
key genes in cardiac development were already inferred by previous studies. The rest of
the genes have been hypothesized as instrumental ones by interpreting and associating
their functions with cardiac development or disorders and thus, need to be experimentally
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verified. Altogether, our results may provide new insights into the potential therapeutic
strategies to the treatment of cardiovascular diseases.
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Table 3.7: Time points, samples, key genes of triclusters and the enriched gene ontology
biological processes and/ or KEGG pathways during cardiomyocytes differenti-
ation. Functions of bold gene symbols have been described in Tables 3.12-3.16.
The contents of the table have been taken from [7].
Tricluster GOBP/ KEGG Pathway Time Points Samples Key Genes
15 BP: GO:0045843: negative regulation of striated muscle
tissue development (LUC7L), GO:0048635: negative
regulation of muscle organ development (LUC7L),
GO:0048634: regulation of muscle organ development
(LUC7L), GO:0014706: striated muscle tissue
development (LUC7L) ; KP: KEGG:00790: folate












25 BP: GO:0035329: hippo signaling (TEAD1),
GO:0070085: glycosylation (ABO), GO:0043413:
macromolecule glycosylation (ABO); KP: KEGG:00601:
Glycosphingolipid biosynthesis - lacto and neolacto series











26 BP: GO:0042427: serotonin biosynthetic process (TPH2),
GO:0042428: serotonin metabolic process (TPH2),
GO:0007623: circadian rhythm (TPH2), GO:0043627:









27 BP: GO:0045742: positive regulation of epidermal
growth factor receptor signaling pathway (GPER),
GO:0019722: calcium-mediated signaling (RGN),
GO:0070374: positive regulation of ERK1 and ERK2
cascade (GPER), GO:0070371: ERK1 and ERK2 cascade












28 BP: GO:0072366: regulation of cellular ketone metabolic
process by positive regulation of transcription from RNA
polymerase II promoter (PPARA), GO:0045923: positive
regulation of fatty acid metabolic process (PPARA),
GO:0006109: regulation of carbohydrate metabolic
process (PPARA), GO:0042157: lipoprotein metabolic













Table 3.8: Time points, samples, key genes of triclusters and the enriched gene ontology
biological processes and/ or KEGG pathways during cardiomyocytes differenti-
ation. Functions of bold gene symbols have been described in Tables 3.12-3.16.
The contents of the table have been taken from [7].
Tricluster GOBP/ KEGG Pathway Time Points Samples Key Genes
33 BP: GO:0060537: muscle tissue development
(COL19A1), GO:0060538: skeletal muscle organ
development (COL19A1), GO:0014706: striated











41 BP: GO:0007229: integrin-mediated signaling







42 BP: GO:0035050: embryonic heart tube development
(LBX1), GO:0007368: determination of left/right
symmetry (LBX1, PKD1L1), GO:0001947: heart
looping (LBX1), GO:0003143: embryonic heart tube
morphogenesis (LBX1), GO:0061371: determination











64 BP: GO:0042157: lipoprotein metabolic process
(PEMT), GO:0018931: naphthalene metabolic
process (CYP2F1), GO:0046498:
S-adenosylhomocysteine metabolic process (PEMT),










76 BP: GO:0014002: astrocyte development (GFAP),









87 BP: GO:0048743: positive regulation of skeletal
muscle fiber development (SHOX2), GO:0060272:
embryonic skeletal joint morphogenesis (SHOX2),
GO:0045844: positive regulation of striated muscle
tissue development (SHOX2), GO:0003230: cardiac
atrium development (SHOX2), GO:0003170: heart
valve development (SHOX2), GO:0003205: cardiac
chamber development (SHOX2). GO:0051147:










Table 3.9: Time points, samples, key genes of triclusters and the enriched gene ontology
biological processes and/ or KEGG pathways since the first heart beat was
observed. Functions of bold gene symbols have been described in Tables 3.12-
3.16. The contents of the table have been taken from [7].
Tricluster GOBP/ KEGG Pathway Time Points Samples Key Genes
8 BP: GO:0043966: histone H3 acetylation
(TADA2A), GO:0016569: covalent chromatin









9 BP: GO:0060263: regulation of respiratory burst









44 BP: GO:0019722: calcium-mediated signaling
(SELE), GO:0002687: positive regulation of
leukocyte migration (SELE), GO:0005977: glycogen
metabolic process (GYG2), GO:0005976:
polysaccharide metabolic process (GYG2),
GO:0044042: glucan metabolic process (GYG2),









63 BP: GO:0050850: positive regulation of
calcium-mediated signaling (TRAT1), GO:0050851:









75 BP: GO:0006801: superoxide metabolic process
(DUOX1, PREX1), GO:0006693: prostaglandin
metabolic process (PDPN), GO:0006690: icosanoid
metabolic process (PDPN), GO:0048286: lung
alveolus development (PDPN), GO:0006692:









86 BP: GO:0051145: smooth muscle cell differentiation
(NFATC3), GO:0001569: patterning of blood vessels
(NFATC3), GO:0055001: muscle cell development
(NFATC3), GO:0006004: fucose metabolic process










98 BP: GO:0009445: putrescine metabolic process
(AGMAT), GO:0009446: putrescine biosynthetic
process (AGMAT), GO:0008295: spermidine
biosynthetic process (AGMAT), GO:0008216:
spermidine metabolic process (AGMAT),
GO:0033146: regulation of estrogen receptor













Table 3.10: Time points, samples, key genes of triclusters and the enriched gene ontology
biological processes and/ or KEGG pathways during all stages of hiPSC-derived
cardiomyocyte differentiation. Functions of bold gene symbols have been de-
scribed in Tables 3.12-3.16. The contents of the table have been taken from [7].
Tricluster GOBP/ KEGG Pathway Time Points Samples Key Genes
24 BP: GO:0060047: heart contraction (TH, ADRBK1),
GO:0003015: heart process (TH, ADRBK1),
GO:0003007: heart morphogenesis (LBX1, TH),
GO:0007507: heart development (LBX1, TH),
GO:0035050: embryonic heart tube development
(LBX1), GO:0001947: heart looping (LBX1),












61 BP: GO:0000093: mitotic telophase (MAD1L1),
GO:0000089: mitotic metaphase (MAD1L1),
GO:0000090: mitotic anaphase (MAD1L1),
GO:0001654: eye development (CRB1), GO:0001754:









79 BP: GO:0003279: cardiac septum development
(FRS2), GO:0003205: cardiac chamber development
(FRS2), GO:0003231: cardiac ventricle development
(FRS2), GO:0003281: ventricular septum
development (FRS2), GO:0000187: activation of
MAPK activity (FRS2), GO:0043406: positive








97 BP: GO:0044336: canonical Wnt receptor signaling
pathway involved in negative regulation of apoptosis
(CTNNB1), GO:0044334: canonical Wnt receptor
signaling pathway involved in positive regulation of
epithelial to mesenchymal transition (CTNNB1),
GO:0060912: cardiac cell fate specification
(CTNNB1), GO:0003306: Wnt receptor signaling
pathway involved in heart development (CTNNB1),
GO:0061316: canonical Wnt receptor signaling
pathway involved in heart development (CTNNB1),
GO:0003129: heart induction (CTNNB1),
GO:0061311: cell surface receptor linked signaling
pathway involved in heart development (CTNNB1);
KP: KEGG:04530: tight junction (CTNNB1),














Table 3.11: Time points, samples, key genes of triclusters and the enriched gene ontology
biological processes and/ or KEGG pathways during maturation. Functions of
bold gene symbols have been described in Tables 3.12-3.16. The contents of
the table have been taken from [7].
Tricluster GOBP/ KEGG Pathway Time Points Samples Key Genes
19 BP: GO:0048934: peripheral nervous system neuron
differentiation (RUNX3), GO:0050680: negative
regulation of epithelial cell proliferation (RUNX3),







43 GO:0042357: thiamine diphosphate metabolic
process (TPK1), GO:0031958: corticosteroid
receptor signaling pathway (NEDD4), GO:0046457:
prostanoid biosynthetic process (CD74),
GO:0048010: vascular endothelial growth factor
receptor signaling pathway (NEDD4); KP:
KEGG:00430: Taurine and hypotaurine metabolism











Table 3.12: Genes that might be associated with cardiac disorders, cardiovascular develop-
ment. The contents of the table have been taken from [7].
Tricluster Genes Functions
15 LUC7L Serine or arginine proteins are known to be associated with cardiac functions [42]. As
LUC7L binds to Arg/Ser-rich domain, we hypothesize LUC7L as a potential drug target
to impede cardiac disorders.
15 GREB1 It is known as estrogen responsive protein and can be used as a potential drug target as
ERalpha has been reported to play an pivotal role in cardioprotection against cardiac
injury [43].
15 SYN1 It is a well known regulator of neurotransmitter release. Hence, this finding is quite
surprising to us. However a previous study reports that the concentration of the
sympathetic nervous neurotransmitter is associated with failing human heart [44].
Thus, SYN1 might be considered as a potential drug target to prevent cardiac failure.
24 ADRBK1 It is known to be a key regulator of LPAR1 signaling which is reported to be involved in
mediating cardiomyocyte hypertrophy by a previous work [45].
24 PCDHA9 Protocadherin alpha-9 plays a key role in the development and maintenance of specific
neuronal connections in the brain. Though it’s quite surprising to us that PCDHA9 has
been identified as one of the hubs in a coexpression network, a previous study inferred
the brain’s effects on the heart for instance neurogenic heart diseases [46].
24 FOXJ3 A previous study reports that FOXJ3 expression is associated with cardiac neural crest
and thus it might provide insights into cardiovascular system development [47].
25 BEST3 It is known to form calcium-sensitive chloride channel which is known to be associated
with heart [48,49].
26 TCTEX1D4 It is known to be an interaction partner of endoglin which is reported to be a potential
drug target to prevent cardiac disorders [50]. Hence, we hypothesize targeting
TCTEX1D4 might provide a promising novel therapeutic approach for individuals with
cardiac dysfunctions.
27 EMR1 It is known to be involved in cell-cell interactions which facilitates in understanding cell
based therapies for restoring cardiomyocyte loss during cardiac diseases [51].
27 NDUFAF6 It participates in assembly of mitochondrial NADH, dehydrogenase of which plays a key
role in cardiotoxicity [52]. Hence, NDUFAF6 can be hypothesized as potential drug
target to prevent heart dysfunctions or muscle damage.
27 FAIM2 It is a well-known regulator of Fas-mediated apoptosis in neurons and this pathway is
reported to be involved in cardiac myxoma which may originate from sensory nerve
tissue [52,53]. So we hypothesize FAIM2 as a potential drug target to prevent cardiac
myxoma.
28 CALML4 It belongs to calmodulin family which may play pivotal role in cardiac function [48,54].
41 SZT2 It may take part in superoxide dismutase which may be involved in regulating cardiac
functions [48,55].
42 CUL9 It is known to regulate subcellular localization of p53. A previous study inferred that
mitochondrial p53 plays an important role in repairing mitochondrial DNA as a
response to oxidative damage of cardiomyocyte [56]. Thus, targeting CUL9 might
prevent oxidative damage of cardiomyocyte.
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Table 3.13: Genes that might be associated with cardiac disorders, cardiovascular develop-
ment. The contents of the table have been taken from [7].
Tricluster Genes Functions
42 DPEP1 It is known to transform leukotriene D4 to leukotriene E4 and thus involved in
regulating activities of leukotrienes myocardial, sedative effects of which play a key role
in cardiac dysfunction [57]. Hence, DPEP1 can be used as a potential drug target to
prevent cardiac abnormality associated with leukotrienes reactions.
42 DNPH1 It is known to generate purine that has cardioprotective effects against hypoxic
stress [58]. Thus, DNPH1 can be used as a potential drug target to impede hypoxic
stress.
42 KRTAP5-4 It is quite surprising that keratin-associated protein 5-4 has been identified as a hub
gene in coexpression network as it is known to be involved in forming resistant hair
shaft. However, an association between mitral valve regurgitation and woolly hair (a
hair shaft disorder) was inferred by a previous study [59]. Thus, we hypothesize
KRTAP5-4 as a potential drug target to prevent mitral valve regurgitation.
43 ANKRD13D It is known to be involved in positive regulation of ligand-activated epidermal growth
factor receptor that may be associated with cardiac diseases [48,60]. Thus, ANKRD13D
can be hypothesized as a potential drug target to prevent cardiac disease.
43 CD74 It is inferred to play a crucial role in processing MHC class II antigen which is capable
of detecting cardiac allograft rejection [48,61]. Thus, CD74 may provide insights into
the context of allograft rejection.
44 CTHRC1 It is known to be involved in collagen deposition modification of which may result in
deterioration of systolic function of heart patients [48,62].
44 CASP4 It plays a pivotal role in endoplasmic reticulum (ER) stress induced apoptosis and thus
can be hypothesized as a potential target to protect heart disease [48,63].
63 AGBL3 A previous study reports that AGBL3 plays an important role to process tubulin which
has has been inferred to have a cardioprotective effect [48,64].
64 DYX1C1 It was inferred to be a potential regulator of estrogen receptor stability; thus can be
hypothesized to play an instrumental role in cardiovascular development. [65,66].
64 IAPP It can be hypothesized to play a crucial role in preventing cardiomegaly by inhibiting
glycogen deposition. [67].
75 MTMR8 It is inferred to act on lipid which is an important enzyme in heart [48,68].
75 ASB12 It is reported to be a mediator of ubiquitination and subsequent proteasomal
degradation to play a cardioprotective role [48,69].
75 LGR6 It enhances canonical Wnt signaling pathway which is one of the most important
regulators of cardiomyocyte differentiation [48,70].
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Table 3.14: Genes that might be associated with cardiac disorders, cardiovascular develop-
ment. The contents of the table have been taken from [7].
Tricluster Genes Functions
76 LAT Linker for activation of T-cells family member 1 (LAT) is known to be needed for T-cell
antigen receptor. A previous study reports the presence of T-cells in coronary arteries
of cardiac allografts from patients with graft arteriosclerosis (GA) [71]. Hence we
hypothesize LAT as a potential drug target to prevent graft arteriosclerosis.
76 GPR50 GPR50 known as melatonin-related receptor, was inferred to play a key role in leptin
signaling which reduces the severity of cardiac disorders [72,73]. Hence, GPR50 can be
hypothesized as a potential drug target to prevent cardiac dysfunctions.
79 ICOS Inducible T-cell costimulator promotes the synthesis of interleukin-10 which is inferred
to protect ischemic heart from reperfusion injury [74]. Hence we can hypothesize ICOS
as a potential drug target for individuals with cardiac reperfusion injury.
79 EPS8L3 It is a well known interaction partner of ABI1 which has a key role in cardiovascular
development [75].
86 LRR1 It is known to activate NF-kappaB by negatively regulating 4-1BB-mediated signaling
cascades. A previous study reports that NF-kappaB is needed for adaptive cardiac
hypertrophy [76]. Thus targeting LRR1 might provide a novel insight into the
treatment of cardiac hypertrophy.
86 FUT2 It is known to create H-antigen which is found to be pertinent to cardiac
transplantation [77]. Thus, targeting FUT2 might provide new insights into the
treatment for heart transplantation.
87 MYO5B It belongs to myosin family. One of the primary structural proteins of cardiac muscle is
myosin, activation which plays an instrumental role in preventing systolic heart
failure [78]. Hence, MYO5B can be hypothesized as a potential drug target to prevent
cardiovascular diseases.
97 PRLH Prolactin-releasing peptide is known to release prolactin (PRL) which is inferred to
provide insights into prognosis of advanced chronic heart failure [79]. Hence we
hypothesize PRLH as a potential target for patients with chronic heart failure.
97 CCNB1IP1 A previous study reports E3 ubiquitin-ligase family of proteins as promising targets to
impede cardiac diseases [80]. As CCNB1IP1 is a E3 ubiquitin-protein ligase, targeting
this protein might provide new insights into therapeutics of heart diseases.
98 NLRP11 It belongs to NLRP family, member of which (NLRP3) is found to be associated with
cardiac disorders [81].
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Table 3.15: Genes that are known to be associated with cardiovascular development. The
contents of the table have been taken from [7].
Tricluster Genes Functions
8 NFATC4 A previous study infers NFATC4 as a potential regulator in heart development [82].
15 DHFR It has been identified as key gene that is known to be a key enzyme in folate mediated
metabolism, playing a pivotal role in heart development [83].
15 ZNF365 It is known to interact with NDE1 depletion of which causes a smaller Kupffer’s
vesicle [84].
19 GABRG1 Gamma-aminobutyric acid (GABA) A receptor, gamma 1 (GABRG1) has proven effects
in cardiac vagal neurons, which play a crucial role in controlling the heart rate and
cardiac function in previous works [85,86].
24 TH It has been inferred in a previous study that tyrosine hydroxylase (TH) plays a key role
in cardiac differentiation and primitive heart tube formation [87].
25 TEAD1 It is a well known regulator of proper heart development [88].
25 PROKR2 Prokineticin receptor-2 is reported to be associated with cardiovascular system
development [89].
26 TPH2 It might play important roles in heart development as it generates serotonin
([5-hydroxytryptamine (5-HT)]) that is involved in regulating differentiation,
proliferation during development and cardiac function [90,91].
27 GPER The role of G-protein-coupled estrogen receptor (GPER) as cardioprotective has been
inferred in previous studies [92,93].
27 RGN It has been suggested in a previous study that RGN, known as regucalcin, plays an
essential role in regulating heart mitochondrial function by increasing Ca2+ ATPase
activity [94].
28 WNT8A It is inferred to play an essential role in heart tube development [95].
28 PPARA Peroxisome proliferator-activated receptor-alpha plays a critical role in heart through
activating fatty acid oxidation [96].
28 EPHB2 Ephrin-B2 is reported to play an important role in cardiac valve maturation [97].
42 LBX1 It acts as a marker of embryonic stem cell induced cardiomyocyte differentiation [98].
42 PKD1L1 It is known to play an essential role in left/ right determination and in cardiac
development [99,100].
43 NEDD4 The Hect domain E3 ubiquitin ligase, NEDD4 is known to play an instrumental role in
cardiac development [101].
61 CRB1 It is reported to be specifically expressed in central nervous system [102].
64 PEMT Inhibition of phosphatidylethanolamine N-methyltransferase (PEMT) is inferred to play
an important role in preventing cardiac dysfunctions [103].
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Table 3.16: Genes that are known to be associated with cardiovascular development. The
contents of the table have been taken from [7].
Tricluster Genes Functions
76 GIPC2 It is known to be an interaction partner of SEMA5A inactivation of which leads to
imperfect remodeling of the cranial vascular system [104].
76 GFAP Its role in cardiac valve has been established in a previous study [105].
79 FRS2 FRS2 phosphorylation is required for activation of MAPK pathway in cardiomyocyte
development [106].
86 NFATC3 It plays an essential role in cardiac development [107].
86 CTSS It has been suggested by a recent report that cathepsin S (CTSS) takes part in normal
accumulation of autophagysomes [108]. Deficiency of autophagy has been inferred to
cause heart disease [109].
86 OLFML2B It is known to bind chondroitin sulfate which has been inferred to be involved in cardiac
AV canal formation [110].
87 SHOX2 The role of SHOX2 in posterior heart field formation has been reported in a previous
work [111].
97 CTNNB1 It is inferred to play an important role in heart development [112].
98 AIDA A previous study reported that AIDA is found to be highly expressed in heart
tissue [113].
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4 Speculating about the Role of ZEB2




Stem cells are capable of differentiating into a specialized cell types during embryogenesis
such as cardiomyocytes, neural progenitors etc. During differentiation into such specific
cell types, the cellular proliferation usually occurs at a higher level at early stage where
the rate becomes relatively low with the progression of the development [1, 2]. Thus the
proper balance between proliferation and regeneration is crucial in the context of stem cell
differentiation into a certain cell type. Moreover, depending on the ability of differentiating
into three germ layers i.e. mesoderm, ectoderm and endoderm, a stem cell can be cate-
gorized into several types such as, pluripotent, multipotent, oligopotent and unipotent. A
pluripotent stem cell can differentiate into any of these germ layers, whereas a unipotent
stem cell has the ability to differentiate into one of these three germ layers only. Stem
cell differentiation into cardiomyocytes is achieved by several steps such as epithelial to
mesenchymal transition, mesoderm differentiation, mesoderm specification, cardiac speci-
fication, cardiomyocytes differentiation and electrical maturation [3]. Differentiation into
ectoderm and mesoderm are crucial for nervous system and muscle (smooth, skeletal, car-
diac) development. A previous study inferred the fact that the crosstalk between neuronal
and cardiac cells are instrumental for the proper development of both the systems [4]. Fur-
thermore, the role of autonomic nervous system was established to be important for proper
heart development by a previous study [5], whereas the deformity in skeletal and smooth
muscle cell development may trigger the central nervous system disorders [6, 7]. Thus,
differentiation into ectoderm and mesoderm are instrumental during cardiomyocytes de-
velopment and controlled by several transcription factors (TFs). Although unveiling the
regulatory mechanisms involved in the cardiomyocytes differentiation is the subject of sub-
stantial number of research over the last decade, how TFs governs the phenotypic changes
of the cell during such differentiation remains poorly understood. Furthermore, the roles
of key genes identified in the previous chapter show an association with the proper car-
diovascular and nervous system development and being motivated by this finding, in this
chapter, we aim at elucidating the transcriptional regulation during the differentiation of a
human induced pluripotent stem cell (hiPSC) into cardiomyocyte by identifying transcrip-
tional regulatory modules (TRMs) which can be defined as a set of genes regulated by a
common set of transcription factors [8]. Though in a complex gene regulatory network,
one TF regulates hundreds or thousands of genes, in this chapter we focus on unveiling the
transcriptional regulatory network (TRN) during different stages of cardiomyocyte differ-
entiation and in such TRN each node and edge represents one transcription factor and the
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regulatory interaction between any two TFs or one TF regulating itself, respectively [9].
Moreover, we have decomposed the inferred regulatory networks into a bow-tie structure
as in biological sciences, bow-tie representation helps us to understand how a large set of
TFs (IN part) regulates a large set of target genes (OUT part) through a relatively small
set of TFs (core part) [10] in order to govern the phenotypic changes of an organism.
4.2 Materials and Methods
4.2.1 Dataset
In order to reprogram hiPSC generated from a human fibroblast, retroviral expression
of SOX2, OCT4, NANOG and LIN28 was used. Afterwards, genetic programming ap-
proaches were employed to a single clone from the reprogrammed cell to increase the pro-
duction of cardiomyocyte population through drug selection such as Blasticidin S deaminase
(BSD) [11].
4.2.2 Methods
Figure 4.1 shows the workflow applied in this chapter in order to accomplish the goal
mentioned in the previous section. First, we have applied EMOA-δ-TRIMAX tricluster-
ing algorithm to retrieve the groups of co-expressed genes which exhibits similar expression
profiles over subsets of replicates and time points. Afterwards, we have performed the tran-
scription factor binding site (TFBS) enrichment analysis in order to identify the potential
transcriptional regulatory modules (TRMs) during different stages of cardiomyocytes dif-
ferentiation. As one particular transcription factor subfamily may have more than one
transcription factors [12], the genes belonging to the corresponding transcriptional regula-
tory module are not necessarily to be co-regulated by each of these paralogous TFs [13].
Moreover, the regulators are not necessarily to be co-expressed with their target genes
because the TFs may also be post-transcriptionally regulated [13]. Hence, to identify the
potential TFs among such paralogous ones, we have computed time lag non-linear distance
correlation coefficient between the expression profiles of the target genes belong to each
of the TRMs over the clustered time points and replicates and the corresponding TFs ex-
pression values either at the clustered time points or at the preceding ones [14,15]. In the
next step, we have used hyper-geometric test [16–18] in order to perform Gene Ontology
Biological Process (GOBP) enrichment analysis for reveling the roles of identified TFs in
governing cardiomyocytes differentiation.
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Figure 4.1: Workflow applied in this chapter.
4.3 Results and Discussion
Through our analysis we have identified five triclusters time points of which apparently
show different stages of cardiomyocyte differentiation and we named them Module 1, Mod-
ule 2, Module 3, Module 4 and Module 5. Figure 4.2 shows the time points and replicates
of the aforementioned identified modules, whereas from Figure 4.3 we can observe the di-
vergence of the median expression profiles of the genes belonging to each of these identified
modules. After reconstructing the transcriptional regulatory networks (TRNs) for each of
these identified modules, we have crumbled the TRNs into three parts of bow-tie structure
i.e. IN, strongly connected component (SCC) and OUT. Afterwards, we have analyzed the
roles of TFs found to be the members of SCCs as they are supposed to drive the phenotypic
changes during cardiac development.
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Figure 4.2: Clustered replicates and time points of the identified modules, namely Module
1, Module 2, Module 3, Module 4 and Module 5.
Figure 4.3: Median expression profiles of the genes belonging to the modules, namely Mod-
ule 1, Module 2, Module 3, Module 4 and Module 5.
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Figure 4.4: The bow-tie structure of transcriptional networks inferred from the Module 1,
Module 2, Module 3, Module 4 and Module 5 and the TFs belong to the SCC
of each of these modules.
4.3.1 SCCs of Module 1
RUNX1 is found to be an instrumental player in averting skeletal muscle disorders [19].
Depletion of BCL6 expression may trigger inflammatory diseases in heart [20]. The role
MAFF has been reported to be crucial during embryonic development of many tissues [21].
NFE2L3 also known as NRF3 plays crucial role in smooth muscle cell differentiation dur-
ing early embryo development [22]. Moreover, our results indicate the role of CREB5 in
regulating systemic arterial blood pressure which was already inferred to be associated
with cardiac output by a previous study [23].
4.3.2 SCCs of Module 2
ASCL2 is known to play an instrumental role in driving nervous system differentiation [24].
A previous study inferred the role of NFIA in regulating neuronal differentiation [25]. More-
over, the involvement of KLF13, SOX6, E2F4, MAZ, NFE2L1 have been established in
governing cardiomyocyte development by previous studies [26–29]. GLIS3 may also play
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an instrumental role in muscle cell differentiation [30]. Furthermore, MYF6 and AR are
known to be involved in skeletal muscle cell differentiation [31,32]. The roles of SOX10 and
NR2F6 were established to be associated with neuronal development [33, 34]. Deficiency
of the expression of NFE2L2, RARB, RXRG, TFEB may trigger cardiac disorder [35–37].
Though the role of NHLH2 has not been established to prevent cardiac disorders, de-
pletion of one of the similar transcription factor NHLH1 expression may cause cardiac
diseases [38]. Additionally, the roles of HAND2, STAT4 and TBX5 have been established
in proper heart development [39–41]. Deletion of the expressions of SP3, JUNB, TFAP2A,
PLAGL1, PPARD and HMGA1 transcription factors may trigger the occurrence of cardiac
disorders [42–47]. Furthermore, the involvement of IKZF4, TAF1 and HNF1B TFs have
been elucidated in governing neuronal development [48–50]. Moreover, a previous study
reports that the interaction between PITX2 and PRRX1 may be instrumental in proper
heart development [51]. The role of ESRRB and ESRRG have also been inferred in main-
taining the pluripotent state of stem cell [52, 53], whereas NFYA play an important role
in embryonic stem cell [54]. Moreover, the abundant expression of NFAT transcription
factors are found in myocardium [55] whereas TGIF1 is known to play an instrumen-
tal role in governing heart looping [56]. NKX2-6 may play an instrumental role in proper
heart development and its expression was observed in each of the three germ layers [57–59].
4.3.3 SCCs of Module 3
Besides the above findings, our results also reveal the roles of PBX2 and MEIS2 in gov-
erning the heart development [60, 61]. Deficiency of the expression of RFX3 may trigger
cardiac disorders [62]. Moreover, ETS1 and FOXD3 may play instrumental roles in neu-
ral crest development which supports proper cardiac development [63, 64]. The abundant
expression of ARID5A and MAFG were also observed by previous studies [21, 65]. Fur-
thermore, deletion of the expression of ZIC5 may cause neural crest disorders [66].
4.3.4 SCCs of Module 4
Additionally, our results infer the roles of SP5 and NPAS1 in the neuronal development
[67, 68]. VDR is known to be associated with sustaining the proper functions of skeletal
muscle [69]. The role of RBPJ was also inferred to be instrumental in neuronal progenitor
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cells [70]. Moreover, SOX13 may play an important role in neurogenesis and its role was
observed in artery wall [71, 72].
Figure 4.5: SCC and OUT parts of the transcriptional regulatory networks for Module 2
on day 03 (a) and day 07 (b). Circular nodes represent the members of the
core part, whereas round-rectangular nodes denote their targets. Green colored
edge shows the interaction between ZEB2 and SMADs.
107
Figure 4.6: SCC and OUT parts of the transcriptional regulatory networks for Module 4
on day 45 (a) and day 60 (b). Circular nodes represent the members of the
core part, whereas round-rectangular nodes denote their targets. Green colored
edge shows the interaction between ZEB2 and SMADs.
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Figure 4.7: SCC and OUT parts of the transcriptional regulatory networks for Module 4
on day 90. Circular nodes represent the members of the core part, whereas
round-rectangular nodes denote their targets. Green colored edge shows the
interaction between ZEB2 and SMADs.
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Figure 4.8: SCC and OUT parts of the transcriptional regulatory networks for Module 5
on day 35 (a) and day 45 (b). Circular nodes represent the members of the
core part, whereas round-rectangular nodes denote their targets. Green colored
edge shows the interaction between ZEB2 and SMADs.
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Figure 4.9: SCC and OUT parts of the transcriptional regulatory networks for Module 5
on day 60 (a) and day 90 (b). Circular nodes represent the members of the
core part, whereas round-rectangular nodes denote their targets. Green colored
edge shows the interaction between ZEB2 and SMADs.
4.3.5 Elucidating the Roles of ZEB2 and SMADs Transcription Factors
During Cardiac Development
Figure 4.4 suggests an important role of ZEB2, also known as SMAD interacting protein
1(SIP1 ), in governing the changes of phenotypic behavior of the cell during the hiPSC
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differentiation into cardiomyocytes as ZEB2 is found to be a part of SCC of the transcrip-
tional regulatory networks inferred from module 1, 4 and 5. To further investigate the
regulatory interactions between ZEB2 and other TFs belonging to the core part of these
transcriptional regulatory networks, we have observed the regulatory interactions between
ZEB2 and different members of SMAD family during the early and late stages of differen-
tiation (Figures 4.5-4.9).
Figure 4.5 shows the interaction between ZEB2 and SMAD2 transcription factors dur-
ing very early stage of differentiation and this finding is not too surprising as the role of
SMAD2 signaling in maintaining the pluripotent stem cell state has already been inferred
by a previous study [73]. In order to further elucidate the involvement of ZEB2 at the
early stage of differentiation, we have observed the potential biological processes associated
with the regulation of both myocytes and neuronal development (Figure 4.10). Although,
mutations in the ZEB2 gene result in the occurrence of MowatWilsonSyndrome, a genetic
disorder that often cooccurs with neurodegenerative malfunctions [74,75], its role in devel-
oping proper heart still remains unclear.
Additionally, Figures 4.6-4.7 evince the significance of the regulatory interactions between
SMAD proteins SMAD2, SMAD5, SMAD6 and ZEB2 at the late stage of differentiation,
where as Figures 4.8-4.9 show the involvement of a two-node feed-back loop comprising
SMAD6 and ZEB2 during days 45, 60 and 90. Figures 4.11-4.12 suggest that in case
of these two modules, ZEB2 is also involved in governing both neural and myocytes de-
velopment. This finding is not too surprising as SMAD6 and SMAD5 are known to be
important players in regulating proper neural and cardiac development [76–78].
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Figure 4.10: Interactions between ZEB2 and SMADs TFs and their roles during the early
stage of stem cell differentiation into cardiomyocytes.
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Figure 4.11: Interactions between ZEB2 and SMADs TFs and their roles during the late
stage of stem cell differentiation into cardiomyocytes.
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Figure 4.12: Interactions between ZEB2 and SMADs TFs and their roles during the mat-
uration stage of stem cell differentiation into cardiomyocytes.
4.4 Conclusion
In this chapter, we applied the proposed triclustering algorithm EMOA-δ-TRIMAX to a
time series gene expression data which contains the expression profiles of genes during stem
cell differentiation into cardiomyocytes in order to retrieve the regulatory modules during
different stages of cardiomyocytes development. Afterwards, the identified modules have
been used to infer the regulatory networks which have then been decomposed into three
parts i.e. IN, SCC and OUT. Our results infer the roles of those TFs that were found to
be members of the SCCs of the identified modules. Most of these TFs were already known
to be associated with the proper development of cardiomyocytes. Moreover, our findings
also indicate a role of ZEB2 in the accomplishment of stem cell differentiation into car-
diomyocytes. Altogether, our results provide new insights into the regulatory mechanisms
involved in driving the phenotypic changes during adolescence of cardiomyocytes.
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5 Co-regulation Analysis of Time Series
Transcriptomics Data Unveils the Roles of
Three Node Feed-Forward Loops in




Extracellular signaling molecules trigger the activation of specific receptors, which are
usually confined to a certain cell type. As a response, these receptors engender cellular
changes by altering gene expressions, metabolic events etc. In the context of breast cancer,
after invading into the cell the estrogen molecule binds to the estrogen receptor which
thereafter binds to specific DNA sites known as estrogen responsive elements (EREs).
Afterwards, EREs regulate their target genes by recruiting co-activators or co-repressors to
prompt assembly of the transcriptoin complex and synthesize messenger RNAs (mRNAs)
from which specific proteins are synthesized. These proteins then cause changes of the
cellular behavior for instance, enhancing the proliferation etc. Targeting these signaling
pathways may provide insightful knowledge about therapeutic strategies as these pathways
trigger the progression of the breast cancer cells [1]. Though over the last decade elucidating
the roles of transcription factors in (i) responding to these signaling pathways and (ii)
specifically enhancing the synthesis of components of the same or other pathways is the
topic of considerable research in the context of breast cancer, the transcriptional regulatory
circuitry still remains poorly understood.
Due to the advancement of microarray technology, over the last decade, it has become
easier to monitor the expression profiles of thousands of genes not only over a set of
replicates but also at a set of time points. The changes of the gene expression profiles
are controlled by transcription factors (TFs) which escalate or diminish specific target
gene expression by interacting with either co-activators or co-repressors, respectively [2].
Moreover, due to the paralogous expansion of the transcription factor subfamily [3], each
of the paralogous transcription factors may not necessarily regulate their target genes.
Gene regulatory networks (GRNs) can be viewed as a collection of interactions between
transcription factors and their target genes. In graph theory, GRNs can be delineated as a
mixed graph G = (N,DE,UE), where N represents a set of vertices, each of which can be
either a gene or a TF (or the gene of a TF). DE denotes the set of directed edges, each of
which represents regulatory relationships between a gene and a TF. UE refers to the set of
undirected edges which can be expounded as the associations between genes deduced from
the degree of similarities in their expression profiles [4]. A gene regulatory network can
further be decomposed as the components of a bow-tie structure i.e. IN, OUT, strongly
connected component (SCC), tendrils and tubes (Figure 5.1). Nodes belonging to the IN
part can act as regulators of the nodes belonging to the SCC and OUT components. Nodes
in the OUT part which are reachable from the IN part without having any connection to
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the SCC part form tube. Nodes are said to be the members of SCC if there is a path
from each of these nodes to every other nodes. Tendrils comprise nodes that are reachable
from IN part, but do not have any link to SCC or the OUT component, and nodes that
can reach OUT component, but are neither linked to the SCC or to the IN component [4].
In the context of developmental biology, TFs in the giant component play crucial roles
in driving the phenotypic changes in an adolescent cell, whereas in the context of disease
biology, these strongly connected transcription factors play instrumental role in disease
progression. Moreover, due to the complexity of the gene regulatory networks, recurrent
network motifs such as, feed-forward or feed-back loops can be used to easily understand
the transcriptional regulatory circuitry and their involvement in governing the disease
progression. Feed-forward loops (FFLs), one of the coregulatory motifs, are reported by
several studies to provide apparent insights into the governance of cellular functions and
in the progression of cancer [5–7]. A three node FFL comprises two transcription factors
one of which regulates the other and a gene which is regulated by these two transcription
factors. A previous study reported the involvement of a cyclic feed-forward loop comprising
SAF-1, RAS and VEGF in governing angiogenesis in breast cancer [8].
In this chapter, we have applied EMOA-δ-TRIMAX algorithm [11] to a time series gene
expression dataset to provide insights into the regulatory mechanisms of signaling during
MCF-7 breast cancer cell exposure to estrogen.
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Figure 5.1: Schematic diagram of bow-tie structure.
5.2 Materials and Method
5.2.1 Dataset
The description of this dataset was provided in chapter 2. The experiment was carried out
to unravel the transcriptional regulatory mechanisms during the exposure of MCF-7 breast
cancer cell to estrogen [12].
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5.2.2 Methods
Figure 5.2: Workflow applied in this work.
Figure 5.2 demonstrates the workflow applied in this work. First we have applied the
EMOA-δ-TRIMAX [11] algorithm to the aforementioned dataset to extract the groups of
genes exhibiting similar expression profiles over a subset of replicates and time points. In
the next step, we have used the Limma package [13] to find out the significantly expressed
genes from each group of the co-expressed genes using clustered time points and replicates,
as we are interested in elucidating the regulatory mechanisms of estrogen induced genes.
Afterwards, performing the transcription factor binding site (TFBS) enrichment analysis
on the groups of co- and significantly expressed genes using TRANSFAC library version
12.2 [14], we have detected the corresponding potential regulators based on the statistical
enrichment of TRANSFAC matrices. The target genes of each of the identified potential
regulators are not necessarily to be co-expressed with TF itself as a transcription factor can
also be post-transcriptionally regulated. Being motivated by this fact, we have computed
the distance correlation coefficient [15] between the median expression profiles of the target
genes and that of the corresponding transcription factors to identify the most specific
regulators. Distance correlation is used to compute the non-linear dependence between
two random variables (V1 and V2) and its value ranges from 0 to 1, where 0 represents the
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distance correlation between two independent variables.
5.3 Results and Discussion
Through our analysis, we have found two modules comprising the time points that clearly
depict the early and late stages of exposure of MCF-7 cells to estrogen. After recon-
structing the gene regulatory network using the aforementioned regulatory modules, we
fragmented the network into IN, OUT and SCC parts. TFs that belong to the SCC are
identified using the igraph package [16]. Figure 5.3 shows the overlap between the mem-
bers belonging to each of the components of the bow-tie structures of the corresponding
gene regulatory networks. We can observe that inspite of having a higher number (Jaccard
similarity coefficient is 0.55) of common transcription factors belonging to the IN parts,
the overlap in case of both the SCC and OUT parts (Jaccard similarity coefficients are 0.15
and 0.19,respectively) are comparatively low. The transcription factors that switch from
each part of the bow-tie structure to every other part are shown in Figure 5.4.
To further investigate the commonalities between the results obtained in this chapter and
chapter 2, we have observed that in case of the early module 64% of all transcription fac-
tors have also been found to be in chapter 2 using the δ-TRIMAX algorithm, whereas this
percentage is 65% in case of the late module. And this finding indicate the robustness of
the two methods used in this work.
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Figure 5.3: Overlap between the members belonging to each part of the bow-tie structure
of the regulatory networks inferred from early and late modules.
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Figure 5.4: Inter-modular switch of transcription factors from each part of the bow-tie
structure to every other part.
Moreover, the identified strongly connected components as shown in Figure 5.5, will
provide insights into several feed-forward or feed-back loops.
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Figure 5.5: The strongly connected components of early (a.) and late (b.) modules.
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In this chapter, we aim at elucidating the roles of 3-node FFL motifs identified through
performing an exhaustive search, in order to unveil how TFs cooperatively accelerate es-
trogen induced breast cancer cell growth and proliferation. From Figure 5.5a, we can
observe that ESR1 also known as estrogen receptor alpha belongs to the strongly con-
nected component of the regulatory network at early time points. Analyzing its targets
in the SCC, we have found the regulatory interactions between ESR1 and E2F2, BCL6
and analyzed the roles of FFLs where E2F2 and BCL6 act as co-regulators with ESR1
in governing the expression of genes involved in signaling pathways which may enhance
breast cancer risks. Table 5.1 shows the lists of signaling pathways which are mediated by
the TFs ESR1, E2F2 and ESR1, BCL6, respectively. A comprehensive list of signaling
pathway genes regulated by two TFs in the identified FFLs are enlisted in Table 5.3 (see
appendix). It is of interest to see that the FFL comprising ESR1, E2F2 and HDAC1 is
involved in diminishing the rate of androgen receptor signaling which is known to block
the ER-alpha signaling [17]. Table 5.2 shows those signaling pathways which are governed
by the transcription factors of the FFLs comprising E2F2 during the late stage of breast
cancer cell exposure to estrogen. A comprehensive list of signaling pathway genes regulated
by two TFs in the identified FFLs during the late stage of cellular exposure to estrogen are
enlisted in Table 5.4 (see appendix). At this stage, we can see the reduction of the rates
of pathways such as bone morphogenetic protein (BMP) signaling, non-canonical Wnt (β-
catenin independent pathway) signaling, prolactin signaling, interleukin-6 (IL-6)-mediated
signaling, macrophage colony-stimulating factor signaling, tumor necrosis factor-mediated
signaling, apoptotic signaling, protein kinase C signaling, transforming growth factor beta
(TGF-β) receptor signaling which may in turn enhance the risks of breast cancer. For
instance, inhibition of BMP signaling may cause mitotic arrest defect which is known to
be involved in chromosomal instability observed in human breast cancer [18, 19]. Non-
canonical Wnt signaling mediates the maintenance of cellular polarity the loss of which
may initiate tumorigenesis [20,21]. Moreover, a previous study reported that the blockage
of prolactin signaling may also be observed in human breast cancer [22]. IL-6 signaling has
been inferred to be an inhibitor of the cellular proliferation in estrogen receptor positive
breast cancer cell [23]. The inhibition of colony-stimulating factor signaling may also trig-
ger breast cancer metastasis [24]. Protein kinase C and transforming growth factor beta
signaling may play instrumental roles in inhibiting breast cancer cell proliferation; thus di-
minishing the rate of these two signaling pathways may positively influence the progression
of breast cancer [25, 26]. Tumor necrosis factor (TNF)-mediated signaling was inferred to
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act as an antagonist of ER-alpha signaling in MCF7 breast cancer cell [27].
Besides, targeting both extrinsic and intrinsic apoptotic signaling pathway has been re-
ported to be therapeutic strategies in the context of breast cancer treatment. TNF-related
apoptosis inducing ligand (TRAIL) triggers the activation of extrinsic apoptotic signaling
which exhibits anti-tumor activities in breast cancer cell [28]. It is of interest to see the
regulation of ”extrinsic apoptotic signaling pathway in the absence of ligand” (Table 5.4)
also treated as an example of intrinsic apoptotic pathway during the late stage of exposure
of MCF-7 cell to estrogen. Additionally, in case of breast cancer cell, mutations in the genes
involved in the regulation of mitochondrial pathways may cause oncogenesis. For instance,
it has been reported by a previous study that the chromosomal translocation of Bcl-2 gene
may cause the over-expression of Bcl-2 family members exhibit the anti-apoptotic behavior
in breast cancer cells [28]. From our results (Table 5.4), the involvement of YWHAQ also
known as 14-3-3, BCL2L11, BCL2L1, SEPT4 also known as ARTS and BCLAF1 becomes
apparent in the regulation of intrinsic apoptotic signaling during the late stage of cellular
exposure to estrogen. 14-3-3 is known to be an instrumental mediator of anti-apoptotic
signal [29], whereas a previous study reported that the over expression of XIAP may in-
hibit the activities of caspase-3 which is known to be instrumental in mediating apoptosis
in breast cancer cell [28, 30]. Furthermore, another previous study inferred that muta-
tion in ARTS may result in promoting the tumor growth [31]. Though BCL2-associated
transcription factor 1 (BCLAF1 ) and BCL2L11 are well known apoptosis inducers, the
co-expression of the former one with other members of BCL-2 family may inhibit its apop-
totic behavior in breast cancer cell, whereas the interaction of the later with GRB10 may
suppress apoptosis [32].
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Figure 5.6: Feed-forward loop comprising three nodes.
Table 5.1: Signaling pathways regulated by three node feed-forward loop in the early mod-

























androgen receptor signaling pathway x
regulation of opioid receptor signaling pathway x x
fibroblast growth factor receptor signaling pathway x
intracellular steroid hormone receptor signaling
pathway
x x
neurotrophin TRK receptor signaling pathway x x
cell surface receptor signaling pathway x




























































































































































































































































regulation of peroxisome proliferator activated receptor signaling
pathway
x x x x x
transmembrane receptor protein serine/threonine kinase signaling
pathway
x x x x
neurotrophin TRK receptor signaling pathway x x x x x x x x x x
transforming growth factor beta receptor signaling pathway x x x x x x x x x x x x x x
Notch signaling involved in heart development x x x x
Wnt signaling pathway involved in forebrain neuroblast division x x x x x x x x x
canonical Wnt signaling pathway involved in cardiac neural crest cell
differentiation involved in heart development
x x x x x x x x x
positive regulation of Wnt signaling pathway involved in
dorsal/ventral axis specification
x x x x x x x x x
canonical Wnt signaling pathway involved in neural crest cell
differentiation
x x x x x x x x x
canonical Wnt signaling pathway involved in positive regulation of
cardiac outflow tract cell proliferation
x x x x x x x x x
canonical Wnt signaling pathway involved in regulation of cell
proliferation
x x x x x x x
canonical Wnt signaling pathway x x x x x x
cell surface receptor signaling pathway x x x x x x x x
transmembrane receptor protein tyrosine kinase signaling pathway x x x x x x
Wnt signaling pathway involved in dorsal/ventral axis specification x x x x
negative regulation of non-canonical Wnt signaling pathway x x x x
Wnt signaling pathway involved in somitogenesis x x x x x x
intracellular receptor signaling pathway x x x x x x x x x x
G-protein coupled receptor signaling pathway coupled to cGMP
nucleotide second messenger
x x x
Notch signaling pathway x x x x x x x x

























































































































































































































































toll-like receptor 10 signaling pathway x x x x x x
toll-like receptor 5 signaling pathway x x x x x x
toll-like receptor TLR1:TLR2 signaling pathway x x x
toll-like receptor TLR6:TLR2 signaling pathway x x x
toll-like receptor 9 signaling pathway x x x
TRIF-dependent toll-like receptor signaling pathway x x x x
toll-like receptor 2 signaling pathway x x x
MyD88-independent toll-like receptor signaling pathway x x x x
toll-like receptor 3 signaling pathway x x x
MyD88-dependent toll-like receptor signaling pathway x x
toll-like receptor 4 signaling pathway x x x
toll-like receptor signaling pathway x x
insulin receptor signaling pathway x x x x x x
regulation of Wnt signaling pathway x x x x x
Wnt signaling pathway x x x x x x x x x x
BMP signaling pathway x x x x
intracellular steroid hormone receptor signaling pathway x x
positive regulation of protein insertion into mitochondrial membrane
involved in apoptotic signaling pathway
x x x x x x
positive regulation of intracellular estrogen receptor signaling pathway x x
fibroblast growth factor receptor signaling pathway involved in
orbitofrontal cortex development
x x x x x

























































































































































































































































negative regulation of Wnt signaling pathway x x x x x
fibroblast growth factor receptor signaling pathway x x x x x x x
regulation of endocannabinoid signaling pathway x x x x x x x
extrinsic apoptotic signaling pathway x x x x
positive regulation of intrinsic apoptotic signaling pathway x x x x x
androgen receptor signaling pathway x x x x
glucocorticoid receptor signaling pathway x x x
epidermal growth factor receptor signaling pathway x x x x x
negative regulation of interleukin-6-mediated signaling pathway x x x x
Fc-epsilon receptor signaling pathway x x x x x
regulation of transforming growth factor beta receptor signaling
pathway
x x x
intracellular estrogen receptor signaling pathway x x x x x x x
negative regulation of cGMP-mediated signaling x x x x
activation of prostate induction by androgen receptor signaling
pathway
x x x
negative regulation of interleukin-2-mediated signaling pathway x x x
negative regulation of prolactin signaling pathway x x x
negative regulation of interleukin-4-mediated signaling pathway x x x
negative regulation of macrophage colony-stimulating factor signaling
pathway
x x x
negative regulation of tumor necrosis factor-mediated signaling
pathway
x x x
extrinsic apoptotic signaling pathway in absence of ligand x x x x x x



























































































































































































































































adenylate cyclase-inhibiting G-protein coupled glutamate receptor
signaling pathway
x x x
autocrine signaling x x
canonical Wnt signaling pathway involved in mesenchymal stem cell
differentiation
x x
canonical Wnt signaling pathway involved in osteoblast differentiation x x
regulation of fibroblast growth factor receptor signaling pathway x x x x
regulation of phosphatidylinositol 3-kinase signaling x x x x
positive regulation of ephrin receptor signaling pathway x
nucleotide-binding domain, leucine rich repeat containing receptor
signaling pathway
x x x
Wnt signaling pathway, calcium modulating pathway x
SREBP signaling pathway x
cytokine-mediated signaling pathway x x
apolipoprotein A-I-mediated signaling pathway x x x
apoptotic signaling pathway x x x x
negative regulation of apoptotic signaling pathway x x
Fc-gamma receptor signaling pathway involved in phagocytosis x x
intrinsic apoptotic signaling pathway x x x x
nucleotide-binding oligomerization domain containing signaling
pathway
x
hippo signaling x x x x
nerve growth factor signaling pathway x
positive regulation of apoptotic signaling pathway x
positive regulation of vascular endothelial growth factor receptor
signaling pathway

























































































































































































































































positive regulation of mitochondrial outer membrane permeabilization
involved in apoptotic signaling pathway
x
steroid hormone mediated signaling pathway x
phospholipase C-activating G-protein coupled glutamate receptor
signaling pathway
x
interleukin-6-mediated signaling pathway x x
negative regulation of cytokine-mediated signaling pathway x
VEGF-activated neuropilin signaling pathway x x
interleukin-27-mediated signaling pathway x x
positive regulation of protein kinase C signaling x
negative regulation of protein kinase C signaling x
interleukin-15-mediated signaling pathway x
positive regulation of cysteine-type endopeptidase activity involved in
apoptotic signaling pathway
x
positive regulation of I-kappaB kinase/NF-kappaB signaling x
canonical Wnt signaling pathway involved in metanephric kidney
development
x
semaphorin-plexin signaling pathway x
semaphorin-plexin signaling pathway involved in neuron projection
guidance
x
regulation of epidermal growth factor receptor signaling pathway x
I-kappaB kinase/NF-kappaB signaling x





In this chapter, we have applied the proposed triclustering algorithm EMOA-δ-TRIMAX to
a time-series gene expression data set monitoring the exposure of MCF-7 breast cancer to
estrogen, in order to reveal the involvement of FFLs comprising two TFs and one common
target gene, in mediating the potential signaling pathways which support uncontrolled
cellular proliferation of breast cancer cell. Most of the identifying signaling pathways,
genes of which are regulated by the TFs of the identified FFLs are known to be involved
in promoting breast tumor growth.
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Table 5.3: Signaling pathways regulated by three node feed-forward loop in the early mod-
ule. A, B and C represent the positions in FFL depicted by Figure 5.6.
GOID GOBPTerm regulated by ESR1 (A) and E2F2 (B) Gene Symbol (C) in the
identified FFLs
GO:0030521 androgen receptor signaling pathway CCNE1
GO:2000474 regulation of opioid receptor signaling pathway SYP
GO:0008543 fibroblast growth factor receptor signaling pathway ERBB2
GO:0030518 intracellular steroid hormone receptor signaling pathway THRAP3
GO:0048011 neurotrophin TRK receptor signaling pathway ERBB2
GO:0007166 cell surface receptor signaling pathway ERBB2
GO:0060766 negative regulation of androgen receptor signaling pathway HDAC1
Table 5.3 continued...
GOID GOBPTerm regulated by ESR1 (A) and BCL6 (B) Gene Symbol (C)
in the identified
FFLs
GO:2000474 regulation of opioid receptor signaling pathway SYP
GO:0030518 intracellular steroid hormone receptor signaling pathway THRAP3
GO:0048011 neurotrophin TRK receptor signaling pathway FGFR4
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Table 5.4: Signaling pathways regulated by three node feed-forward loop in the late module.
A, B and C represent the positions in FFL depicted by Figure 5.6.
GOID GOBPTerm regulated by E2F2 (A) and ARNTL (B) Gene Symbol (C)
in the identified
FFLs
GO:0035358 regulation of peroxisome proliferator activated receptor
signaling pathway
SIRT1
GO:0007178 transmembrane receptor protein serine/threonine kinase
signaling pathway
TRPS1
GO:0048011 neurotrophin TRK receptor signaling pathway TIAM1
GO:0007179 transforming growth factor beta receptor signaling pathway CDK8
GO:0061314 Notch signaling involved in heart development JAG1
GO:0021874 Wnt signaling pathway involved in forebrain neuroblast
division
LRP6
GO:0061310 canonical Wnt signaling pathway involved in cardiac neural
crest cell differentiation involved in heart development
LRP6
GO:2000055 positive regulation of Wnt signaling pathway involved in
dorsal/ventral axis specification
LRP6
GO:0044335 canonical Wnt signaling pathway involved in neural crest cell
differentiation
LRP6
GO:0061324 canonical Wnt signaling pathway involved in positive
regulation of cardiac outflow tract cell proliferation
LRP6
GO:0044340 canonical Wnt signaling pathway involved in regulation of
cell proliferation
LRP6
GO:0060070 canonical Wnt signaling pathway KDM6A
GO:0007166 cell surface receptor signaling pathway FZD3
GO:0007169 transmembrane receptor protein tyrosine kinase signaling
pathway
MTSS1
GO:0044332 Wnt signaling pathway involved in dorsal/ventral axis
specification
LRP6
GO:2000051 negative regulation of non-canonical Wnt signaling pathway LRP6
GO:0090244 Wnt signaling pathway involved in somitogenesis LRP6
GO:0030522 intracellular receptor signaling pathway NR2F2
GO:0007199 G-protein coupled receptor signaling pathway coupled to
cGMP nucleotide second messenger
FZD3
GO:0007219 Notch signaling pathway CDK8
GO:0030514 negative regulation of BMP signaling pathway TRIM33
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Table 5.4 continued...
GOID GOBPTerm regulated by E2F2 (A) and ATF1 (B) Gene Symbol (C)
in the identified
FFLs
GO:0034166 toll-like receptor 10 signaling pathway MEF2A
GO:0034146 toll-like receptor 5 signaling pathway MEF2A
GO:0038123 toll-like receptor TLR1:TLR2 signaling pathway MEF2A
GO:0038124 toll-like receptor TLR6:TLR2 signaling pathway MEF2A
GO:0034162 toll-like receptor 9 signaling pathway MEF2A
GO:0035666 TRIF-dependent toll-like receptor signaling pathway MEF2A
GO:0034134 toll-like receptor 2 signaling pathway MEF2A
GO:0002756 MyD88-independent toll-like receptor signaling pathway MEF2A
GO:0034138 toll-like receptor 3 signaling pathway MEF2A
GO:0002755 MyD88-dependent toll-like receptor signaling pathway MEF2A
GO:0034142 toll-like receptor 4 signaling pathway MEF2A
GO:0002224 toll-like receptor signaling pathway MEF2A
GO:0007179 transforming growth factor beta receptor signaling pathway CGN
GO:0008286 insulin receptor signaling pathway AKT2
GO:0030111 regulation of Wnt signaling pathway SENP2
GO:0007166 cell surface receptor signaling pathway STC2
GO:0007169 transmembrane receptor protein tyrosine kinase signaling
pathway
AHI1
GO:0016055 Wnt signaling pathway MARK2
GO:0030522 intracellular receptor signaling pathway NR2F2
GO:0030509 BMP signaling pathway EGR1
GO:0030518 intracellular steroid hormone receptor signaling pathway MED14
GO:1900740 positive regulation of protein insertion into mitochondrial
membrane involved in apoptotic signaling pathway
YWHAQ





GOID GOBPTerm regulated by E2F2 (A) and CLOCK (B) Gene Symbol (C)
in the identified
FFLs
GO:0035358 regulation of peroxisome proliferator activated receptor
signaling pathway
SIRT1
GO:0007178 transmembrane receptor protein serine/threonine kinase
signaling pathway
TRPS1
GO:0048011 neurotrophin TRK receptor signaling pathway TIAM1
GO:0007179 transforming growth factor beta receptor signaling pathway CDK8
GO:0061314 Notch signaling involved in heart development JAG1
GO:0021874 Wnt signaling pathway involved in forebrain neuroblast
division
LRP6
GO:0061310 canonical Wnt signaling pathway involved in cardiac neural
crest cell differentiation involved in heart development
LRP6
GO:2000055 positive regulation of Wnt signaling pathway involved in
dorsal/ventral axis specification
LRP6
GO:0044335 canonical Wnt signaling pathway involved in neural crest cell
differentiation
LRP6
GO:0061324 canonical Wnt signaling pathway involved in positive
regulation of cardiac outflow tract cell proliferation
LRP6
GO:0044340 canonical Wnt signaling pathway involved in regulation of
cell proliferation
LRP6
GO:0060070 canonical Wnt signaling pathway KDM6A
GO:0007166 cell surface receptor signaling pathway FZD3
GO:0007169 transmembrane receptor protein tyrosine kinase signaling
pathway
MTSS1
GO:0044332 Wnt signaling pathway involved in dorsal/ventral axis
specification
LRP6
GO:2000051 negative regulation of non-canonical Wnt signaling pathway LRP6
GO:0090244 Wnt signaling pathway involved in somitogenesis LRP6
GO:0030522 intracellular receptor signaling pathway NR2F2
GO:0007199 G-protein coupled receptor signaling pathway coupled to
cGMP nucleotide second messenger
FZD3
GO:0007219 Notch signaling pathway CDK8
GO:0030514 negative regulation of BMP signaling pathway TRIM33
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Table 5.4 continued...
GOID GOBPTerm regulated by E2F2 (A) and EGR1 (B) Gene Symbol (C)
in the identified
FFLs
GO:0034166 toll-like receptor 10 signaling pathway TAB2
GO:0034146 toll-like receptor 5 signaling pathway TAB2
GO:0038123 toll-like receptor TLR1:TLR2 signaling pathway TAB2
GO:0038124 toll-like receptor TLR6:TLR2 signaling pathway TAB2
GO:0034162 toll-like receptor 9 signaling pathway TAB2
GO:0035666 TRIF-dependent toll-like receptor signaling pathway TAB2
GO:0034134 toll-like receptor 2 signaling pathway TAB2
GO:0002756 MyD88-independent toll-like receptor signaling pathway TAB2
GO:0034138 toll-like receptor 3 signaling pathway TAB2
GO:0002755 MyD88-dependent toll-like receptor signaling pathway TAB2
GO:0034142 toll-like receptor 4 signaling pathway TAB2
GO:0002224 toll-like receptor signaling pathway TAB2
GO:0048011 neurotrophin TRK receptor signaling pathway FGFR1
GO:0007179 transforming growth factor beta receptor signaling pathway NLK
GO:0008286 insulin receptor signaling pathway FGFR1
GO:0035607 fibroblast growth factor receptor signaling pathway involved
in orbitofrontal cortex development
FGFR1
GO:0038028 insulin receptor signaling pathway via phosphatidylinositol
3-kinase
PIK3CA
GO:0007166 cell surface receptor signaling pathway IL13RA1
GO:0030178 negative regulation of Wnt signaling pathway NLK
GO:0090244 Wnt signaling pathway involved in somitogenesis PPP2R3A
GO:0030522 intracellular receptor signaling pathway NR2F2
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Table 5.4 continued...
GOID GOBPTerm regulated by E2F2 (A) and EGR1 (B) Gene Symbol (C)
in the identified
FFLs
GO:0008543 fibroblast growth factor receptor signaling pathway FGFR1
GO:2000124 regulation of endocannabinoid signaling pathway MGLL
GO:0097191 extrinsic apoptotic signaling pathway SMAD3
GO:2001244 positive regulation of intrinsic apoptotic signaling pathway BCLAF1
GO:0030521 androgen receptor signaling pathway MED14
GO:0042921 glucocorticoid receptor signaling pathway ARID1A
GO:0007173 epidermal growth factor receptor signaling pathway FGFR1
GO:0070104 negative regulation of interleukin-6-mediated signaling
pathway
PTPN2
GO:0030518 intracellular steroid hormone receptor signaling pathway MED14
GO:0038095 Fc-epsilon receptor signaling pathway FGFR1
GO:0017015 regulation of transforming growth factor beta receptor
signaling pathway
LTBP4
GO:0030520 intracellular estrogen receptor signaling pathway ARID1A
GO:0010754 negative regulation of cGMP-mediated signaling THBS1
GO:0060520 activation of prostate induction by androgen receptor
signaling pathway
AR
GO:1902206 negative regulation of interleukin-2-mediated signaling
pathway
PTPN2
GO:1902212 negative regulation of prolactin signaling pathway PTPN2
GO:1902215 negative regulation of interleukin-4-mediated signaling
pathway
PTPN2
GO:1902227 negative regulation of macrophage colony-stimulating factor
signaling pathway
PTPN2
GO:0010804 negative regulation of tumor necrosis factor-mediated
signaling pathway
RFFL
GO:0033148 positive regulation of intracellular estrogen receptor signaling
pathway
AR
GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand BCL2L11





GOID GOBPTerm regulated by E2F2 (A) and GATA3 (B) Gene Symbol (C)
in the identified
FFLs
GO:0007196 adenylate cyclase-inhibiting G-protein coupled glutamate
receptor signaling pathway
GRM8
GO:0035607 fibroblast growth factor receptor signaling pathway involved
in orbitofrontal cortex development
FGFR1
GO:0030178 negative regulation of Wnt signaling pathway NLK
GO:0030522 intracellular receptor signaling pathway NR2F2
GO:0035425 autocrine signaling FZD1
GO:0044338 canonical Wnt signaling pathway involved in mesenchymal
stem cell differentiation
FZD1
GO:0044339 canonical Wnt signaling pathway involved in osteoblast
differentiation
FZD1
GO:0040036 regulation of fibroblast growth factor receptor signaling
pathway
FAM20C
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling C3orf58
GO:0030520 intracellular estrogen receptor signaling pathway RARA
GO:0010754 negative regulation of cGMP-mediated signaling THBS1
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Table 5.4 continued...
GOID GOBPTerm regulated by E2F2 (A) and HIF1A (B) Gene Symbol (C)
in the identified
FFLs
GO:0035358 regulation of peroxisome proliferator activated receptor
signaling pathway
SIRT1
GO:0007178 transmembrane receptor protein serine/threonine kinase
signaling pathway
TRPS1
GO:0048011 neurotrophin TRK receptor signaling pathway TIAM1
GO:0007179 transforming growth factor beta receptor signaling pathway CDK8
GO:0061314 Notch signaling involved in heart development JAG1
GO:0021874 Wnt signaling pathway involved in forebrain neuroblast
division
LRP6
GO:0061310 canonical Wnt signaling pathway involved in cardiac neural
crest cell differentiation involved in heart development
LRP6
GO:1901189 positive regulation of ephrin receptor signaling pathway RBPJ
GO:2000055 positive regulation of Wnt signaling pathway involved in
dorsal/ventral axis specification
LRP6
GO:0044335 canonical Wnt signaling pathway involved in neural crest cell
differentiation
LRP6
GO:0061324 canonical Wnt signaling pathway involved in positive
regulation of cardiac outflow tract cell proliferation
LRP6
GO:0044340 canonical Wnt signaling pathway involved in regulation of
cell proliferation
LRP6
GO:0060070 canonical Wnt signaling pathway TCF7L1
GO:0007166 cell surface receptor signaling pathway FZD1
GO:0030178 negative regulation of Wnt signaling pathway LRP6
GO:0007169 transmembrane receptor protein tyrosine kinase signaling
pathway
MTSS1
GO:0016055 Wnt signaling pathway RTF1
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Table 5.4 continued...
GOID GOBPTerm regulated by E2F2 (A) and HIF1A (B) Gene Symbol (C)
in the identified
FFLs
GO:0044332 Wnt signaling pathway involved in dorsal/ventral axis
specification
LRP6
GO:2000051 negative regulation of non-canonical Wnt signaling pathway LRP6
GO:0090244 Wnt signaling pathway involved in somitogenesis LRP6
GO:0030522 intracellular receptor signaling pathway NR2F2
GO:0030509 BMP signaling pathway EGR1
GO:0035425 autocrine signaling FZD1
GO:0044338 canonical Wnt signaling pathway involved in mesenchymal
stem cell differentiation
FZD1
GO:0044339 canonical Wnt signaling pathway involved in osteoblast
differentiation
FZD1
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling C3orf58
GO:0035872 nucleotide-binding domain, leucine rich repeat containing
receptor signaling pathway
TAB2
GO:2001244 positive regulation of intrinsic apoptotic signaling pathway BCL2L11
GO:0007223 Wnt signaling pathway, calcium modulating pathway FZD1
GO:0007199 G-protein coupled receptor signaling pathway coupled to
cGMP nucleotide second messenger
FZD1
GO:0007219 Notch signaling pathway CDK8
GO:0030514 negative regulation of BMP signaling pathway FZD1
GO:1900740 positive regulation of protein insertion into mitochondrial
membrane involved in apoptotic signaling pathway
BCL2L11
GO:0030520 intracellular estrogen receptor signaling pathway RBFOX2
GO:0032933 SREBP signaling pathway INSIG1
GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand FOXO3
GO:0019221 cytokine-mediated signaling pathway NUP188
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Table 5.4 continued...
GOID GOBPTerm regulated by E2F2 (A) and MAX (B) Gene Symbol (C)
in the identified
FFLs
GO:0007179 transforming growth factor beta receptor signaling pathway NLK
GO:0021874 Wnt signaling pathway involved in forebrain neuroblast
division
LRP6
GO:0061310 canonical Wnt signaling pathway involved in cardiac neural
crest cell differentiation involved in heart development
LRP6
GO:2000055 positive regulation of Wnt signaling pathway involved in
dorsal/ventral axis specification
LRP6
GO:0044335 canonical Wnt signaling pathway involved in neural crest cell
differentiation
LRP6
GO:0061324 canonical Wnt signaling pathway involved in positive
regulation of cardiac outflow tract cell proliferation
LRP6
GO:0044340 canonical Wnt signaling pathway involved in regulation of
cell proliferation
LRP6
GO:0016055 Wnt signaling pathway NLK
GO:2000124 regulation of endocannabinoid signaling pathway MGLL
GO:0007219 Notch signaling pathway CDK8
GO:0038027 apolipoprotein A-I-mediated signaling pathway ABCA1
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Table 5.4 continued...
GOID GOBPTerm regulated by E2F2 (A) and MYB/ MYBL1 (B) Gene Symbol (C)
in the identified
FFLs
GO:0007196 adenylate cyclase-inhibiting G-protein coupled glutamate
receptor signaling pathway
GRM8
GO:0035358 regulation of peroxisome proliferator activated receptor
signaling pathway
SIRT1
GO:0048011 neurotrophin TRK receptor signaling pathway BRAF
GO:0007179 transforming growth factor beta receptor signaling pathway NLK
GO:0097190 apoptotic signaling pathway FASTK
GO:2001234 negative regulation of apoptotic signaling pathway PCGF2
GO:0021874 Wnt signaling pathway involved in forebrain neuroblast
division
LRP6
GO:0061310 canonical Wnt signaling pathway involved in cardiac neural
crest cell differentiation involved in heart development
LRP6
GO:2000055 positive regulation of Wnt signaling pathway involved in
dorsal/ventral axis specification
LRP6
GO:0044335 canonical Wnt signaling pathway involved in neural crest cell
differentiation
LRP6
GO:0061324 canonical Wnt signaling pathway involved in positive
regulation of cardiac outflow tract cell proliferation
LRP6
GO:0030111 regulation of Wnt signaling pathway LEF1
GO:0030178 negative regulation of Wnt signaling pathway LZTS2
GO:0016055 Wnt signaling pathway LZTS2
GO:0030522 intracellular receptor signaling pathway NR2F2
GO:2000124 regulation of endocannabinoid signaling pathway MGLL
GO:0097191 extrinsic apoptotic signaling pathway SMAD3
GO:0038096 Fc-gamma receptor signaling pathway involved in
phagocytosis
NCK1
GO:0035872 nucleotide-binding domain, leucine rich repeat containing
receptor signaling pathway
TAB3
GO:0097193 intrinsic apoptotic signaling pathway YWHAQ
GO:0070423 nucleotide-binding oligomerization domain containing
signaling pathway
TAB3
GO:0030521 androgen receptor signaling pathway UBE3A
GO:0042921 glucocorticoid receptor signaling pathway NR3C1
GO:1900740 positive regulation of protein insertion into mitochondrial
membrane involved in apoptotic signaling pathway
YWHAQ
GO:0035329 hippo signaling STK3
GO:0030520 intracellular estrogen receptor signaling pathway ARID1A
GO:0038027 apolipoprotein A-I-mediated signaling pathway ABCA1
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Table 5.4 continued...
GOID GOBPTerm regulated by E2F2 (A) and NFYB/ NFYC (B) Gene Symbol (C)
in the identified
FFLs
GO:0034166 toll-like receptor 10 signaling pathway NFKB2
GO:0034146 toll-like receptor 5 signaling pathway NFKB2
GO:0038123 toll-like receptor TLR1:TLR2 signaling pathway NFKB2
GO:0038124 toll-like receptor TLR6:TLR2 signaling pathway NFKB2
GO:0034162 toll-like receptor 9 signaling pathway NFKB2
GO:0035666 TRIF-dependent toll-like receptor signaling pathway NFKB2
GO:0034134 toll-like receptor 2 signaling pathway NFKB2
GO:0002756 MyD88-independent toll-like receptor signaling pathway NFKB2
GO:0048011 neurotrophin TRK receptor signaling pathway CASP2
GO:0097190 apoptotic signaling pathway CASP2
GO:0060070 canonical Wnt signaling pathway GSK3B
GO:0016055 Wnt signaling pathway GSK3B
GO:0038180 nerve growth factor signaling pathway SORT1
GO:0008543 fibroblast growth factor receptor signaling pathway GSK3B
GO:0038096 Fc-gamma receptor signaling pathway involved in
phagocytosis
WASF2
GO:0097193 intrinsic apoptotic signaling pathway BCL2L1
GO:2001244 positive regulation of intrinsic apoptotic signaling pathway SEPT4
GO:2001235 positive regulation of apoptotic signaling pathway CASP2
GO:0007219 Notch signaling pathway SEL1L
GO:0030949 positive regulation of vascular endothelial growth factor
receptor signaling pathway
HIF1A
GO:1901030 positive regulation of mitochondrial outer membrane
permeabilization involved in apoptotic signaling pathway
GSK3B
GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand CASP2
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Table 5.4 continued...
GOID GOBPTerm regulated by E2F2 (A) and PATZ1 (B) Gene Symbol (C)
in the identified
FFLs
GO:0007179 transforming growth factor beta receptor signaling pathway NLK
GO:0007166 cell surface receptor signaling pathway STC2
GO:0008543 fibroblast growth factor receptor signaling pathway FOXO3
GO:0007173 epidermal growth factor receptor signaling pathway REPS2
GO:0070104 negative regulation of interleukin-6-mediated signaling
pathway
PTPN2
GO:0038095 Fc-epsilon receptor signaling pathway FOXO3
GO:1902206 negative regulation of interleukin-2-mediated signaling
pathway
PTPN2
GO:1902212 negative regulation of prolactin signaling pathway PTPN2
GO:1902215 negative regulation of interleukin-4-mediated signaling
pathway
PTPN2
GO:1902227 negative regulation of macrophage colony-stimulating factor
signaling pathway
PTPN2




GOID GOBPTerm regulated by E2F2 (A) and RUNX1/ RUNX2 (B) Gene Symbol (C)
in the identified
FFLs
GO:0048011 neurotrophin TRK receptor signaling pathway PPP2R5D
GO:0007179 transforming growth factor beta receptor signaling pathway NLK
GO:0008286 insulin receptor signaling pathway PHIP
GO:0016055 Wnt signaling pathway NLK
GO:0008543 fibroblast growth factor receptor signaling pathway YWHAB
GO:1900740 positive regulation of protein insertion into mitochondrial
membrane involved in apoptotic signaling pathway
YWHAE
GO:0035329 hippo signaling YWHAE
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Table 5.4 continued...
GOID GOBPTerm regulated by E2F2 (A) and SP1/ SP3 (B) Gene Symbol (C)
in the identified
FFLs
GO:0034166 toll-like receptor 10 signaling pathway TAB2
GO:0034146 toll-like receptor 5 signaling pathway TAB2
GO:0035666 TRIF-dependent toll-like receptor signaling pathway TAB2
GO:0002756 MyD88-independent toll-like receptor signaling pathway TAB2
GO:0034138 toll-like receptor 3 signaling pathway TAB2
GO:0034142 toll-like receptor 4 signaling pathway TAB2
GO:0007178 transmembrane receptor protein serine/threonine kinase
signaling pathway
TRPS1
GO:0048011 neurotrophin TRK receptor signaling pathway FRS2
GO:0007179 transforming growth factor beta receptor signaling pathway SMAD2
GO:0097190 apoptotic signaling pathway FASTK
GO:2001234 negative regulation of apoptotic signaling pathway PCGF2
GO:0043401 steroid hormone mediated signaling pathway BMP7
GO:0021874 Wnt signaling pathway involved in forebrain neuroblast
division
LRP6
GO:0061310 canonical Wnt signaling pathway involved in cardiac neural
crest cell differentiation involved in heart development
LRP6
GO:2000055 positive regulation of Wnt signaling pathway involved in
dorsal/ventral axis specification
LRP6
GO:0008286 insulin receptor signaling pathway FRS2
GO:0007206 phospholipase C-activating G-protein coupled glutamate
receptor signaling pathway
HOMER1
GO:0035607 fibroblast growth factor receptor signaling pathway involved
in orbitofrontal cortex development
FGFR1
GO:0044335 canonical Wnt signaling pathway involved in neural crest cell
differentiation
LRP6
GO:0061324 canonical Wnt signaling pathway involved in positive
regulation of cardiac outflow tract cell proliferation
LRP6
GO:0038028 insulin receptor signaling pathway via phosphatidylinositol
3-kinase
PIK3CA
GO:0044340 canonical Wnt signaling pathway involved in regulation of
cell proliferation
LRP6
GO:0030111 regulation of Wnt signaling pathway LEF1
GO:0007166 cell surface receptor signaling pathway STC2
GO:0030178 negative regulation of Wnt signaling pathway LZTS2
GO:0007169 transmembrane receptor protein tyrosine kinase signaling
pathway
FRS2
GO:0016055 Wnt signaling pathway RTF1
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Table 5.4 continued...
GOID GOBPTerm regulated by E2F2 (A) and SP1/ SP3 (B) Gene Symbol (C)
in the identified
FFLs
GO:0090244 Wnt signaling pathway involved in somitogenesis PPP2R3A
GO:0030522 intracellular receptor signaling pathway NR2F2
GO:0030509 BMP signaling pathway BMP7
GO:0008543 fibroblast growth factor receptor signaling pathway FRS2
GO:2000124 regulation of endocannabinoid signaling pathway MGLL
GO:0097191 extrinsic apoptotic signaling pathway SMAD3
GO:0040036 regulation of fibroblast growth factor receptor signaling
pathway
RUNX2
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling C3orf58
GO:0097193 intrinsic apoptotic signaling pathway XIAP
GO:0042921 glucocorticoid receptor signaling pathway ARID1A
GO:0007173 epidermal growth factor receptor signaling pathway FRS2
GO:0070104 negative regulation of interleukin-6-mediated signaling
pathway
PTPN2
GO:1900740 positive regulation of protein insertion into mitochondrial
membrane involved in apoptotic signaling pathway
BCL2L11
GO:0038095 Fc-epsilon receptor signaling pathway FRS2
GO:0070102 interleukin-6-mediated signaling pathway CTR9
GO:0035329 hippo signaling STK3
GO:0030520 intracellular estrogen receptor signaling pathway ARID1A
GO:0030949 positive regulation of vascular endothelial growth factor
receptor signaling pathway
VEGFA
GO:0001960 negative regulation of cytokine-mediated signaling pathway SIGIRR
GO:0010754 negative regulation of cGMP-mediated signaling THBS1
GO:0038190 VEGF-activated neuropilin signaling pathway VEGFA
GO:0060520 activation of prostate induction by androgen receptor
signaling pathway
AR
GO:0070106 interleukin-27-mediated signaling pathway IL6ST
GO:1902206 negative regulation of interleukin-2-mediated signaling
pathway
PTPN2
GO:1902212 negative regulation of prolactin signaling pathway PTPN2
GO:1902215 negative regulation of interleukin-4-mediated signaling
pathway
PTPN2
GO:1902227 negative regulation of macrophage colony-stimulating factor
signaling pathway
PTPN2
GO:0010804 negative regulation of tumor necrosis factor-mediated
signaling pathway
RFFL
GO:0090037 positive regulation of protein kinase C signaling VEGFA
GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand FOXO3
GO:0097296 activation of cysteine-type endopeptidase activity involved in
apoptotic signaling pathway
SMAD3
GO:0019221 cytokine-mediated signaling pathway KPNB1
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Table 5.4 continued...
GOID GOBPTerm regulated by E2F2 (A) and STAT5B/ STAT6 (B) Gene Symbol (C)
in the identified
FFLs
GO:0007179 transforming growth factor beta receptor signaling pathway NLK
GO:0021874 Wnt signaling pathway involved in forebrain neuroblast
division
LRP6
GO:0061310 canonical Wnt signaling pathway involved in cardiac neural
crest cell differentiation involved in heart development
LRP6
GO:2000055 positive regulation of Wnt signaling pathway involved in
dorsal/ventral axis specification
LRP6
GO:0044335 canonical Wnt signaling pathway involved in neural crest cell
differentiation
LRP6
GO:0061324 canonical Wnt signaling pathway involved in positive
regulation of cardiac outflow tract cell proliferation
LRP6
GO:0044340 canonical Wnt signaling pathway involved in regulation of
cell proliferation
LRP6
GO:0044332 Wnt signaling pathway involved in dorsal/ventral axis
specification
LRP6
GO:2000051 negative regulation of non-canonical Wnt signaling pathway LRP6
GO:0090244 Wnt signaling pathway involved in somitogenesis LRP6
GO:2001244 positive regulation of intrinsic apoptotic signaling pathway SEPT4
GO:0070104 negative regulation of interleukin-6-mediated signaling
pathway
IL6ST
GO:0070102 interleukin-6-mediated signaling pathway IL6ST
GO:0070106 interleukin-27-mediated signaling pathway IL6ST
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Table 5.4 continued...
GOID GOBPTerm regulated by E2F2 (A) and TEAD1/ TEAD2 (B) Gene Symbol (C)
in the identified
FFLs
GO:0034166 toll-like receptor 10 signaling pathway TAB2
GO:0034146 toll-like receptor 5 signaling pathway TAB2
GO:0048011 neurotrophin TRK receptor signaling pathway FGFR1
GO:0007179 transforming growth factor beta receptor signaling pathway NLK
GO:0061314 Notch signaling involved in heart development JAG1
GO:0008286 insulin receptor signaling pathway FGFR1
GO:0035607 fibroblast growth factor receptor signaling pathway involved
in orbitofrontal cortex development
FGFR1
GO:0038028 insulin receptor signaling pathway via phosphatidylinositol
3-kinase
PIK3CA
GO:0090038 negative regulation of protein kinase C signaling GPD1L
GO:0060070 canonical Wnt signaling pathway LEF1
GO:0030111 regulation of Wnt signaling pathway LEF1
GO:0016055 Wnt signaling pathway NLK
GO:0030522 intracellular receptor signaling pathway NR2F2
GO:0030509 BMP signaling pathway LEF1
GO:0008543 fibroblast growth factor receptor signaling pathway FGFR1
GO:2000124 regulation of endocannabinoid signaling pathway MGLL
GO:0040036 regulation of fibroblast growth factor receptor signaling
pathway
RUNX2
GO:0007219 Notch signaling pathway MIB1
GO:0030521 androgen receptor signaling pathway ARID1A
GO:0007173 epidermal growth factor receptor signaling pathway FGFR1
GO:0038095 Fc-epsilon receptor signaling pathway FGFR1
GO:0017015 regulation of transforming growth factor beta receptor
signaling pathway
LTBP4
GO:0030520 intracellular estrogen receptor signaling pathway ARID1A
GO:0010754 negative regulation of cGMP-mediated signaling THBS1
GO:0035723 interleukin-15-mediated signaling pathway PLCB1
GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand FOXO3
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Table 5.4 continued...





GO:0034166 toll-like receptor 10 signaling pathway TAB2
GO:0034146 toll-like receptor 5 signaling pathway TAB2
GO:0007196 adenylate cyclase-inhibiting G-protein coupled glutamate
receptor signaling pathway
GRM8
GO:0035358 regulation of peroxisome proliferator activated receptor
signaling pathway
SIRT1
GO:0048011 neurotrophin TRK receptor signaling pathway TIAM1
GO:0007179 transforming growth factor beta receptor signaling pathway NLK
GO:0097190 apoptotic signaling pathway TIAM1
GO:2001269 positive regulation of cysteine-type endopeptidase activity
involved in apoptotic signaling pathway
TFAP4
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling TAB2
GO:0021874 Wnt signaling pathway involved in forebrain neuroblast
division
LRP6
GO:0061310 canonical Wnt signaling pathway involved in cardiac neural
crest cell differentiation involved in heart development
LRP6
GO:2000055 positive regulation of Wnt signaling pathway involved in
dorsal/ventral axis specification
LRP6
GO:0008286 insulin receptor signaling pathway FRS2
GO:0035607 fibroblast growth factor receptor signaling pathway involved
in orbitofrontal cortex development
FGFR1
GO:0044335 canonical Wnt signaling pathway involved in neural crest cell
differentiation
LRP6
GO:0061324 canonical Wnt signaling pathway involved in positive
regulation of cardiac outflow tract cell proliferation
LRP6
GO:0038028 insulin receptor signaling pathway via phosphatidylinositol
3-kinase
PIK3CA
GO:0061290 canonical Wnt signaling pathway involved in metanephric
kidney development
GATA3
GO:0060070 canonical Wnt signaling pathway KDM6A
GO:0030111 regulation of Wnt signaling pathway SENP2
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Table 5.4 continued...





GO:0007166 cell surface receptor signaling pathway IL13RA1
GO:0007169 transmembrane receptor protein tyrosine kinase signaling
pathway
FRS2
GO:0016055 Wnt signaling pathway LZTS2
GO:0030522 intracellular receptor signaling pathway NR2F2
GO:0008543 fibroblast growth factor receptor signaling pathway FRS2
GO:0071526 semaphorin-plexin signaling pathway SEMA4C
GO:2000124 regulation of endocannabinoid signaling pathway MGLL
GO:0097191 extrinsic apoptotic signaling pathway SMAD3
GO:0040036 regulation of fibroblast growth factor receptor signaling
pathway
RUNX2
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling C3orf58
GO:1902285 semaphorin-plexin signaling pathway involved in neuron
projection guidance
SEMA3F
GO:0035872 nucleotide-binding domain, leucine rich repeat containing
receptor signaling pathway
TAB2
GO:0097193 intrinsic apoptotic signaling pathway XIAP
GO:2001244 positive regulation of intrinsic apoptotic signaling pathway BCLAF1
GO:0007219 Notch signaling pathway MIB1
GO:0030521 androgen receptor signaling pathway UBE3A
GO:0042058 regulation of epidermal growth factor receptor signaling
pathway
RHBDF1
GO:0007173 epidermal growth factor receptor signaling pathway FRS2
GO:1900740 positive regulation of protein insertion into mitochondrial
membrane involved in apoptotic signaling pathway
YWHAQ
GO:0038095 Fc-epsilon receptor signaling pathway FRS2
GO:0017015 regulation of transforming growth factor beta receptor
signaling pathway
LTBP4
GO:0035329 hippo signaling TEAD2
GO:0007249 I-kappaB kinase/NF-kappaB signaling TAB2
GO:0030520 intracellular estrogen receptor signaling pathway ARID1A
GO:0030949 positive regulation of vascular endothelial growth factor
receptor signaling pathway
VEGFA
GO:0030512 negative regulation of transforming growth factor beta
receptor signaling pathway
SMAD3
GO:0038190 VEGF-activated neuropilin signaling pathway VEGFA
GO:0060520 activation of prostate induction by androgen receptor
signaling pathway
AR
GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand FOXO3





GOID GOBPTerm regulated by E2F2 (A) and USF2 (B) Gene Symbol (C)
in the identified
FFLs
GO:0007179 transforming growth factor beta receptor signaling pathway NLK
GO:0021874 Wnt signaling pathway involved in forebrain neuroblast
division
LRP6
GO:0061310 canonical Wnt signaling pathway involved in cardiac neural
crest cell differentiation involved in heart development
LRP6
GO:2000055 positive regulation of Wnt signaling pathway involved in
dorsal/ventral axis specification
LRP6
GO:0044335 canonical Wnt signaling pathway involved in neural crest cell
differentiation
LRP6
GO:0061324 canonical Wnt signaling pathway involved in positive
regulation of cardiac outflow tract cell proliferation
LRP6
GO:0044340 canonical Wnt signaling pathway involved in regulation of
cell proliferation
LRP6
GO:0016055 Wnt signaling pathway NLK
GO:2000124 regulation of endocannabinoid signaling pathway MGLL
GO:0007219 Notch signaling pathway CDK8
GO:0030949 positive regulation of vascular endothelial growth factor
receptor signaling pathway
HIF1A
GO:0038027 apolipoprotein A-I-mediated signaling pathway ABCA1
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6 Unraveling Potential Signaling Pathways
During the Exposure of Several Tissues to
Different Toxicants in Different Species
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6.1 Introduction
Maintaining proper cellular functions usually requires the crosstalk between several sig-
naling pathways. Several toxic agents may impinge on such signaling pathways in a dose-
dependent manner which in turn alters the activities of the signaling pathways and triggers
the activation or inhibition of cellular apoptosis [1]. Studying toxicology may provide in-
sights into the effects of several toxicants on living organisms. Advancement of microarray
technology over the last decade not only provides ample opportunity to measure the gene
expression over a set of time points during the exposure of tissues to certain chemical sub-
stances such as naphthalene, 1,2,3-trichloropropane etc. but also facilitates to monitor the
gene expression changes over a set of doses of a particular toxicant. Furthermore, these
substances may be potential in causing cancer and work in a dose-dependent manner. Ex-
ploratory analysis, such as gene co-expression studies, may help us to elucidate the relevant
signaling pathways perturbed by those substances. In this chapter, we have applied the
proposed triclustering algorithm EMOA-δ-TRIMAX [2] to four microarray gene expression
datasets to reveal the signaling pathways which may be perturbed by the toxicants either
over different time points or at different dosages.
6.2 Materials and Methods
6.2.1 Dataset 1
In the study of J.C. Snyder et al. and A.C. Zemke et al. [3, 4], experiments were carried
out to investigate the role of imperfect epithelial repair in extracellular matrix (ECM)
displacement and causing pulmonary fibrosis. Expression profiles of 18675 probe ids were
measured over 5 time points (control, Days 1, 2, 3 and 6) and 4 replicates during the
exposure of mouse lung tissue to naphthalene (GSE17693) [3, 4].
6.2.2 Dataset 2
Expression profiles of 45101 probe ids were monitored across 4 replicates during the ex-
posure of female mouse lung tumor cell to the air and naphthalene toxicant with different
doses (0.5, 3, 10, 20 and 30 parts per million (ppm)) to unveil potential biomarkers involved
in causing lung cancer (GSE17993) [5].
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Figure 6.1: Workflow applied in this work.
6.2.3 Dataset 3
Expression profiles of 45101 probe ids were monitored across 4 replicates during the expo-
sure of female mouse liver tumor cell to distilled water, air, naphthalene (0.5, 3, 10, 20 and
30 ppm) and 1,2,3-trichloropropane (2, 6, 20, 40 and 60 mg/kg) substances with different
doses to unveil potential biomarkers involved in causing hepatic cancer (GSE18858) [6].
6.2.4 Dataset 4
To infer the role of matrix metalloproteinase 7 (MMP7) in diminishing ciliogenesis during
wound repair, expression profiles of 45101 probe ids were measured over 4 replicates using
MMP7-null and wild type mice exposed to naphthalene (GSE38513) [7].
6.2.5 Workflow
Figure 6.1 shows the workflow used in this chapter.
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6.3 Results and Discussion
Table 6.1 shows the values assigned to the input parameters of EMOA-δ-TRIMAX algo-
rithm for each of the datasets used in this chapter.
Table 6.1: Values of input parameters of EMOA-δ-TRIMAX algorithm.




Dataset 1 1.2 0.063 100 100
Dataset 2 1.2 0.00253 100 100
Dataset 3 1.2 110.216 100 100
Dataset 4 1.2 0.0041 100 100
We have used the minSum metric delineated in chapter 2 to examine whether solutions
converge towards the Pareto optimal front around its center region. From Figure 6.2,
we can see the convergence of solutions towards the Pareto optimal front for each of the
aforementioned datasets. For instance, for dataset 1 and 2 the solutions converge after
78th generation, whereas in case of dataset 3, the convergence of the solutions occurs after
30th generation.
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Figure 6.2: Convergence of solutions towards the Pareto optimal front. minSum values
are plotted for dataset 1 (a), dataset 2 (b), dataset 3 (c) and dataset 4 (d)
6.3.1 Results on Dataset 1
From Tables 6.3-6.4 (see Appendix), we can see the list of signaling pathways that are
triggered by naphthalene at different stages of the treatment. Moreover, the activation
of ERBB, epidermal growth factor receptor signaling, unfolded protein response signaling
protein, Fc-receptor mediated signaling, endoplasmic reticulum (ER) to nucleus signaling,
corticosteroid receptor signaling, glucocorticoid receptor signaling, NF-kappaB signaling,
arginine metabolism, thromboxane A2 signaling, neurotrophin signaling, PPAR signaling,
Wnt signaling, sphingosine-1-phosphate signaling, JAK-STAT pathway, Notch signaling
have been inferred to be associated with pulmonary fibrosis, supported by previously pub-
lished evidences [8–23]. Moreover, the co-occurrence of diseases such as pulmonary fibrosis,
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diabetes mellitus, Vibrio cholerae infection, acute myeloid leukemia, Alzheimers disease
have also been established by previous studies [24–27]. Furthermore, type I interferon and
MDA-5 signaling both jointly play crucial roles in the context of pulmonary fibrosis [28].
In addition to the aforementioned signaling pathways, finding the inhibition of BMP, ac-
tivin receptor and protein kinase C signaling pathways is not astonishing to us as deletion
of these pathways may trigger the pulmonary fibrosis [29–31]. From Figure 6.3a, we can
see that those that start early, which are most of the triggered pathways (41%), persist
for at least 3 days, additional 30% persist for the whole period of exposure to the toxic
substance. Among the very late ones (activated on days 3-6) are those that are specific for
lung cancer (either small-cell or non-small cell lung cancer) and several other cancer types.
From Figure 6.3b, we can obtain the similar trend i.e. 58% of the triggered pathways start
early and persist for at least 3 days, whereas additional 12% persist for the whole period
of exposure to the toxic substance. Additional 3% of the triggered pathways are found to
persist on days 3-6 and these pathways include somatostatin receptor, insulin-like growth
factor receptor signaling which were also inferred to be associated with the pulmonary
fibrosis in previous studies [32,33].
Furthermore, to investigated whether there is a overlap between the pathways found to
be significant for the up- and down-regulated genes, we have computed Jaccard similar-
ity coefficient which is 0.14 in case of this dataset. This overlap is due to the molecules
constituting it.
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Figure 6.3: Venn diagram showing the overlap between the lists of pathways found to be
perturbed for over- (a.) and under (b.)-expressed genes across different days of
cellular exposure to naphthalene (NPTH) for dataset 1.
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6.3.2 Results on Dataset 2
From Table 6.5 and Table 6.6 (see Appendix), we can see that estrogen receptor plays an
important role in driving the growth of lung tumor through stimulating steroid hormone
receptor signaling; this fact has already been established by a previous study [34]. More-
over, from the lists of signaling pathways, we can observe the inverse relationships between
ERBB signaling and estrogen receptor signaling and this finding was also supported by
a previous study [35, 36]. Our results also indicate that Shigellosis, renal cell carcinoma,
depression are known to co-occur with lung cancer [37–39]. Furthermore, insulin receptor
signaling, mTOR signaling, lipopolysaccharide-mediated signaling, GnRH signaling, He-
licobacter pylori infection, roundabout signaling, apoptotic signaling, natural killer cell,
calcium signaling, gamma-aminobutyric acid signaling have already been inferred to play
crucial roles in driving lung tumor growth [40–50]. Moreover, finding the involvement
of the genes expressed at lower levels in purinergic receptor signaling, may indicate the
fact that dysregulation of purinergic signaling may be associated with the risk for lung
infection [51]. Figure 6.4a shows that most of the triggered pathways (45%) are found to
be perturbed by the two lowest doses of naphthalene, whereas additional 10% pathways
are found to be activated by each of the doses of the toxic substance. Additional 16% of
the pathways are perturbed by the three highest doses of the toxicant. Moreover, it is of
interest to see that additional 4%, 3% and 8% pathways are perturbed by the two lowest
doses and the highest dose of the toxic substance, respectively. From Figure 6.4b, we can
see that 34% of the triggered pathways are found to be activated by the two lowest doses
of naphthalene, whereas additional 8% pathways are found to be perturbed by the two
highest doses only. Additional 6% pathways are found to be perturbed by all doses of the
toxic substance, whereas additional 14% of the triggered pathways are activated by the
three highest doses of naphthalene. Furthermore, this figure also indicates the fact that
perturbation of the pathways may occur in a dose-dependent manner as additional 9%, 5%
and 8% pathways are uniquely activated by the two lowest doses and the highest dose of
naphthalene, respectively.
Furthermore, to investigated whether there is a overlap between the pathways found to
be significant for the up- and down-regulated genes, we have computed Jaccard similar-
ity coefficient which is 0.40 in case of this dataset. This overlap is due to the molecules
constituting it.
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Figure 6.4: Venn diagram showing the overlap between the lists of pathways found to be
perturbed for over- (a.) and under (b.)-expressed genes at different doses of
naphthalene (NPTH) for dataset 2.
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6.3.3 Results on Dataset 3
From Tables 6.7-6.8 (see Appendix), we can observe the inhibition of transforming growth
factor beta receptor signaling and this finding may indicate the fact that hormone-mediated
signaling play crucial roles in liver cancer growth as TGF-beta signaling was inferred to be
a suppressor in hormone-induced cancers [52]. Co-enrichment of PPAR signaling and fatty
acid metabolism is also biologically meaningful as PPAR is known to trigger the fatty acid
catabolism in the context of liver cancer [53]. Moreover, adiponectin and porphyrin were
inferred to be major players in governing the liver tumor growth [54, 55]. Figures 6.5-6.6
show the overlap between the lists of pathways found to be activated by two toxic sub-
stances namely, naphthalene and 1,2,3-trichloropropane (TCPN), respectively. Figures 6.5a
and 6.6a show that 18% and 30% of the triggered pathways are perturbed by all doses of
naphthalene and 1,2,3-trichloropropane, respectively. Moreover, from Figure 6.5a, we can
see that 4% of the triggered pathways are activated by the four highest doses of naphtha-
lene, whereas additional 9% pathways are perturbed by the first four doses of the toxic
substance. From figure 6.5a it becomes apparent that naphthalene activates the pathways
in a dose-dependent manner as additional 7%, 1%, 3% and 6% pathways are found to be
perturbed by the first three doses and the highest dose of naphthalene, respectively. From
Figure 6.5b, we can observe that most of the triggered pathways (36%) are activated by all
doses of naphthalene, whereas additional 21 % pathways are found to be perturbed by the
first and last three doses of the toxic substance. Another 4% pathways pathways are found
to be perturbed by the last four doses of naphthalene, whereas additional 5% pathways
are activated by the first four doses of the toxic substance. Furthermore, additional 2%,
2%, 1% and 2% pathways are found to be unique at 0.5, 3, 10 and 30 parts per million
of naphthalene, respectively. Besides, from Figure 6.6a, we can see that 8% pathways are
triggered by the three highest doses of TCPN, whereas another 6% pathways persist at the
two lowest doses of the toxic substance. Additional 6% of the triggered pathways persist
at the two highest doses of TCPN, whereas another 1% and 6% pathways are found to
be unique at 2 and 60 mg/kg of 1,2,3-trichloropropane, respectively. From figure 6.6b, it
becomes apparent that most of the triggered pathways persist at all doses of TCPN, ad-
ditional 20% pathways persist only the two lowest doses of the toxic substance. Moreover,
another 9% pathways are found to be triggered by the three highest doses, whereas addi-
tional 4% pathways persist at the first four doses of TCPN. Furthermore, additional 1%
pathways are found to be unique at 6 and 20mg/kg of 1,2,3-trichloropropane. Altogether,
from figures 6.5-6.6, it becomes apparent that the pathways are perturbed by naphthalene
177
and 1,2,3-trichloropropane in a dose-dependent manner.
Additionally, Figure 6.7 shows to what extent the pathways activated by the toxic sub-
stances namely, naphthalene and 1,2,3-trichloropropane overlap or differ. From this figure,
we can conclude the fact that there is a large overlap between the pathways perturbed
by these two toxic substances in case of both the up- and down-regulated genes (Jaccard
similarity coefficient is 0.81 and 0.58, respectively).
Furthermore, to investigated whether there is a overlap between the pathways found to
be significant for the up- and down-regulated genes, we have computed Jaccard similar-
ity coefficient which is 0.46 in case of this dataset. This overlap is due to the molecules
constituting it.
6.3.4 Results on Dataset 4
The aim of generating this data was to unveil the role of matrix metalloproteinase 7
(MMP7) in injured airway epithelial cells. Overexpression of MMP7 may facilitate profi-
brotic effects in pulmonary fibrosis by enhancing wound healing and tissue inflammation,
whereas diminishing its expression may result in differentiation of ciliated cells in the ep-
ithelial barrier [7]. Tables 6.9-6.10 (see Appendix) indicate that the involvement of insulin
receptor signaling, G-protein coupled receptor signaling, adrenergic receptor signaling,
TGF-beta signaling induced by a bile compound, lipopolysaccharide-mediated signaling
(LPS), protein kinase A signaling in both matrix metalloproteinase 7 (MMP7)-null and
wild type mice injured airway epithelial cells. Each of these aforementioned pathways have
been reported to be associated with injured airway epithelial cells [56–62]. Furthermore,
it is of interest to see the pathways such as thyroid hormone mediated signaling, androgen
receptor signaling, vitamin D receptor signaling, estrogen receptor signaling, oncostatin-M-
mediated signaling, purine metabolism are coming up in the MMP7-null mice only in case
of the up-regulated genes as these signaling pathways were inferred to exhibit anti-fibrotic
or anti-inflammatory activities by the previously published literatures [63–68].
Furthermore, to investigated whether there is a overlap between the pathways found to
be significant for the up- and down-regulated genes, we have computed Jaccard similarity
coefficient which is 0 in case of this dataset.
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Figure 6.5: Venn diagram showing the overlap between the lists of pathways found to be
perturbed for over- (a.) and under (b.)-expressed genes at different doses of
naphthalene (NPTH) for dataset 3.
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Figure 6.6: Venn diagram showing the overlap between the lists of pathways found to be
perturbed for over- (a.) and under (b.)-expressed genes at different doses of
1,2,3-trichloropropane (TCPN) for dataset 3.
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Figure 6.7: Venn diagram showing the overlap between the lists of pathways found to be
perturbed for over- (a.) and under (b.)-expressed genes by naphthalene and
1,2,3-trichloropropane for dataset 3.
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Tables 6.11-6.12 (see Appendix) provide a comprehensive list of pathways that are found
to be perturbed by several chemical substances in case of all datasets. To further investigate
the degree of similarity and diversity between the lists of pathways for every pair of datasets,
we have computed the Jaccard similarity coefficient. From Table 6.2, we can observe a low
Jaccard similarity coefficient in case of each pair of the datasets and this is not too surprising
as the experimental backgrounds differ from each other either in terms of tissues or doses
of the toxicants used in the studies.
Table 6.2: Jaccard similarity coefficient (JSC) between the pathways found to be significant







Dataset 1 - Dataset 2 0.2125 0.2889
Dataset 1 - Dataset 3 0.213 0.2357
Dataset 1 - Dataset 4 0.0305 0.0728
Dataset 2 - Dataset 3 0.2664 0.3191
Dataset 2 - Dataset 4 0.0374 0.0372
Dataset 3 - Dataset 4 0.0469 0.0598
6.4 Conclusion
This chapter emphasizes the application of EMOA-δ-TRIMAX triclustering algorithm in
the analysis of 3D gene expression datasets which consist of expression profiles of thousands
of genes during the exposure of specific tissues to several toxicants either in a time- or dose
dependent manner in order to identify the signaling pathways triggered by the activation
of different toxicants. Our results indicate the lists of signaling pathways that can either
be activated or blocked by different toxicants in order to affect several tissues such as lung,
liver etc. Most the identified pathways have already been found to be associated with
diseases caused by toxicants by several studies over the last decade and hence, the others
need to be experimentally verified. Thus altogether, this chapter may provide new insights
into the mechanisms of inhalation toxicology.
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Table 6.3: Enriched pathways for over expressed genes for dataset 1. ”x” stands for ”found









apoptotic signaling pathway x x x x
regulation of apoptotic signaling pathway x x x x
intrinsic apoptotic signaling pathway in response to DNA damage x x x x
regulation of cytokine-mediated signaling pathway x x x x
adenosine receptor signaling pathway x x x
G-protein coupled purinergic receptor signaling pathway x x x
intrinsic apoptotic signaling pathway x x x x
positive regulation of I-kappaB kinase/NF-kappaB signaling x x x x
positive regulation of apoptotic signaling pathway x x x x
extrinsic apoptotic signaling pathway via death domain receptors x x x x
regulation of interferon-gamma-mediated signaling pathway x x x x
growth hormone receptor signaling pathway x x x x
intrinsic apoptotic signaling pathway by p53 class mediator x x x x
regulation of Fc receptor mediated stimulatory signaling pathway x x x x
ER-nucleus signaling pathway x x x x
JAK-STAT cascade involved in growth hormone signaling pathway x x x x
platelet-derived growth factor receptor-beta signaling pathway x x x
extrinsic apoptotic signaling pathway x x x x
regulation of intrinsic apoptotic signaling pathway x x x
negative regulation of intrinsic apoptotic signaling pathway x x x
negative regulation of cytokine-mediated signaling pathway x x x x
positive regulation of metanephric mesenchymal cell migration by platelet-derived
growth factor receptor-beta signaling pathway
x x x
regulation of metanephric mesenchymal cell migration by platelet-derived growth factor
receptor-beta signaling pathway
x x x
positive regulation of cysteine-type endopeptidase activity involved in apoptotic
signaling pathway
x x x
activation of signaling protein activity involved in unfolded protein response x x x x
negative regulation of protein kinase B signaling x x x
regulation of I-kappaB kinase/NF-kappaB signaling x x x
protein insertion into mitochondrial membrane involved in apoptotic signaling pathway x x x x
regulation of mitochondrial outer membrane permeabilization involved in apoptotic
signaling pathway
x x x
I-kappaB kinase/NF-kappaB signaling x x x
adenylate cyclase-activating dopamine receptor signaling pathway x x x x
regulation of protein insertion into mitochondrial membrane involved in apoptotic
signaling pathway
x x x x
positive regulation of protein insertion into mitochondrial membrane involved in
apoptotic signaling pathway
x x x x











MyD88-independent toll-like receptor signaling pathway x x x
toll-like receptor 3 signaling pathway x x x
positive regulation of intrinsic apoptotic signaling pathway x x x
cytokine-mediated signaling pathway x x x
interferon-gamma-mediated signaling pathway x x x
type I interferon signaling pathway x x x
Fc receptor mediated stimulatory signaling pathway x x x x
dopamine receptor signaling pathway x x x x
immune response-regulating cell surface receptor signaling pathway involved in
phagocytosis
x x x x
Fc-gamma receptor signaling pathway involved in phagocytosis x x x x
positive regulation of extrinsic apoptotic signaling pathway in absence of ligand x x x x
positive regulation of cytokine-mediated signaling pathway x x x
interleukin-4-mediated signaling pathway x x x
MDA-5 signaling pathway x x x x
positive regulation of mitochondrial outer membrane permeabilization involved in
apoptotic signaling pathway
x x x x
Fc-gamma receptor signaling pathway x x x x
toll-like receptor 4 signaling pathway x x x
toll-like receptor 2 signaling pathway x x x
regulation of BMP signaling pathway x x
negative regulation of BMP signaling pathway x x
BMP signaling pathway x x
regulation of transmembrane receptor protein serine/threonine kinase signaling pathway x x
negative regulation of transmembrane receptor protein serine/threonine kinase signaling
pathway
x x
negative regulation of activin receptor signaling pathway x x
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator x x x
transmembrane receptor protein serine/threonine kinase signaling pathway x x
regulation of adenosine receptor signaling pathway x x
negative regulation of adenosine receptor signaling pathway x x
neurotrophin TRK receptor signaling pathway x x x
neurotrophin signaling pathway x x x
intrinsic apoptotic signaling pathway in response to oxidative stress x x x
thromboxane A2 signaling pathway x x x
negative regulation of protein kinase C signaling x x
regulation of opioid receptor signaling pathway x x
sphingosine-1-phosphate signaling pathway x x
sphingolipid mediated signaling pathway x x
Wnt signaling pathway, calcium modulating pathway x x
regulation of intrinsic apoptotic signaling pathway in response to DNA damage x x
regulation of toll-like receptor 4 signaling pathway x x
positive regulation of toll-like receptor 4 signaling pathway x x











immune response-regulating signaling pathway x x
regulation of toll-like receptor signaling pathway x x
regulation of tumor necrosis factor-mediated signaling pathway x x x
transmembrane receptor protein tyrosine kinase signaling pathway x x x
toll-like receptor 5 signaling pathway x x x
toll-like receptor 10 signaling pathway x x x
insulin receptor signaling pathway x x x
toll-like receptor 9 signaling pathway x x x
negative regulation of tumor necrosis factor-mediated signaling pathway x x x
negative regulation of fibroblast growth factor receptor signaling pathway x x x
tumor necrosis factor-mediated signaling pathway x x x
regulation of extrinsic apoptotic signaling pathway x x x
toll-like receptor TLR1:TLR2 signaling pathway x x x
toll-like receptor TLR6:TLR2 signaling pathway x x x
negative regulation of apoptotic signaling pathway x x x
fibroblast growth factor receptor signaling pathway x x x
regulation of signaling x x x
negative regulation of signaling x x x
vascular endothelial growth factor receptor signaling pathway x x x
phospholipase C-activating dopamine receptor signaling pathway x x x
regulation of cysteine-type endopeptidase activity involved in apoptotic signaling
pathway
x x x
intracellular steroid hormone receptor signaling pathway x x x
transforming growth factor beta receptor signaling pathway x x x
intracellular receptor signaling pathway x x x
retinoic acid receptor signaling pathway x x x
positive regulation of Wnt signaling pathway, planar cell polarity pathway x x x
regulation of androgen receptor signaling pathway x x x
regulation of transforming growth factor beta receptor signaling pathway x x x
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage x x
activin receptor signaling pathway x x x
positive regulation of signaling x x x
negative regulation of phosphatidylinositol 3-kinase signaling x x x
negative regulation of intrinsic apoptotic signaling pathway in response to oxidative
stress
x x x
regulation of intrinsic apoptotic signaling pathway in response to oxidative stress x x x
glucocorticoid receptor signaling pathway x x x x
rhodopsin mediated signaling pathway x x x x
corticosteroid receptor signaling pathway x x x x
positive regulation of epidermal growth factor receptor signaling pathway x x x x
positive regulation of ERBB signaling pathway x x x x
canonical Wnt signaling pathway involved in mesenchymal stem cell differentiation x x x x











Amoebiasis x x x
Non-small cell lung cancer x x
PPAR signaling pathway x x
Chronic myeloid leukemia x x x x
Pancreatic cancer x x x x
Axon guidance x x
ECM-receptor interaction x x x
Small cell lung cancer x x
Prostate cancer x x
Biotin metabolism x x
Pyrimidine metabolism x x
Glycosylphosphatidylinositol(GPI)-anchor biosynthesis x x x x
DNA replication x x
Toxoplasmosis x x
Antigen processing and presentation x x
Colorectal cancer x x
Amyotrophic lateral sclerosis (ALS) x x x
Prion diseases x x x
Lysosome x x
Vibrio cholerae infection x x x x
Phagosome x x
Chagas disease (American trypanosomiasis) x x x
MAPK signaling pathway x x x
Focal adhesion x x
Bladder cancer x x x
Melanoma x x x
Glycerolipid metabolism x x x
mTOR signaling pathway x x x
Glycerophospholipid metabolism x x x
Fat digestion and absorption x x x
Glyoxylate and dicarboxylate metabolism x x x x
Ether lipid metabolism x x x
Mucin type O-Glycan biosynthesis x x x x
Vasopressin-regulated water reabsorption x x x x
Cell cycle x x
Oocyte meiosis x x
p53 signaling pathway x x
Progesterone-mediated oocyte maturation x x
RNA transport x x x
Fructose and mannose metabolism x x x











Huntington’s disease x x x x
Parkinson’s disease x x x x
Oxidative phosphorylation x x x x
Protein processing in endoplasmic reticulum x x x x
Alzheimer’s disease x x x x
Metabolic pathways x x x x
Ribosome x x x x
Arginine and proline metabolism x x x
mRNA surveillance pathway x x x x
Base excision repair x x x
Ubiquitin mediated proteolysis x x x x
Proteasome x x x
Pathogenic Escherichia coli infection x x x
Insulin signaling pathway x x x x
Bacterial invasion of epithelial cells x x x
Shigellosis x x x
Fc gamma R-mediated phagocytosis x x x
Alanine, aspartate and glutamate metabolism x x x
RNA polymerase x x x
Neurotrophin signaling pathway x x x x
Apoptosis x x x x
Ribosome biogenesis in eukaryotes x x x x
Adipocytokine signaling pathway x x x
N-Glycan biosynthesis x x x x
Other types of O-glycan biosynthesis x x x
Glycosphingolipid biosynthesis - globo series x x x
Glycosphingolipid biosynthesis - lacto and neolacto series x x x x
Type II diabetes mellitus x x x x
Notch signaling pathway x x x
Peroxisome x x x x
Thiamine metabolism x x x
Jak-STAT signaling pathway x x x
Acute myeloid leukemia x x x x
Amino sugar and nucleotide sugar metabolism x x x
Renal cell carcinoma x x x
Glutathione metabolism x x x
Protein digestion and absorption x x x
Glioma x x
Galactose metabolism x x x











hepatocyte growth factor receptor signaling pathway x x x
positive regulation of non-canonical Wnt signaling pathway x x x
thrombopoietin-mediated signaling pathway x x x x
negative regulation of dopamine receptor signaling pathway x x
positive regulation of dopamine receptor signaling pathway x x
adenylate cyclase-inhibiting dopamine receptor signaling pathway x x
regulation of dopamine receptor signaling pathway x x
desensitization of G-protein coupled receptor protein signaling pathway x x
negative adaptation of signaling pathway x x
adaptation of signaling pathway x x
positive regulation of G-protein coupled receptor protein signaling pathway x x
protein kinase C-activating G-protein coupled receptor signaling pathway x x x
positive regulation of extrinsic apoptotic signaling pathway x x x
extrinsic apoptotic signaling pathway in absence of ligand x x x
regulation of extrinsic apoptotic signaling pathway in absence of ligand x x x
positive regulation of type I interferon-mediated signaling pathway x x x
TRIF-dependent toll-like receptor signaling pathway x x x
regulation of type I interferon-mediated signaling pathway x x x x
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glutamate receptor signaling pathway x x x
negative regulation of TOR signaling x x x
regulation of extrinsic apoptotic signaling pathway via death domain receptors x x x
extrinsic apoptotic signaling pathway via death domain receptors x x x
cell-cell signaling involved in cardiac conduction x x x
Fas signaling pathway x x x
glucocorticoid mediated signaling pathway x x x
regulation of glucocorticoid mediated signaling pathway x x x
regulation of Fas signaling pathway x x x
multicellular organismal signaling x x x
transmembrane receptor protein tyrosine kinase signaling pathway x x x
regulation of cardiac muscle contraction by calcium ion signaling x x x
regulation of glutamate receptor signaling pathway x x x
negative regulation of transforming growth factor beta receptor signaling pathway x x x
enzyme linked receptor protein signaling pathway x x x
reelin-mediated signaling pathway x x x
semaphorin-plexin signaling pathway involved in neuron projection guidance x x x x
transmembrane receptor protein tyrosine phosphatase signaling pathway x x x
interferon-gamma-mediated signaling pathway x x x
interleukin-2-mediated signaling pathway x x x
calcineurin-NFAT signaling cascade x x x x
regulation of calcineurin-NFAT signaling cascade x x x x
type I interferon signaling pathway x x x
TRAM-dependent toll-like receptor signaling pathway x x x
TRAM-dependent toll-like receptor 4 signaling pathway x x x
semaphorin-plexin signaling pathway x x x
positive regulation of transforming growth factor beta receptor signaling pathway x x x
cytokine-mediated signaling pathway x x
negative regulation of stress-activated protein kinase signaling cascade x x
regulation of interferon-gamma-mediated signaling pathway x x
regulation of type I interferon-mediated signaling pathway x x
positive regulation of Wnt signaling pathway x x
interleukin-15-mediated signaling pathway x x x
canonical Wnt signaling pathway involved in positive regulation of apoptotic process x x x x
interleukin-12-mediated signaling pathway x x x
nerve growth factor signaling pathway x x x x
G-protein coupled acetylcholine receptor signaling pathway x x x
smoothened signaling pathway involved in regulation of cerebellar granule cell precursor
cell proliferation
x x x
canonical Wnt signaling pathway involved in negative regulation of apoptotic process x x x x











lipopolysaccharide-mediated signaling pathway x x
immune response-regulating cell surface receptor signaling pathway involved in
phagocytosis
x x
Fc-gamma receptor signaling pathway involved in phagocytosis x x
Fc-gamma receptor signaling pathway x x
Fc receptor mediated stimulatory signaling pathway x x
immune response-activating cell surface receptor signaling pathway x x
Fc receptor signaling pathway x x
regulation of signaling x x
immune response-regulating cell surface receptor signaling pathway x x
cell surface receptor signaling pathway x x
regulation of stress-activated protein kinase signaling cascade x x x
immune response-regulating signaling pathway x x
fibroblast growth factor receptor signaling pathway x x
signaling x x
single organism signaling x x
epidermal growth factor receptor signaling pathway x x
stress-activated protein kinase signaling cascade x x
ERBB signaling pathway x x
negative regulation of insulin receptor signaling pathway x x
regulation of insulin receptor signaling pathway x x
neurotrophin TRK receptor signaling pathway x x
Tie signaling pathway x x x
negative regulation of epidermal growth factor receptor signaling pathway x x x
negative regulation of ERBB signaling pathway x x x
regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53
class mediator
x x x
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage
by p53 class mediator
x x x
regulation of epidermal growth factor receptor signaling pathway x x x
regulation of ERBB signaling pathway x x x
negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator x x x
regulation of intrinsic apoptotic signaling pathway by p53 class mediator x x x
phosphatidylinositol-mediated signaling x x x
inositol lipid-mediated signaling x x x
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator x x x
collagen-activated tyrosine kinase receptor signaling pathway x x x
collagen-activated signaling pathway x x x
leukemia inhibitory factor signaling pathway x x x
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage x x x
phosphatidylinositol 3-kinase signaling x x x
cAMP-mediated signaling x x
cyclic-nucleotide-mediated signaling x x











Ribosome biogenesis in eukaryotes x x x x
Circadian rhythm - mammal x x x
Phosphatidylinositol signaling system x x x
Ubiquitin mediated proteolysis x x x
Biotin metabolism x x x
Renal cell carcinoma x x x
Focal adhesion x x x
VEGF signaling pathway x x x
TGF-beta signaling pathway x x x
Vascular smooth muscle contraction x x x
Toxoplasmosis x x x
Axon guidance x x x
Leukocyte transendothelial migration x x x
Huntington’s disease x x x
RNA transport x x x
Endocytosis x x x
ABC transporters x x x
Gastric acid secretion x x x x
T cell receptor signaling pathway x x x
Basal transcription factors x x
Leishmaniasis x x
Pancreatic cancer x x
Adherens junction x x x
Wnt signaling pathway x x x x
Basal cell carcinoma x x x
Viral myocarditis x x
Complement and coagulation cascades x x
Hematopoietic cell lineage x x
Long-term potentiation x x x
Fc gamma R-mediated phagocytosis x x
Calcium signaling pathway x x
Pancreatic secretion x x x
Oocyte meiosis x x x
Jak-STAT signaling pathway x x x
Glioma x x x
Melanoma x x x
Acute myeloid leukemia x x x
Prostate cancer x x x
Drug metabolism - cytochrome P450 x x x











negative regulation of signaling x x x
regulation of nucleotide-binding oligomerization domain containing signaling pathway x x x x
regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway x x x x
regulation of RIG-I signaling pathway x x x x
positive regulation of protein kinase A signaling x x x
BMP signaling pathway x x x
Chronic myeloid leukemia x x x
Staphylococcus aureus infection x x
Non-small cell lung cancer x x x
Cell cycle x x x
Pathways in cancer x x x
Spliceosome x x x
Regulation of actin cytoskeleton x x x x
Bile secretion x x x x
Lysine biosynthesis x x x
Long-term depression x x x
Notch signaling pathway x x x x
Inositol phosphate metabolism x x x
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Dorso-ventral axis formation x
Endocytosis x x x x x
ECM-receptor interaction x
Leishmaniasis x
mRNA surveillance pathway x
Jak-STAT signaling pathway x
Pancreatic cancer x x
Notch signaling pathway x x
Small cell lung cancer x x
RNA transport x x
Viral myocarditis x x
Fc epsilon RI signaling pathway x x
Base excision repair x x
Wnt signaling pathway x x
Chronic myeloid leukemia x x
Ubiquitin mediated proteolysis x x
ErbB signaling pathway x x
Acute myeloid leukemia x x
Fc gamma R-mediated phagocytosis x x
Shigellosis x x
Prostate cancer x x
Non-small cell lung cancer x x
Renal cell carcinoma x x
Axon guidance x x x x x
Glioma x x
Pathogenic Escherichia coli infection x x
Pathways in cancer x x
T cell receptor signaling pathway x x













Type II diabetes mellitus x x x x x
Epithelial cell signaling in Helicobacter pylori infection x x
Protein processing in endoplasmic reticulum x x
B cell receptor signaling pathway x x
Tight junction x x
Cell cycle x x
Adherens junction x x
GnRH signaling pathway x x
Phosphatidylinositol signaling system x x
Fatty acid elongation in mitochondria x x
Neurotrophin signaling pathway x x
Amino sugar and nucleotide sugar metabolism x x
mTOR signaling pathway x x
Oocyte meiosis x x
Natural killer cell mediated cytotoxicity x x
Insulin signaling pathway x x
Long-term potentiation x x
transforming growth factor beta receptor signaling pathway x x
negative regulation of transforming growth factor beta receptor signaling pathway x x
transmembrane receptor protein serine/threonine kinase signaling pathway x x
enzyme linked receptor protein signaling pathway x x x x x
regulation of transforming growth factor beta receptor signaling pathway x x
negative regulation of transmembrane receptor protein serine/threonine kinase signaling
pathway
x x
positive regulation of intracellular steroid hormone receptor signaling pathway x x x x x
positive regulation of intracellular estrogen receptor signaling pathway x x x x x
regulation of transmembrane receptor protein serine/threonine kinase signaling pathway x x
signaling x x x x x
single organism signaling x x x x x
transmembrane receptor protein tyrosine kinase signaling pathway x x x x x
intracellular receptor signaling pathway x x













mesenchymal-epithelial cell signaling involved in prostate gland development x
cell surface receptor signaling pathway x x x x x
regulation of intracellular estrogen receptor signaling pathway x x
lipopolysaccharide-mediated signaling pathway x x
neurotrophin signaling pathway x x
apoptotic signaling pathway x x
regulation of G-protein coupled receptor protein signaling pathway x x
neurotrophin TRK receptor signaling pathway x x
regulation of rhodopsin mediated signaling pathway x x
regulation of lipopolysaccharide-mediated signaling pathway x x
intrinsic apoptotic signaling pathway in response to DNA damage x x
rhodopsin mediated signaling pathway x x
TOR signaling x x
positive regulation of Notch signaling pathway x x
adenylate cyclase-activating dopamine receptor signaling pathway x x
regulation of epidermal growth factor receptor signaling pathway x x x x x
negative regulation of G-protein coupled receptor protein signaling pathway x x
cAMP-mediated signaling x x x x x
regulation of ERBB signaling pathway x x x x x
negative regulation of epidermal growth factor receptor signaling pathway x x x x x
epidermal growth factor receptor signaling pathway x x x x x
ERBB signaling pathway x x x x x
negative regulation of ERBB signaling pathway x x x x x
Fc receptor signaling pathway x x
immune response-regulating cell surface receptor signaling pathway involved in
phagocytosis
x x
Fc-gamma receptor signaling pathway involved in phagocytosis x x
immune response-regulating cell surface receptor signaling pathway x x
Fc-gamma receptor signaling pathway x x
Fc receptor mediated stimulatory signaling pathway x x
regulation of signaling x x x x x













Roundabout signaling pathway x x
negative regulation of signaling x x
immune response-activating cell surface receptor signaling pathway x x
nucleotide-binding oligomerization domain containing signaling pathway x x
regulation of chemokine-mediated signaling pathway x x
intracellular estrogen receptor signaling pathway x x
toll-like receptor 5 signaling pathway x x
toll-like receptor 10 signaling pathway x x
MyD88-independent toll-like receptor signaling pathway x x
stress-activated protein kinase signaling cascade x x
fibroblast growth factor receptor signaling pathway x x
regulation of stress-activated protein kinase signaling cascade x x x
insulin receptor signaling pathway x x
Glycosylphosphatidylinositol(GPI)-anchor biosynthesis x x x
Phenylalanine, tyrosine and tryptophan biosynthesis x x x
Biosynthesis of unsaturated fatty acids x x x
Phenylalanine metabolism x x x
Maturity onset diabetes of the young x x x
negative regulation of BMP signaling pathway x
regulation of BMP signaling pathway x
BMP signaling pathway x
negative regulation of retinoic acid receptor signaling pathway x x x
regulation of retinoic acid receptor signaling pathway x x x
activation of signaling protein activity involved in unfolded protein response x
ER-nucleus signaling pathway x
protein kinase B signaling x
Neuroactive ligand-receptor interaction x x x
Alanine, aspartate and glutamate metabolism x x x
Cell adhesion molecules (CAMs) x x x
Other glycan degradation x x x













gamma-aminobutyric acid signaling pathway x x x
positive regulation of I-kappaB kinase/NF-kappaB signaling x x x
cyclic-nucleotide-mediated signaling x x x
regulation of I-kappaB kinase/NF-kappaB signaling x x x
positive regulation of signaling x x x
glutamate receptor signaling pathway x x x
I-kappaB kinase/NF-kappaB signaling x x x
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress x x x
protein kinase C-activating G-protein coupled receptor signaling pathway x x x
regulation of adenylate cyclase activity involved in G-protein coupled receptor signaling
pathway
x x x
positive regulation of adenylate cyclase activity involved in G-protein coupled receptor
signaling pathway
x x x
TRAM-dependent toll-like receptor signaling pathway x x x
TRAM-dependent toll-like receptor 4 signaling pathway x x x
glucocorticoid mediated signaling pathway x x x
regulation of glucocorticoid mediated signaling pathway x x x
regulation of cardiac muscle contraction by calcium ion signaling x x x
platelet-derived growth factor receptor signaling pathway x x x
retinoic acid receptor signaling pathway x x x
phospholipase C-activating G-protein coupled glutamate receptor signaling pathway x x x
thyroid-stimulating hormone signaling pathway x x x
positive regulation of retinoic acid receptor signaling pathway x x x
positive regulation of interferon-gamma-mediated signaling pathway x x x
regulation of vitamin D receptor signaling pathway x x x
Purine metabolism x x
Gastric acid secretion x x
Tyrosine metabolism x x
negative regulation of extrinsic apoptotic signaling pathway x x
mesodermal-endodermal cell signaling x x
somatostatin receptor signaling pathway x x
somatostatin signaling pathway x x















stromal-epithelial cell signaling involved in prostate gland development x x
regulation of canonical Wnt signaling pathway involved in controlling type B pancreatic
cell proliferation
x x
negative regulation of canonical Wnt signaling pathway involved in controlling type B
pancreatic cell proliferation
x x
regulation of insulin-like growth factor receptor signaling pathway x x
negative regulation of apoptotic signaling pathway x x
Metabolic pathways x
Butirosin and neomycin biosynthesis x
Sphingolipid metabolism x
negative regulation of Wnt signaling pathway involved in dorsal/ventral axis
specification
x
canonical Wnt signaling pathway involved in regulation of cell proliferation x
regulation of Wnt signaling pathway involved in dorsal/ventral axis specification x
Wnt signaling pathway involved in dorsal/ventral axis specification x
Wnt signaling pathway involved in somitogenesis x
negative regulation of non-canonical Wnt signaling pathway x
insulin-like growth factor receptor signaling pathway x
regulation of extrinsic apoptotic signaling pathway x
positive regulation of insulin-like growth factor receptor signaling pathway x
negative regulation of insulin-like growth factor receptor signaling pathway x
positive regulation of non-canonical Wnt signaling pathway x
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Steroid hormone biosynthesis x
Glycosphingolipid biosynthesis - globo series x x
Wnt signaling pathway x x x x
Lysosome x x
Chagas disease (American trypanosomiasis) x x
ErbB signaling pathway x x x x x
Bile secretion x x
Other glycan degradation x x
Gastric acid secretion x x
Glycosphingolipid biosynthesis - lacto and neolacto series x x
Renal cell carcinoma x x
Calcium signaling pathway x x
Phosphatidylinositol signaling system x x
Adherens junction x x
Pathways in cancer x x x x x
Endometrial cancer x x x x x
Axon guidance x x x x x
Melanogenesis x x
Dilated cardiomyopathy x x x
Jak-STAT signaling pathway x x
Long-term depression x x x
Inositol phosphate metabolism x x
Olfactory transduction x x
Glioma x x x x x
Acute myeloid leukemia x x













Type II diabetes mellitus x x x x x
Gap junction x x
Toxoplasmosis x x
Long-term potentiation x x x
Fc gamma R-mediated phagocytosis x x
Alanine, aspartate and glutamate metabolism x x
Circadian rhythm - mammal x x
mTOR signaling pathway x x
Neuroactive ligand-receptor interaction x x
Regulation of actin cytoskeleton x x
MAPK signaling pathway x x x
Melanoma x x x x x
Type I diabetes mellitus x x
Mucin type O-Glycan biosynthesis x x
osmosensory signaling pathway x
somatostatin receptor signaling pathway x
somatostatin signaling pathway x
glucocorticoid mediated signaling pathway x
canonical Wnt signaling pathway involved in regulation of type B pancreatic cell
proliferation
x
stromal-epithelial cell signaling involved in prostate gland development x
canonical Wnt signaling pathway involved in cardiac muscle cell fate commitment x
regulation of glucocorticoid mediated signaling pathway x
regulation of canonical Wnt signaling pathway involved in controlling type B pancreatic
cell proliferation
x
negative regulation of canonical Wnt signaling pathway involved in controlling type B
pancreatic cell proliferation
x
negative regulation of extrinsic apoptotic signaling pathway x
negative regulation of apoptotic signaling pathway x
canonical Wnt signaling pathway involved in neural crest cell differentiation x
negative regulation of Wnt signaling pathway involved in dorsal/ventral axis
specification
x
intracellular receptor signaling pathway x x
signaling x x x x













intracellular estrogen receptor signaling pathway x x
positive regulation of retinoic acid receptor signaling pathway x x
regulation of retinoic acid receptor signaling pathway x x
intracellular steroid hormone receptor signaling pathway x x
regulation of nucleotide-binding oligomerization domain containing signaling pathway x x
cAMP-mediated signaling x x
second-messenger-mediated signaling x x x x x
cyclic-nucleotide-mediated signaling x x
NIK/NF-kappaB signaling x x
regulation of cardiac muscle contraction by calcium ion signaling x x x x x
regulation of intracellular estrogen receptor signaling pathway x x
transmembrane receptor protein tyrosine kinase signaling pathway x x x x
positive regulation of intracellular steroid hormone receptor signaling pathway x x
positive regulation of intracellular estrogen receptor signaling pathway x x
retinoic acid receptor signaling pathway x x
regulation of signaling x x x x
negative regulation of signaling x x
cell surface receptor signaling pathway x x x x
negative regulation of epidermal growth factor receptor signaling pathway x x x
cell-cell signaling x x
purinergic receptor signaling pathway x x
negative regulation of ERBB signaling pathway x x x
multicellular organismal signaling x x
regulation of intracellular steroid hormone receptor signaling pathway x x
enzyme linked receptor protein signaling pathway x x x x
phospholipase C-activating G-protein coupled glutamate receptor signaling pathway x x
bile acid signaling pathway x x
regulation of epidermal growth factor receptor signaling pathway x x
regulation of ERBB signaling pathway x x
extrinsic apoptotic signaling pathway in absence of ligand x x













steroid hormone mediated signaling pathway x x
Fc receptor signaling pathway x x
gamma-aminobutyric acid signaling pathway x x
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress x x
negative regulation of stress-activated protein kinase signaling cascade x x
positive regulation of TOR signaling x x
neurotrophin signaling pathway x x
negative regulation of intracellular steroid hormone receptor signaling pathway x x
G-protein coupled glutamate receptor signaling pathway x x
Fc-epsilon receptor signaling pathway x x
stress-activated protein kinase signaling cascade x x
glutamate receptor signaling pathway x x
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex
development
x x
neurotrophin TRK receptor signaling pathway x x
G-protein coupled receptor signaling pathway x x
insulin-like growth factor receptor signaling pathway x x
epidermal growth factor receptor signaling pathway x x x x x
positive regulation of signaling x x
regulation of stress-activated protein kinase signaling cascade x x x x
ERBB signaling pathway x x x x x
Base excision repair x
RNA transport x x x
Mismatch repair x x x
Taste transduction x x x
Staphylococcus aureus infection x
intrinsic apoptotic signaling pathway by p53 class mediator x x x
immune response-regulating cell surface receptor signaling pathway involved in
phagocytosis
x x x x
Fc-gamma receptor signaling pathway involved in phagocytosis x x x x
Fc-gamma receptor signaling pathway x x x x
Fc receptor mediated stimulatory signaling pathway x x x x













intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator x x x
intrinsic apoptotic signaling pathway x x x
platelet-derived growth factor receptor signaling pathway x x x
immune response-activating cell surface receptor signaling pathway x x x
adiponectin-activated signaling pathway x x x
reelin-mediated signaling pathway x x x
G-protein coupled acetylcholine receptor signaling pathway x x x
cytokine-mediated signaling pathway x x x
adenylate cyclase-activating dopamine receptor signaling pathway x x x
regulation of G-protein coupled receptor protein signaling pathway x x x
interleukin-6-mediated signaling pathway x
negative regulation of insulin-like growth factor receptor signaling pathway x
regulation of insulin-like growth factor receptor signaling pathway x
positive regulation of Notch signaling pathway x
JAK-STAT cascade involved in growth hormone signaling pathway x
growth hormone receptor signaling pathway x
regulation of Notch signaling pathway x
Non-small cell lung cancer x x x
Small cell lung cancer x x x
Prostate cancer x x x
Chronic myeloid leukemia x x x
Pancreatic cancer x x x
Cell adhesion molecules (CAMs) x x x
Citrate cycle (TCA cycle) x x x
Neurotrophin signaling pathway x x x
Proximal tubule bicarbonate reclamation x x x
Apoptosis x x x
Shigellosis x x x
Cell cycle x x x
Arrhythmogenic right ventricular cardiomyopathy (ARVC) x x x













Cyanoamino acid metabolism x x x
Viral myocarditis x x x
TRAM-dependent toll-like receptor signaling pathway x x x
TRAM-dependent toll-like receptor 4 signaling pathway x x x
regulation of smoothened signaling pathway involved in dorsal/ventral neural tube
patterning
x x x
negative regulation of smoothened signaling pathway involved in dorsal/ventral neural
tube patterning
x x x
positive regulation of I-kappaB kinase/NF-kappaB signaling x x x
activation of signaling protein activity involved in unfolded protein response x x x
Roundabout signaling pathway x x x
regulation of adrenergic receptor signaling pathway x x x
ER-nucleus signaling pathway x x x
positive regulation of protein kinase A signaling x x x
chemokine-mediated signaling pathway x x x
calcium-mediated signaling x x x
RNA polymerase x x
Ribosome biogenesis in eukaryotes x x
Glycerolipid metabolism x x
Notch signaling pathway x x
Proteasome x x
lipopolysaccharide-mediated signaling pathway x x
positive regulation of hippo signaling x x
Fas signaling pathway x x
collagen-activated tyrosine kinase receptor signaling pathway x x
collagen-activated signaling pathway x x
activation of prostate induction by androgen receptor signaling pathway x x
regulation of thrombin receptor signaling pathway x x
negative regulation of thrombin receptor signaling pathway x x
regulation of Fas signaling pathway x x
positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator x x














Ubiquitin mediated proteolysis x
Pathogenic Escherichia coli infection x
Metabolic pathways x
Fatty acid elongation in mitochondria x
transforming growth factor beta receptor signaling pathway x
regulation of protein insertion into mitochondrial membrane involved in apoptotic
signaling pathway
x
positive regulation of protein insertion into mitochondrial membrane involved in
apoptotic signaling pathway
x
protein insertion into mitochondrial membrane involved in apoptotic signaling pathway x
hippo signaling x
regulation of mitochondrial outer membrane permeabilization involved in apoptotic
signaling pathway
x
regulation of hippo signaling x
regulation of skeletal muscle contraction by calcium ion signaling x
negative regulation of chemokine-mediated signaling pathway x
positive regulation of lipopolysaccharide-mediated signaling pathway x
fibroblast growth factor receptor signaling pathway x
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Lysosome x x x x x x x x x x
Terpenoid backbone biosynthesis x x x x x x x x
Glycosaminoglycan degradation x x x x x x x x x
Bladder cancer x x x x x x x x
Proteasome x x x x x
Non-small cell lung cancer x x x x x x x x
Inositol phosphate metabolism x x x x x x x
Pathways in cancer x x x x x x x x x x
RNA transport x x x x x x x x x
Leishmaniasis x x x x x x
Phosphatidylinositol signaling system x x x x x x
Protein digestion and absorption x x x x x x x x x x
Small cell lung cancer x x x x x x x x x x
Pancreatic secretion x x x x x x x
Toxoplasmosis x x x x x x
Jak-STAT signaling pathway x x x x x x
Ribosome biogenesis in eukaryotes x x x x x x x x x x
Protein processing in endoplasmic reticulum x x x x x x
mRNA surveillance pathway x x x x x x























Complement and coagulation cascades x x x x x x x x x x
Notch signaling pathway x x x x x x x x x x
Neurotrophin signaling pathway x x x x x x x x x
Alzheimer’s disease x x x x x x
Wnt signaling pathway x x x x x x
Basal transcription factors x x x x x x x
Nucleotide excision repair x x x x x x x
adenylate cyclase-activating adrenergic
receptor signaling pathway
x x x x x x x x
adenylate cyclase-activating dopamine
receptor signaling pathway
x x x x x x x x x x
G-protein coupled receptor signaling
pathway coupled to cGMP nucleotide
second messenger
x x x x x x x x x
positive regulation of cAMP-mediated
signaling
x x x x x x x x
G-protein coupled receptor signaling
pathway, coupled to cyclic nucleotide
second messenger
x x x x x x x x x
regulation of cAMP-mediated signaling x x x x x x x x
adrenergic receptor signaling pathway x x x x x x x x x
regulation of protein insertion into
mitochondrial membrane involved in
apoptotic signaling pathway
x x x x x x x x
positive regulation of protein insertion into
mitochondrial membrane involved in
apoptotic signaling pathway
x x x x x x x x
protein insertion into mitochondrial
membrane involved in apoptotic signaling
pathway
x x x x x x x x
regulation of mitochondrial outer membrane
permeabilization involved in apoptotic
signaling pathway
x x x x x
intrinsic apoptotic signaling pathway by
p53 class mediator
x x x x x
intrinsic apoptotic signaling pathway in
response to DNA damage
x x x x x
regulation of interleukin-6-mediated
signaling pathway

























x x x x x x x
regulation of interleukin-2-mediated
signaling pathway
x x x x x x x
negative regulation of
interleukin-2-mediated signaling pathway
x x x x x x x
regulation of prolactin signaling pathway x x x x x x x
negative regulation of prolactin signaling
pathway
x x x x x x x
regulation of interleukin-4-mediated
signaling pathway
x x x x x x x
negative regulation of
interleukin-4-mediated signaling pathway
x x x x x x x
regulation of macrophage
colony-stimulating factor signaling pathway
x x x x x x x
negative regulation of macrophage
colony-stimulating factor signaling pathway
x x x x x x x
prolactin signaling pathway x x x x x x x
negative regulation of type I
interferon-mediated signaling pathway
x x x x x x x
positive regulation of chemokine-mediated
signaling pathway
x x x x x x x x x x
regulation of platelet-derived growth factor
receptor-beta signaling pathway
x x x x x x x
negative regulation of platelet-derived
growth factor receptor-beta signaling
pathway
x x x x x x x
transmembrane receptor protein tyrosine
phosphatase signaling pathway
x x x x x x x x x
macrophage colony-stimulating factor
signaling pathway
x x x x x x x
regulation of hepatocyte growth factor
receptor signaling pathway
x x x x x x x
negative regulation of tumor necrosis
factor-mediated signaling pathway
x x x x x x x
interleukin-4-mediated signaling pathway x x x x x x x



























interleukin-6-mediated signaling pathway x x x x x x
atrial cardiac muscle cell to AV node cell
signaling
x x x x x x x x x
negative regulation of platelet-derived
growth factor receptor signaling pathway
x x x x x x
platelet-derived growth factor receptor-beta
signaling pathway
x x x x x x
negative regulation of insulin-like growth
factor receptor signaling pathway
x x x x x x
hepatocyte growth factor receptor signaling
pathway
x x x x x x
regulation of chemokine-mediated signaling
pathway
x x x x x x x x x x
cytokine-mediated signaling pathway x x x x x x
negative regulation of TOR signaling x x x x x x x x x
cell-cell signaling involved in cardiac
conduction
x x x x x x x
positive regulation of vascular endothelial
growth factor receptor signaling pathway
x x x x x
regulation of lipopolysaccharide-mediated
signaling pathway
x x x x x x
ionotropic glutamate receptor signaling
pathway
x x x x x
positive regulation of signaling x x x x x x
positive regulation of cytokine-mediated
signaling pathway
x x x x x
intrinsic apoptotic signaling pathway in
response to endoplasmic reticulum stress
x x x x x x x x
negative regulation of transforming growth
factor beta receptor signaling pathway
x x x x x x
activation of signaling protein activity
involved in unfolded protein response
x x x x x x x x
SREBP signaling pathway x x x x x x x x
regulation of transforming growth factor
beta receptor signaling pathway
x x x x x x
negative regulation of transmembrane
receptor protein serine/threonine kinase
signaling pathway























ER-nucleus signaling pathway x x x x x x
enzyme linked receptor protein signaling
pathway
x x x x x x
cell surface receptor signaling pathway x x x x x x x x x x
brain-derived neurotrophic factor receptor
signaling pathway
x x x x x
ciliary receptor clustering involved in
smoothened signaling pathway
x x x x x x x
smoothened signaling pathway involved in
ventral spinal cord patterning
x x x x x x x
smoothened signaling pathway involved in
regulation of cerebellar granule cell
precursor cell proliferation
x x x x x x x
cerebellar Purkinje cell-granule cell
precursor cell signaling involved in
regulation of granule cell precursor cell
proliferation
x x x x x x x
epithelial-mesenchymal cell signaling x x x x x x x
calcium-mediated signaling using
intracellular calcium source
x x x x x
positive regulation of smoothened signaling
pathway
x x x x x
apoptotic signaling pathway x x x x x x x x x x
negative regulation of epidermal growth
factor receptor signaling pathway
x x x x x x x x x
negative regulation of ERBB signaling
pathway
x x x x x x x x x
regulation of epidermal growth factor
receptor signaling pathway
x x x x x x x x x
regulation of ERBB signaling pathway x x x x x x x x x
extrinsic apoptotic signaling pathway via
death domain receptors
x x x x x x x x x
T cell receptor signaling pathway x x x x x x x x x
antigen receptor-mediated signaling
pathway
x x x x x x
negative regulation of apoptotic signaling
pathway
x x x x x x x x x
immune response-activating cell surface
receptor signaling pathway























epidermal growth factor receptor signaling
pathway
x x x x x x
ERBB signaling pathway x x x x x x
extrinsic apoptotic signaling pathway x x x x x x x x
positive regulation of phosphatidylinositol
3-kinase signaling
x x x x
transmembrane receptor protein tyrosine
kinase signaling pathway




positive regulation of transforming growth
factor beta receptor signaling pathway
x x x x x x
insulin-like growth factor receptor signaling
pathway
x x x x x x x
adenylate cyclase-inhibiting G-protein
coupled receptor signaling pathway
x x x
positive regulation of transmembrane
receptor protein serine/threonine kinase
signaling pathway
x x x
intrinsic apoptotic signaling pathway x x x x x x x x x
negative regulation of intrinsic apoptotic
signaling pathway
x x x x x x x x x
Cell adhesion molecules (CAMs) x x x x x x x x
Phagosome x x x x x x x x
Pathogenic Escherichia coli infection x x x x x x x x
Olfactory transduction x x x x x x x
RNA polymerase x x x x x x x
Cytosolic DNA-sensing pathway x x x x x x x
Long-term potentiation x x x x x x x x x
Arrhythmogenic right ventricular
cardiomyopathy (ARVC)
x x x x x x x x























Hypertrophic cardiomyopathy (HCM) x x x x x x x x
Dilated cardiomyopathy x x x x x x x x
adiponectin-activated signaling pathway x x x x x x x
interferon-gamma-mediated signaling
pathway
x x x x x x x
regulation of intrinsic apoptotic signaling
pathway
x x x x x
regulation of apoptotic signaling pathway x x x x x
integrin-mediated signaling pathway x x x x x x x x x
chemokine-mediated signaling pathway x x x x x x x x
negative regulation of signaling x x x x x x x x
transforming growth factor beta receptor
signaling pathway
x x x x
phosphatidylinositol-mediated signaling x x x x x x x
inositol lipid-mediated signaling x x x x x x x
Tight junction x x x x x x x
Porphyrin and chlorophyll metabolism x x x x x x x x
Other glycan degradation x x x x
Long-term depression x x x x x
Vascular smooth muscle contraction x x x x x
regulation of TOR signaling x x x x x x
TOR signaling x x x x x x
TRAM-dependent toll-like receptor
signaling pathway
x x x x x
TRAM-dependent toll-like receptor 4
signaling pathway























neurotrophin TRK receptor signaling
pathway
x x x x x x x
neurotrophin signaling pathway x x x x x x x
adenylate cyclase-modulating G-protein
coupled receptor signaling pathway
x x x x x
Wnt signaling pathway involved in wound
healing, spreading of epidermal cells
x x x x
Intestinal immune network for IgA
production
x x x
Leukocyte transendothelial migration x x x
activation of MAPK activity by adrenergic
receptor signaling pathway
x x x
epidermal growth factor-activated receptor
transactivation by G-protein coupled
receptor signaling pathway
x x x
positive regulation of epidermal growth
factor receptor signaling pathway
x x x
positive regulation of ERBB signaling
pathway
x x x
regulation of intrinsic apoptotic signaling
pathway in response to oxidative stress
x x x x x x
intrinsic apoptotic signaling pathway in
response to oxidative stress
x x x x x
cAMP-mediated signaling x
cyclic-nucleotide-mediated signaling x
VEGF signaling pathway x x x x x
B cell receptor signaling pathway x x x x x
Carbohydrate digestion and absorption x x x x x
Endometrial cancer x x x x x
mTOR signaling pathway x x x x x
Acute myeloid leukemia x x x x x























Glioma x x x x x
Chronic myeloid leukemia x x x x x
Renal cell carcinoma x x x x x
Pancreatic cancer x x x x x
Fc epsilon RI signaling pathway x x x x x
Apoptosis x x x x x
ErbB signaling pathway x x x x x
Melanoma x x x x x
Progesterone-mediated oocyte maturation x x x x x
Fc gamma R-mediated phagocytosis x x x x x
Natural killer cell mediated cytotoxicity x x
Prostate cancer x x x x x
Toll-like receptor signaling pathway x x x x x
Chagas disease (American trypanosomiasis) x x x x x
Osteoclast differentiation x x x x x
Insulin signaling pathway x x x x x
Hepatitis C x x x x x
Vitamin digestion and absorption x x
Fatty acid metabolism x x x x
PPAR signaling pathway x x x























Peroxisome x x x
Steroid biosynthesis x x
Glycosphingolipid biosynthesis - lacto and
neolacto series
x x x x
Alanine, aspartate and glutamate
metabolism
x x x
Amino sugar and nucleotide sugar
metabolism
x x x




Spliceosome x x x
Staphylococcus aureus infection x x
Systemic lupus erythematosus x x
negative regulation of intrinsic apoptotic
signaling pathway in response to oxidative
stress
x x x x x
Fc-epsilon receptor signaling pathway x x
hormone-mediated signaling pathway x x x
negative regulation of extrinsic apoptotic
signaling pathway
x
regulation of extrinsic apoptotic signaling
pathway
x
G-protein coupled acetylcholine receptor
signaling pathway
x x x x
epiblast cell-extraembryonic ectoderm cell
signaling involved in anterior/posterior axis
specification
x x
transforming growth factor beta receptor
signaling pathway involved in primitive
streak formation
x x
positive regulation of nodal signaling
pathway involved in determination of
lateral mesoderm left/right asymmetry
x x
adenylate cyclase-activating G-protein



























regulation of nodal signaling pathway
involved in determination of left/right
asymmetry
x x
regulation of nodal signaling pathway
involved in determination of lateral
mesoderm left/right asymmetry
x x
regulation of signaling x x x x
positive regulation of activin receptor
signaling pathway
x x
nodal signaling pathway involved in
determination of left/right asymmetry
x x
regulation of nodal signaling pathway x x
nodal signaling pathway involved in
determination of lateral mesoderm
left/right asymmetry
x x
negative regulation of androgen receptor
signaling pathway
x x
calcium-mediated signaling x x
nodal signaling pathway x x
Regulation of actin cytoskeleton x x x x
Biosynthesis of unsaturated fatty acids x x x
alpha-Linolenic acid metabolism x x x
Viral myocarditis x x x
























regulation of smoothened signaling pathway x x x x
smoothened signaling pathway x x x
glucocorticoid mediated signaling pathway x x x
regulation of glucocorticoid mediated
signaling pathway
x x x
nucleotide-binding domain, leucine rich
repeat containing receptor signaling
pathway
x x
dopamine receptor signaling pathway x x
regulation of rhodopsin mediated signaling
pathway
x x
Steroid hormone biosynthesis x x x
RIG-I-like receptor signaling pathway x x x
Chemokine signaling pathway x x x
Focal adhesion x x x
MAPK signaling pathway x x x
protein kinase B signaling x x x
positive regulation of protein kinase B
signaling
x x x
regulation of protein kinase B signaling x x x
negative regulation of stress-activated
protein kinase signaling cascade
x x x
G-protein coupled receptor signaling
pathway
x x x
negative regulation of extrinsic apoptotic
signaling pathway in absence of ligand
x x x
Melanogenesis x x
Riboflavin metabolism x x
positive regulation of nucleotide-binding


























oligomerization domain containing 1
signaling pathway
x x
positive regulation of nucleotide-binding




oligomerization domain containing 2
signaling pathway
x x
positive regulation of nucleotide-binding
oligomerization domain containing 2
signaling pathway
x x
regulation of growth hormone receptor
signaling pathway
x x








containing 1 signaling pathway
x x
signaling x
single organism signaling x
canonical Wnt signaling pathway involved
in regulation of type B pancreatic cell
proliferation
x
stromal-epithelial cell signaling involved in
prostate gland development
x
regulation of canonical Wnt signaling
pathway involved in controlling type B
pancreatic cell proliferation
x
negative regulation of canonical Wnt
signaling pathway involved in controlling
type B pancreatic cell proliferation
x
negative regulation of Wnt signaling
pathway involved in dorsal/ventral axis
specification
x
non-canonical Wnt signaling pathway x
canonical Wnt signaling pathway involved
in regulation of cell proliferation
x
regulation of Wnt signaling pathway
involved in dorsal/ventral axis specification
x

























negative regulation of non-canonical Wnt
signaling pathway
x
androgen receptor signaling pathway x
Wnt signaling pathway involved in
dorsal/ventral axis specification
x




Table 6.8: Enriched pathways for under expressed genes for dataset 3. ”x” stands for






















Alzheimer’s disease x x x x x x x x x x
Protein processing in endoplasmic reticulum x x x x x x x x x x
Biosynthesis of unsaturated fatty acids x x x x x x x x x x
alpha-Linolenic acid metabolism x x x x x x x x x x
Taste transduction x x x x x x x x x x
RNA transport x x x x x x x x x x
Small cell lung cancer x x x x x x x x x x
Ribosome biogenesis in eukaryotes x x x x x x x x x x
Hematopoietic cell lineage x x x x x x
Lysosome x x x x x x x x x x
RNA degradation x x x x x x x x x x
mRNA surveillance pathway x x x x x x x x x
Tyrosine metabolism x x x x x x
Proteasome x x x x x
Nucleotide excision repair x x x x x x x x x
Regulation of actin cytoskeleton x x x x x x
Glycosaminoglycan degradation x x x x x x
Other glycan degradation x x x x x x x x
Renal cell carcinoma x x x x x x x x x























MAPK signaling pathway x x x x x x x x x x
Carbohydrate digestion and absorption x x x x x x x x x x
Endometrial cancer x x x x x x x x
Non-small cell lung cancer x x x x x x x x
mTOR signaling pathway x x x x x x x x
Acute myeloid leukemia x x x x x x x x
Colorectal cancer x x x x x x x x
Adipocytokine signaling pathway x x x x x x
Long-term depression x x x x x x
Glioma x x x x x x
VEGF signaling pathway x x x x x x x x x
Chronic myeloid leukemia x x x x x x
B cell receptor signaling pathway x x x x x x x x x x
Pancreatic cancer x x x x x x
Fc epsilon RI signaling pathway x x x x x x
Apoptosis x x x x x x
ErbB signaling pathway x x x x x x
Melanoma x x x x x x
Progesterone-mediated oocyte maturation x x x x x x
Fc gamma R-mediated phagocytosis x x x x x x























Toll-like receptor signaling pathway x x x x x x
Vascular smooth muscle contraction x x x x x x
Chagas disease (American trypanosomiasis) x x x x x x
Osteoclast differentiation x x x x x x
Tight junction x x x x x x
T cell receptor signaling pathway x x x x x x
Toxoplasmosis x x x x x x
Ether lipid metabolism x x x x x x x x
Basal cell carcinoma x x x x x x x x x x
Hedgehog signaling pathway x x x x x x x x x x
Pathways in cancer x x x x x x x x
DNA replication x x x x x x x
Cardiac muscle contraction x x x x x x
Oxidative phosphorylation x x x x x x x x
Parkinson’s disease x x x x x x x
Huntington’s disease x x x x x x x x x
Vibrio cholerae infection x x x
Epithelial cell signaling in Helicobacter
pylori infection
x x x
Rheumatoid arthritis x x x
Phagosome x x x x x x x x x x























Glycosphingolipid biosynthesis - lacto and
neolacto series
x x x x x x x x x x
cGMP-mediated signaling x x x x x x x x x x
G-protein coupled receptor signaling
pathway coupled to cGMP nucleotide
second messenger
x x x x x x x x x x
antigen receptor-mediated signaling
pathway
x x x x x x x x x x
ionotropic glutamate receptor signaling
pathway
x x x x x x x x x x
smoothened signaling pathway x x x x x x x x x x
intracellular steroid hormone receptor
signaling pathway
x x x x x x x x
regulation of smoothened signaling pathway x x x x x x x x x x
androgen receptor signaling pathway x x x x x x x x
mesodermal-endodermal cell signaling x x x x x x x x
TRAM-dependent toll-like receptor
signaling pathway
x x x x x x x x x
TRAM-dependent toll-like receptor 4
signaling pathway
x x x x x x x x x
canonical Wnt signaling pathway involved
in regulation of type B pancreatic cell
proliferation
x x x x x x x x
stromal-epithelial cell signaling involved in
prostate gland development
x x x x x x x x
semaphorin-plexin signaling pathway
involved in bone trabecula morphogenesis
x x x x x x x x
regulation of canonical Wnt signaling
pathway involved in controlling type B
pancreatic cell proliferation
x x x x x x x x
negative regulation of canonical Wnt
signaling pathway involved in controlling
type B pancreatic cell proliferation
x x x x x x x x
negative regulation of intracellular steroid
hormone receptor signaling pathway
x x x x x x x x
integrin-mediated signaling pathway x x x x x x x x x
negative regulation of transmembrane
receptor protein serine/threonine kinase
signaling pathway
x x x x x x x x
negative regulation of Wnt signaling
pathway involved in dorsal/ventral axis
specification























negative regulation of BMP signaling
pathway
x x x x x x x x
canonical Wnt signaling pathway involved
in regulation of cell proliferation
x x x x x x x x
regulation of Wnt signaling pathway
involved in dorsal/ventral axis specification
x x x x x x x x
regulation of intracellular steroid hormone
receptor signaling pathway
x x x x x x x x
Wnt signaling pathway involved in
dorsal/ventral axis specification
x x x x x x x x
Wnt signaling pathway involved in
somitogenesis
x x x x x x x x
intrinsic apoptotic signaling pathway in
response to endoplasmic reticulum stress
x x x x x x x x x x
semaphorin-plexin signaling pathway
involved in outflow tract morphogenesis
x x x x x x x x x x
positive regulation of semaphorin-plexin
signaling pathway involved in outflow tract
morphogenesis
x x x x x x x x x x
regulation of semaphorin-plexin signaling
pathway
x x x x x x x x x x
positive regulation of semaphorin-plexin
signaling pathway
x x x x x x x x x x
cholecystokinin signaling pathway x x x x x x x x
negative regulation of insulin-like growth
factor receptor signaling pathway
x x x x x x
negative regulation of retinoic acid receptor
signaling pathway
x x x x x x x x x
regulation of retinoic acid receptor signaling
pathway
x x x x x x x x x
retinoic acid receptor signaling pathway x x x x x x x x x
semaphorin-plexin signaling pathway x x x x x x x x x
cell surface receptor signaling pathway
involved in heart development
x x x x x x x x x
Notch signaling pathway x x x x x x x x
positive regulation of chemokine-mediated
signaling pathway
x x x x x























regulation of chemokine-mediated signaling
pathway
x x x x x
negative regulation of TOR signaling x x x x x x x x
negative regulation of intrinsic apoptotic
signaling pathway in response to oxidative
stress
x x x x x x x x x x
regulation of intrinsic apoptotic signaling
pathway in response to oxidative stress
x x x x x x x x x x
negative regulation of stress-activated
protein kinase signaling cascade
x x x x x x x x x x
regulation of protein insertion into
mitochondrial membrane involved in
apoptotic signaling pathway
x x x x x x x x x x
positive regulation of protein insertion into
mitochondrial membrane involved in
apoptotic signaling pathway
x x x x x x x x x x
protein insertion into mitochondrial
membrane involved in apoptotic signaling
pathway
x x x x x x x x x x
regulation of TOR signaling x x x x x x x x x x
G-protein coupled receptor signaling
pathway
x x x x x x
intrinsic apoptotic signaling pathway in
response to oxidative stress
x x x x x x x x
insulin-like growth factor receptor signaling
pathway
x x x x x x x x x x
negative regulation of extrinsic apoptotic
signaling pathway in absence of ligand
x x x x x x x x
TOR signaling x x x x x x
regulation of mitochondrial outer membrane
permeabilization involved in apoptotic
signaling pathway
x x x x x x x x
negative regulation of intrinsic apoptotic
signaling pathway
x x x x x x x x x
regulation of extrinsic apoptotic signaling
pathway in absence of ligand
x x x x x x
extrinsic apoptotic signaling pathway in
absence of ligand
x x x x x x
regulation of intrinsic apoptotic signaling
pathway
x x x x x x x x
negative regulation of extrinsic apoptotic
signaling pathway
x x x x x x x x x x
adenylate cyclase-modulating G-protein
coupled receptor signaling pathway























protein kinase B signaling x x x x x x x x x x
negative regulation of apoptotic signaling
pathway
x x x x x x x x x x
regulation of stress-activated protein kinase
signaling cascade
x x x x x x
Fc-epsilon receptor signaling pathway x x x x x x
G-protein coupled receptor signaling
pathway, coupled to cyclic nucleotide
second messenger
x x x x x x x x x x
regulation of extrinsic apoptotic signaling
pathway
x x x x x x x x x x
fibroblast growth factor receptor signaling
pathway
x x x x x x
phosphatidylinositol-mediated signaling x x x x x x x x x x
inositol lipid-mediated signaling x x x x x x x x x x
insulin receptor signaling pathway x x x x x x
epidermal growth factor receptor signaling
pathway
x x x x x x
stress-activated protein kinase signaling
cascade
x x x x x x
Fc receptor signaling pathway x x x x x x
ERBB signaling pathway x x x x x x
extrinsic apoptotic signaling pathway x x x x x x x x x x
intrinsic apoptotic signaling pathway x x x x x x x x
cell surface receptor signaling pathway x x x x x x x x
neurotrophin TRK receptor signaling
pathway
x x x x x x x x
neurotrophin signaling pathway x x x x x x
mesenchymal smoothened signaling pathway
involved in prostate gland development
x x x x x x
epithelial-mesenchymal signaling involved
in prostate gland development























regulation of nodal signaling pathway
involved in determination of left/right
asymmetry
x x x x x x
regulation of nodal signaling pathway
involved in determination of lateral
mesoderm left/right asymmetry
x x x x x x
smoothened signaling pathway involved in
regulation of cerebellar granule cell
precursor cell proliferation
x x x x x x x x x
nodal signaling pathway involved in
determination of left/right asymmetry
x x x x x x
regulation of nodal signaling pathway x x x x x x
nodal signaling pathway involved in
determination of lateral mesoderm
left/right asymmetry
x x x x x x
cerebellar Purkinje cell-granule cell
precursor cell signaling involved in
regulation of granule cell precursor cell
proliferation
x x x x x x x x x
epithelial-mesenchymal cell signaling x x x x x x x x x
regulation of transmembrane receptor
protein serine/threonine kinase signaling
pathway
x x x x x x
nodal signaling pathway x x x x x x
regulation of activin receptor signaling
pathway
x x x x x x
positive regulation of smoothened signaling
pathway
x x x x x x x x x
transmembrane receptor protein
serine/threonine kinase signaling pathway
x x x x x x
activin receptor signaling pathway x x x x x x
ciliary receptor clustering involved in
smoothened signaling pathway
x x x x x x
smoothened signaling pathway involved in
ventral spinal cord patterning
x x x x x x
cAMP-mediated signaling x x x x x x x x
signaling x x x x x x
single organism signaling x x x x x x
regulation of thrombin receptor signaling
pathway
x x x x x x x
negative regulation of thrombin receptor
signaling pathway























thrombin receptor signaling pathway x x x x x x x
negative regulation of platelet-derived
growth factor receptor signaling pathway
x x x x x x x
regulation of platelet-derived growth factor
receptor signaling pathway
x x x x x x x
brain-derived neurotrophic factor receptor
signaling pathway
x x x x x x x x x x
calcium-mediated signaling using
intracellular calcium source
x x x x x x x x x x
transforming growth factor beta receptor
signaling pathway
x x x x x x
enzyme linked receptor protein signaling
pathway
x x x x x x
positive regulation of transforming growth
factor beta receptor signaling pathway
x x x x x x x x
chemokine-mediated signaling pathway x x x x x x x x x
Long-term potentiation x x x x x x x
Adherens junction x x x x x x x x x
Neurotrophin signaling pathway x x x x x x x x
Glycerophospholipid metabolism x x x x x x x
Natural killer cell mediated cytotoxicity x x x x x x x
ECM-receptor interaction x x x x x x x x
Focal adhesion x x x x x x x x
regulation of lipopolysaccharide-mediated
signaling pathway
x x x x x x x x x
regulation of fibroblast growth factor
receptor signaling pathway
x x x x x x x x x
negative regulation of smoothened signaling
pathway
x x x x x x x x x
lipopolysaccharide-mediated signaling
pathway
x x x x x x x x x
positive regulation of insulin-like growth
factor receptor signaling pathway























apoptotic signaling pathway x x x x x x x x x
regulation of insulin-like growth factor
receptor signaling pathway
x x x x x x x
regulation of apoptotic signaling pathway x x x x x x x
glutamate receptor signaling pathway x x x x x x x
positive regulation of G-protein coupled
receptor protein signaling pathway
x x x x x x x
gamma-aminobutyric acid signaling
pathway
x x x x x x x
positive regulation of phosphatidylinositol
3-kinase signaling
x x x x x
regulation of phosphatidylinositol 3-kinase
signaling
x x x x
phosphatidylinositol 3-kinase signaling x x x x
calcium-mediated signaling x x x x
regulation of protein kinase B signaling x x x x x
second-messenger-mediated signaling x x x x
mesenchymal-epithelial cell signaling
involved in prostate gland development
x x x x x x x x
negative regulation of epidermal growth
factor receptor signaling pathway
x x x x x x x x
negative regulation of ERBB signaling
pathway
x x x x x x x x
regulation of epidermal growth factor
receptor signaling pathway
x x x x x x x x
regulation of ERBB signaling pathway x x x x x x x x
steroid hormone mediated signaling
pathway
x x x x x x x x
mesenchymal-epithelial cell signaling x x x x x x x x
Fatty acid metabolism x x x























Inositol phosphate metabolism x x x x x
Complement and coagulation cascades x x x x
Phosphatidylinositol signaling system x x x x
Pancreatic secretion x x x x x x
RIG-I-like receptor signaling pathway x x x x
Type II diabetes mellitus x x x x x
Melanogenesis x x x x
Salivary secretion x x x x
negative regulation of signaling x x x
transmembrane receptor protein tyrosine
phosphatase signaling pathway
x x x x x
extrinsic apoptotic signaling pathway via
death domain receptors
x x x x
regulation of glutamate receptor signaling
pathway
x x x x x x x
immune response-regulating cell surface
receptor signaling pathway involved in
phagocytosis
x x x x
Fc-gamma receptor signaling pathway
involved in phagocytosis
x x x x
Fc-gamma receptor signaling pathway x x x x
Fc receptor mediated stimulatory signaling
pathway
x x x x
MyD88-independent toll-like receptor
signaling pathway
x x x x
toll-like receptor 4 signaling pathway x x x x
positive regulation of I-kappaB
kinase/NF-kappaB signaling
x x x x
toll-like receptor signaling pathway x x x x
pattern recognition receptor signaling
pathway























immune response-activating cell surface
receptor signaling pathway
x x x x
regulation of I-kappaB kinase/NF-kappaB
signaling
x x x x
I-kappaB kinase/NF-kappaB signaling x x x x
negative regulation of canonical Wnt
signaling pathway
x x x x x
negative regulation of Wnt signaling
pathway
x x x x x
regulation of canonical Wnt signaling
pathway
x x x x x
regulation of Wnt signaling pathway x x x x x
Glycosaminoglycan biosynthesis - keratan
sulfate
x x x x x x
Glyoxylate and dicarboxylate metabolism x x x x x x
Porphyrin and chlorophyll metabolism x x x x x x
serotonin receptor signaling pathway x x x x
Fatty acid elongation in mitochondria x x
Spliceosome x x x
Ubiquitin mediated proteolysis x x x
RNA polymerase x x x























Metabolic pathways x x x
N-Glycan biosynthesis x x x
Cytosolic DNA-sensing pathway x x x
Aminoacyl-tRNA biosynthesis x x
Antigen processing and presentation x x
Renin-angiotensin system x x
African trypanosomiasis x x
regulation of toll-like receptor 3 signaling
pathway
x x
positive regulation of toll-like receptor 3
signaling pathway
x x
Toll signaling pathway x x
regulation of toll-like receptor 4 signaling
pathway
x x
positive regulation of toll-like receptor 4
signaling pathway
x x
positive regulation of protein kinase B
signaling
x x






Aldosterone-regulated sodium reabsorption x x
Proximal tubule bicarbonate reclamation x x x
Citrate cycle (TCA cycle) x x x
Pyruvate metabolism x x x
Calcium signaling pathway x x x























transmembrane receptor protein tyrosine
kinase signaling pathway
x
activation of MAPK activity by adrenergic
receptor signaling pathway
x x x
epidermal growth factor-activated receptor
transactivation by G-protein coupled
receptor signaling pathway
x x x
positive regulation of epidermal growth
factor receptor signaling pathway
x x x
positive regulation of ERBB signaling
pathway
x x x
adrenergic receptor signaling pathway x x x x
intrinsic apoptotic signaling pathway in
response to DNA damage by p53 class
mediator







positive regulation of cAMP-mediated
signaling
x x x
regulation of cAMP-mediated signaling x x x






Phenylalanine metabolism x x
One carbon pool by folate x x x
Steroid hormone biosynthesis x x x
intrinsic apoptotic signaling pathway by
p53 class mediator
x x x
positive regulation of protein kinase A
signaling
x x x
regulation of intrinsic apoptotic signaling
pathway in response to DNA damage by
p53 class mediator
x x x
negative regulation of intrinsic apoptotic
signaling pathway in response to DNA




























negative regulation of intrinsic apoptotic
signaling pathway by p53 class mediator
x x x
protein kinase A signaling x x x
regulation of protein kinase A signaling x x x
regulation of intrinsic apoptotic signaling
pathway by p53 class mediator
x x x
negative regulation of intrinsic apoptotic
signaling pathway in response to DNA
damage
x x x
regulation of intrinsic apoptotic signaling
pathway in response to DNA damage
x x x
intrinsic apoptotic signaling pathway in
response to DNA damage
x x x
positive regulation of signaling x x
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Table 6.9: Enriched pathways for over expressed genes for dataset 4. ”x” stands for ”found








adrenergic receptor signaling pathway involved in positive regulation of heart rate x x
extrinsic apoptotic signaling pathway x x
regulation of extrinsic apoptotic signaling pathway x x
cell surface receptor signaling pathway x x
adenylate cyclase-activating adrenergic receptor signaling pathway x x
adrenergic receptor signaling pathway involved in heart process x x
regulation of apoptotic signaling pathway x x
G-protein coupled receptor signaling pathway involved in heart process x x
apoptotic signaling pathway x x
positive regulation of insulin receptor signaling pathway x x
regulation of signaling x x
extrinsic apoptotic signaling pathway in absence of ligand x x
negative regulation of extrinsic apoptotic signaling pathway x x
T cell receptor signaling pathway x x
Bile secretion x x
Toxoplasmosis x x
Hepatitis C x x
Endocytosis x x
Vascular smooth muscle contraction x x
Steroid biosynthesis x x
TGF-beta signaling pathway x x
thyroid hormone mediated signaling pathway x
oncostatin-M-mediated signaling pathway x
positive regulation of interferon-gamma-mediated signaling pathway x
regulation of vitamin D receptor signaling pathway x
vitamin D receptor signaling pathway x
interferon-gamma-mediated signaling pathway x
androgen receptor signaling pathway x
positive regulation of intracellular steroid hormone receptor signaling pathway x
positive regulation of intracellular estrogen receptor signaling pathway x
cytokine-mediated signaling pathway x
Alanine, aspartate and glutamate metabolism x
Purine metabolism x
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Table 6.10: Enriched pathways for under expressed genes for dataset 4. ”x” stands for








negative regulation of insulin receptor signaling pathway x x
regulation of insulin receptor signaling pathway x x
Notch signaling pathway x x
positive regulation of protein kinase A signaling x x
regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53
class mediator
x x
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage
by p53 class mediator
x x
positive regulation of lipopolysaccharide-mediated signaling pathway x x
negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator x x
protein kinase A signaling x x
regulation of protein kinase A signaling x x
regulation of intrinsic apoptotic signaling pathway by p53 class mediator x x
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage x x
regulation of intrinsic apoptotic signaling pathway in response to DNA damage x x
regulation of lipopolysaccharide-mediated signaling pathway x x
adiponectin-activated signaling pathway x x
androgen receptor signaling pathway x x
intracellular steroid hormone receptor signaling pathway x x
insulin receptor signaling pathway x x
Adherens junction x x
Cell adhesion molecules (CAMs) x x
Protein processing in endoplasmic reticulum x x
Phenylalanine metabolism x x
Collecting duct acid secretion x x
fibroblast growth factor receptor signaling pathway involved in negative regulation of
apoptotic process in bone marrow
x
fibroblast growth factor receptor signaling pathway involved in hemopoiesis x
fibroblast growth factor receptor signaling pathway involved in positive regulation of
cell proliferation in bone marrow
x
fibroblast growth factor receptor signaling pathway involved in mammary gland
specification
x
nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway x
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex
development
x
granzyme-mediated apoptotic signaling pathway x
Toll signaling pathway x
N-Glycan biosynthesis x
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Table 6.11: Summarization of the enriched pathways for over expressed genes for all data
sets. ”x” stands for ”found to be significant”.
Pathways D1 D2 D3 D4
apoptotic signaling pathway x x x x
regulation of apoptotic signaling pathway x x x
intrinsic apoptotic signaling pathway in response to DNA damage x x x
regulation of cytokine-mediated signaling pathway x
adenosine receptor signaling pathway x
G-protein coupled purinergic receptor signaling pathway x
intrinsic apoptotic signaling pathway x x
positive regulation of I-kappaB kinase/NF-kappaB signaling x x
positive regulation of apoptotic signaling pathway x
extrinsic apoptotic signaling pathway via death domain receptors x x
regulation of interferon-gamma-mediated signaling pathway x
growth hormone receptor signaling pathway x
intrinsic apoptotic signaling pathway by p53 class mediator x x
regulation of Fc receptor mediated stimulatory signaling pathway x
ER-nucleus signaling pathway x x x
JAK-STAT cascade involved in growth hormone signaling pathway x
platelet-derived growth factor receptor-beta signaling pathway x x
extrinsic apoptotic signaling pathway x x x
regulation of intrinsic apoptotic signaling pathway x x
negative regulation of intrinsic apoptotic signaling pathway x x
negative regulation of cytokine-mediated signaling pathway x
positive regulation of metanephric mesenchymal cell migration by platelet-derived
growth factor receptor-beta signaling pathway
x
regulation of metanephric mesenchymal cell migration by platelet-derived growth factor
receptor-beta signaling pathway
x
positive regulation of cysteine-type endopeptidase activity involved in apoptotic
signaling pathway
x
activation of signaling protein activity involved in unfolded protein response x x x
negative regulation of protein kinase B signaling x
regulation of I-kappaB kinase/NF-kappaB signaling x x
protein insertion into mitochondrial membrane involved in apoptotic signaling pathway x x
regulation of mitochondrial outer membrane permeabilization involved in apoptotic
signaling pathway
x x
I-kappaB kinase/NF-kappaB signaling x x
adenylate cyclase-activating dopamine receptor signaling pathway x x x
regulation of protein insertion into mitochondrial membrane involved in apoptotic
signaling pathway
x x
positive regulation of protein insertion into mitochondrial membrane involved in
apoptotic signaling pathway
x x
androgen receptor signaling pathway x x x
positive regulation of extrinsic apoptotic signaling pathway x
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Table 6.11 continued...
Pathways D1 D2 D3 D4
extrinsic apoptotic signaling pathway in absence of ligand x x
regulation of extrinsic apoptotic signaling pathway in absence of ligand x
positive regulation of type I interferon-mediated signaling pathway x
TRIF-dependent toll-like receptor signaling pathway x
regulation of type I interferon-mediated signaling pathway x
MyD88-independent toll-like receptor signaling pathway x x
toll-like receptor 3 signaling pathway x
positive regulation of intrinsic apoptotic signaling pathway x
cytokine-mediated signaling pathway x x x
interferon-gamma-mediated signaling pathway x x x
type I interferon signaling pathway x
Fc receptor mediated stimulatory signaling pathway x x
dopamine receptor signaling pathway x x
immune response-regulating cell surface receptor signaling pathway involved in
phagocytosis
x x
Fc-gamma receptor signaling pathway involved in phagocytosis x x
positive regulation of extrinsic apoptotic signaling pathway in absence of ligand x
positive regulation of cytokine-mediated signaling pathway x x
interleukin-4-mediated signaling pathway x x
MDA-5 signaling pathway x
positive regulation of mitochondrial outer membrane permeabilization involved in
apoptotic signaling pathway
x
Fc-gamma receptor signaling pathway x x
toll-like receptor 4 signaling pathway x
toll-like receptor 2 signaling pathway x
regulation of BMP signaling pathway x x
negative regulation of BMP signaling pathway x x
BMP signaling pathway x x
regulation of transmembrane receptor protein serine/threonine kinase signaling pathway x x
negative regulation of transmembrane receptor protein serine/threonine kinase signaling
pathway
x x x
negative regulation of activin receptor signaling pathway x
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator x
transmembrane receptor protein serine/threonine kinase signaling pathway x x
regulation of adenosine receptor signaling pathway x
negative regulation of adenosine receptor signaling pathway x
neurotrophin TRK receptor signaling pathway x x x
neurotrophin signaling pathway x x x
intrinsic apoptotic signaling pathway in response to oxidative stress x x
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Table 6.11 continued...
Pathways D1 D2 D3 D4
thromboxane A2 signaling pathway x
negative regulation of protein kinase C signaling x
regulation of opioid receptor signaling pathway x
sphingosine-1-phosphate signaling pathway x
sphingolipid mediated signaling pathway x
Wnt signaling pathway, calcium modulating pathway x
regulation of intrinsic apoptotic signaling pathway in response to DNA damage x
regulation of toll-like receptor 4 signaling pathway x
positive regulation of toll-like receptor 4 signaling pathway x
positive regulation of toll-like receptor signaling pathway x
immune response-regulating signaling pathway x
regulation of toll-like receptor signaling pathway x
regulation of tumor necrosis factor-mediated signaling pathway x
transmembrane receptor protein tyrosine kinase signaling pathway x x x
toll-like receptor 5 signaling pathway x x
toll-like receptor 10 signaling pathway x x
insulin receptor signaling pathway x x
toll-like receptor 9 signaling pathway x
negative regulation of tumor necrosis factor-mediated signaling pathway x x
negative regulation of fibroblast growth factor receptor signaling pathway x
tumor necrosis factor-mediated signaling pathway x
regulation of extrinsic apoptotic signaling pathway x x x x
toll-like receptor TLR1:TLR2 signaling pathway x
toll-like receptor TLR6:TLR2 signaling pathway x
negative regulation of apoptotic signaling pathway x x x
fibroblast growth factor receptor signaling pathway x x
regulation of signaling x x x x
negative regulation of signaling x x x
vascular endothelial growth factor receptor signaling pathway x
phospholipase C-activating dopamine receptor signaling pathway x
regulation of cysteine-type endopeptidase activity involved in apoptotic signaling
pathway
x
intracellular steroid hormone receptor signaling pathway x
transforming growth factor beta receptor signaling pathway x x x
intracellular receptor signaling pathway x x
retinoic acid receptor signaling pathway x x
positive regulation of Wnt signaling pathway, planar cell polarity pathway x
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Table 6.11 continued...
Pathways D1 D2 D3 D4
regulation of androgen receptor signaling pathway x
regulation of transforming growth factor beta receptor signaling pathway x x x
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage x
activin receptor signaling pathway x
positive regulation of signaling x x x
negative regulation of phosphatidylinositol 3-kinase signaling x
negative regulation of intrinsic apoptotic signaling pathway in response to oxidative
stress
x x
regulation of intrinsic apoptotic signaling pathway in response to oxidative stress x x
glucocorticoid receptor signaling pathway x
rhodopsin mediated signaling pathway x x
corticosteroid receptor signaling pathway x
positive regulation of epidermal growth factor receptor signaling pathway x x
positive regulation of ERBB signaling pathway x x
canonical Wnt signaling pathway involved in mesenchymal stem cell differentiation x
canonical Wnt signaling pathway involved in osteoblast differentiation x
hepatocyte growth factor receptor signaling pathway x x
positive regulation of non-canonical Wnt signaling pathway x x
thrombopoietin-mediated signaling pathway x
negative regulation of dopamine receptor signaling pathway x
positive regulation of dopamine receptor signaling pathway x
adenylate cyclase-inhibiting dopamine receptor signaling pathway x
regulation of dopamine receptor signaling pathway x
desensitization of G-protein coupled receptor protein signaling pathway x
negative adaptation of signaling pathway x
adaptation of signaling pathway x
positive regulation of G-protein coupled receptor protein signaling pathway x




Protein processing in endoplasmic reticulum x x x
Alzheimer’s disease x x
Metabolic pathways x x
Ribosome x
Arginine and proline metabolism x
mRNA surveillance pathway x x x
249
Table 6.11 continued...
Pathways D1 D2 D3 D4
Base excision repair x x
Ubiquitin mediated proteolysis x x
Proteasome x x
Pathogenic Escherichia coli infection x x x
Insulin signaling pathway x x x
Bacterial invasion of epithelial cells x
Shigellosis x x
Fc gamma R-mediated phagocytosis x x x
Alanine, aspartate and glutamate metabolism x x x x
RNA polymerase x x
Neurotrophin signaling pathway x x x
Apoptosis x x
Ribosome biogenesis in eukaryotes x x
Adipocytokine signaling pathway x x
N-Glycan biosynthesis x
Other types of O-glycan biosynthesis x
Glycosphingolipid biosynthesis - globo series x x
Glycosphingolipid biosynthesis - lacto and neolacto series x x
Type II diabetes mellitus x x
Notch signaling pathway x x x
Peroxisome x x
Thiamine metabolism x
Jak-STAT signaling pathway x x x
Acute myeloid leukemia x x x
Amino sugar and nucleotide sugar metabolism x x x
Renal cell carcinoma x x x
Glutathione metabolism x
Protein digestion and absorption x x
Glioma x x x
Galactose metabolism x x
Citrate cycle (TCA cycle) x
Amoebiasis x
Non-small cell lung cancer x x x
PPAR signaling pathway x x
Chronic myeloid leukemia x x x
Pancreatic cancer x x x
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Table 6.11 continued...
Pathways D1 D2 D3 D4
Axon guidance x x
ECM-receptor interaction x x x
Small cell lung cancer x x x
Prostate cancer x x x
Biotin metabolism x
Pyrimidine metabolism x
Glycosylphosphatidylinositol(GPI)-anchor biosynthesis x x
DNA replication x
Toxoplasmosis x x x
Antigen processing and presentation x
Colorectal cancer x x
Amyotrophic lateral sclerosis (ALS) x
Prion diseases x
Lysosome x x
Vibrio cholerae infection x
Phagosome x x
Chagas disease (American trypanosomiasis) x x
MAPK signaling pathway x x
Focal adhesion x x
Bladder cancer x x
Melanoma x x
Glycerolipid metabolism x
mTOR signaling pathway x x x
Glycerophospholipid metabolism x
Fat digestion and absorption x
Glyoxylate and dicarboxylate metabolism x
Ether lipid metabolism x x
Mucin type O-Glycan biosynthesis x
Vasopressin-regulated water reabsorption x
Cell cycle x x
Oocyte meiosis x x
p53 signaling pathway x
Progesterone-mediated oocyte maturation x x
RNA transport x x x
Fructose and mannose metabolism x
Circadian rhythm - mammal x
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Table 6.11 continued...
Pathways D1 D2 D3 D4
Lysine degradation x
Dorso-ventral axis formation x
Endocytosis x x
Leishmaniasis x x
Viral myocarditis x x
Fc epsilon RI signaling pathway x x
Wnt signaling pathway x x
ErbB signaling pathway x x
Pathways in cancer x x
T cell receptor signaling pathway x x x
VEGF signaling pathway x x
Epithelial cell signaling in Helicobacter pylori infection x
B cell receptor signaling pathway x x
Tight junction x x
Adherens junction x
GnRH signaling pathway x
Phosphatidylinositol signaling system x x
Fatty acid elongation in mitochondria x
Natural killer cell mediated cytotoxicity x x
Long-term potentiation x x
negative regulation of transforming growth factor beta receptor signaling pathway x x
enzyme linked receptor protein signaling pathway x x
positive regulation of intracellular steroid hormone receptor signaling pathway x x
positive regulation of intracellular estrogen receptor signaling pathway x x
signaling x x
single organism signaling x x
thyroid hormone mediated signaling pathway x x
mesenchymal-epithelial cell signaling involved in prostate gland development x
cell surface receptor signaling pathway x x x
regulation of intracellular estrogen receptor signaling pathway x
lipopolysaccharide-mediated signaling pathway x x
regulation of G-protein coupled receptor protein signaling pathway x
regulation of rhodopsin mediated signaling pathway x x
regulation of lipopolysaccharide-mediated signaling pathway x x
TOR signaling x x
positive regulation of Notch signaling pathway x
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Table 6.11 continued...
Pathways D1 D2 D3 D4
regulation of epidermal growth factor receptor signaling pathway x x
negative regulation of G-protein coupled receptor protein signaling pathway x
cAMP-mediated signaling x x
regulation of ERBB signaling pathway x x
negative regulation of epidermal growth factor receptor signaling pathway x x
epidermal growth factor receptor signaling pathway x x
ERBB signaling pathway x x
negative regulation of ERBB signaling pathway x x
Fc receptor signaling pathway x
immune response-regulating cell surface receptor signaling pathway x
Fc-epsilon receptor signaling pathway x x
Roundabout signaling pathway x
immune response-activating cell surface receptor signaling pathway x x
nucleotide-binding oligomerization domain containing signaling pathway x
regulation of chemokine-mediated signaling pathway x x
intracellular estrogen receptor signaling pathway x
stress-activated protein kinase signaling cascade x
regulation of stress-activated protein kinase signaling cascade x
Phenylalanine, tyrosine and tryptophan biosynthesis x
Biosynthesis of unsaturated fatty acids x x
Phenylalanine metabolism x
Maturity onset diabetes of the young x
negative regulation of retinoic acid receptor signaling pathway x
regulation of retinoic acid receptor signaling pathway x
protein kinase B signaling x x
Neuroactive ligand-receptor interaction x
Cell adhesion molecules (CAMs) x x
Other glycan degradation x x
cell-cell signaling x
gamma-aminobutyric acid signaling pathway x x
cyclic-nucleotide-mediated signaling x x
glutamate receptor signaling pathway x
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress x x
regulation of adenylate cyclase activity involved in G-protein coupled receptor signaling
pathway
x
positive regulation of adenylate cyclase activity involved in G-protein coupled receptor
signaling pathway
x
TRAM-dependent toll-like receptor signaling pathway x x
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Table 6.11 continued...
Pathways D1 D2 D3 D4
TRAM-dependent toll-like receptor 4 signaling pathway x x
glucocorticoid mediated signaling pathway x x
regulation of glucocorticoid mediated signaling pathway x x
regulation of cardiac muscle contraction by calcium ion signaling x
platelet-derived growth factor receptor signaling pathway x
phospholipase C-activating G-protein coupled glutamate receptor signaling pathway x
thyroid-stimulating hormone signaling pathway x
positive regulation of retinoic acid receptor signaling pathway x
positive regulation of interferon-gamma-mediated signaling pathway x x
regulation of vitamin D receptor signaling pathway x x
Purine metabolism x x
Gastric acid secretion x
Tyrosine metabolism x
negative regulation of extrinsic apoptotic signaling pathway x x x
mesodermal-endodermal cell signaling x
somatostatin receptor signaling pathway x
somatostatin signaling pathway x
canonical Wnt signaling pathway involved in regulation of type B pancreatic cell
proliferation
x x
stromal-epithelial cell signaling involved in prostate gland development x x
regulation of canonical Wnt signaling pathway involved in controlling type B pancreatic
cell proliferation
x x
negative regulation of canonical Wnt signaling pathway involved in controlling type B
pancreatic cell proliferation
x x
regulation of insulin-like growth factor receptor signaling pathway x
Butirosin and neomycin biosynthesis x
Sphingolipid metabolism x
negative regulation of Wnt signaling pathway involved in dorsal/ventral axis
specification
x x
canonical Wnt signaling pathway involved in regulation of cell proliferation x x
regulation of Wnt signaling pathway involved in dorsal/ventral axis specification x x
Wnt signaling pathway involved in dorsal/ventral axis specification x x
Wnt signaling pathway involved in somitogenesis x x
negative regulation of non-canonical Wnt signaling pathway x x
insulin-like growth factor receptor signaling pathway x x
positive regulation of insulin-like growth factor receptor signaling pathway x
negative regulation of insulin-like growth factor receptor signaling pathway x x
Terpenoid backbone biosynthesis x
Glycosaminoglycan degradation x
Inositol phosphate metabolism x
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Table 6.11 continued...
Pathways D1 D2 D3 D4
Pancreatic secretion x
Complement and coagulation cascades x
Basal transcription factors x
Nucleotide excision repair x
adenylate cyclase-activating adrenergic receptor signaling pathway x x
G-protein coupled receptor signaling pathway coupled to cGMP nucleotide second
messenger
x
positive regulation of cAMP-mediated signaling x
G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second
messenger
x
regulation of cAMP-mediated signaling x
adrenergic receptor signaling pathway x
regulation of interleukin-6-mediated signaling pathway x
negative regulation of interleukin-6-mediated signaling pathway x
regulation of interleukin-2-mediated signaling pathway x
negative regulation of interleukin-2-mediated signaling pathway x
regulation of prolactin signaling pathway x
negative regulation of prolactin signaling pathway x
regulation of interleukin-4-mediated signaling pathway x
negative regulation of interleukin-4-mediated signaling pathway x
regulation of macrophage colony-stimulating factor signaling pathway x
negative regulation of macrophage colony-stimulating factor signaling pathway x
prolactin signaling pathway x
negative regulation of type I interferon-mediated signaling pathway x
positive regulation of chemokine-mediated signaling pathway x
regulation of platelet-derived growth factor receptor-beta signaling pathway x
negative regulation of platelet-derived growth factor receptor-beta signaling pathway x
transmembrane receptor protein tyrosine phosphatase signaling pathway x
macrophage colony-stimulating factor signaling pathway x
regulation of hepatocyte growth factor receptor signaling pathway x
interleukin-2-mediated signaling pathway x
negative regulation of interferon-gamma-mediated signaling pathway x
interleukin-6-mediated signaling pathway x
atrial cardiac muscle cell to AV node cell signaling x
negative regulation of platelet-derived growth factor receptor signaling pathway x
negative regulation of TOR signaling x
cell-cell signaling involved in cardiac conduction x
positive regulation of vascular endothelial growth factor receptor signaling pathway x
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Table 6.11 continued...
Pathways D1 D2 D3 D4
ionotropic glutamate receptor signaling pathway x
SREBP signaling pathway x
brain-derived neurotrophic factor receptor signaling pathway x
ciliary receptor clustering involved in smoothened signaling pathway x
smoothened signaling pathway involved in ventral spinal cord patterning x
smoothened signaling pathway involved in regulation of cerebellar granule cell precursor
cell proliferation
x
cerebellar Purkinje cell-granule cell precursor cell signaling involved in regulation of
granule cell precursor cell proliferation
x
epithelial-mesenchymal cell signaling x
calcium-mediated signaling using intracellular calcium source x
positive regulation of smoothened signaling pathway x
antigen receptor-mediated signaling pathway x
positive regulation of phosphatidylinositol 3-kinase signaling x
positive regulation of transforming growth factor beta receptor signaling pathway x
adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway x




Cytosolic DNA-sensing pathway x
Arrhythmogenic right ventricular cardiomyopathy (ARVC) x
Hypertrophic cardiomyopathy (HCM) x
Dilated cardiomyopathy x
adiponectin-activated signaling pathway x
integrin-mediated signaling pathway x
chemokine-mediated signaling pathway x
phosphatidylinositol-mediated signaling x
inositol lipid-mediated signaling x
Porphyrin and chlorophyll metabolism x
Long-term depression x
Vascular smooth muscle contraction x x
regulation of TOR signaling x
adenylate cyclase-modulating G-protein coupled receptor signaling pathway x
Wnt signaling pathway involved in wound healing, spreading of epidermal cells x
Intestinal immune network for IgA production x
Leukocyte transendothelial migration x
activation of MAPK activity by adrenergic receptor signaling pathway x
epidermal growth factor-activated receptor transactivation by G-protein coupled
receptor signaling pathway
x
Carbohydrate digestion and absorption x
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Table 6.11 continued...
Pathways D1 D2 D3 D4
Endometrial cancer x
Toll-like receptor signaling pathway x
Osteoclast differentiation x
Hepatitis C x x
Vitamin digestion and absorption x
Fatty acid metabolism x
Steroid biosynthesis x x
Spliceosome x
Staphylococcus aureus infection x
Systemic lupus erythematosus x
hormone-mediated signaling pathway x
G-protein coupled acetylcholine receptor signaling pathway x
epiblast cell-extraembryonic ectoderm cell signaling involved in anterior/posterior axis
specification
x
transforming growth factor beta receptor signaling pathway involved in primitive streak
formation
x
positive regulation of nodal signaling pathway involved in determination of lateral
mesoderm left/right asymmetry
x
adenylate cyclase-activating G-protein coupled receptor signaling pathway x
regulation of nodal signaling pathway involved in determination of left/right asymmetry x
regulation of nodal signaling pathway involved in determination of lateral mesoderm
left/right asymmetry
x
positive regulation of activin receptor signaling pathway x
nodal signaling pathway involved in determination of left/right asymmetry x
regulation of nodal signaling pathway x
nodal signaling pathway involved in determination of lateral mesoderm left/right
asymmetry
x
negative regulation of androgen receptor signaling pathway x
calcium-mediated signaling x
nodal signaling pathway x
Regulation of actin cytoskeleton x
alpha-Linolenic acid metabolism x
Taste transduction x
Phototransduction x
regulation of smoothened signaling pathway x
smoothened signaling pathway x
nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway x
Steroid hormone biosynthesis x
RIG-I-like receptor signaling pathway x
Chemokine signaling pathway x
positive regulation of protein kinase B signaling x
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Table 6.11 continued...
Pathways D1 D2 D3 D4
regulation of protein kinase B signaling x
negative regulation of stress-activated protein kinase signaling cascade x
G-protein coupled receptor signaling pathway x
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand x
Melanogenesis x
Riboflavin metabolism x
positive regulation of nucleotide-binding oligomerization domain containing signaling
pathway
x
regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway x
positive regulation of nucleotide-binding oligomerization domain containing 1 signaling
pathway
x
regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway x
positive regulation of nucleotide-binding oligomerization domain containing 2 signaling
pathway
x
regulation of growth hormone receptor signaling pathway x
positive regulation of growth hormone receptor signaling pathway x
regulation of nucleotide-binding oligomerization domain containing signaling pathway x
nucleotide-binding oligomerization domain containing 1 signaling pathway x
non-canonical Wnt signaling pathway x
positive regulation of canonical Wnt signaling pathway x
adrenergic receptor signaling pathway involved in positive regulation of heart rate x
adrenergic receptor signaling pathway involved in heart process x
G-protein coupled receptor signaling pathway involved in heart process x
positive regulation of insulin receptor signaling pathway x
Bile secretion x
TGF-beta signaling pathway x
oncostatin-M-mediated signaling pathway x
vitamin D receptor signaling pathway x
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Table 6.12: Summarization of the enriched pathways for under expressed genes for all data
sets. ”x” stands for ”found to be significant”.
Pathways D1 D2 D3 D4
glutamate receptor signaling pathway x x x
negative regulation of TOR signaling x x
regulation of extrinsic apoptotic signaling pathway via death domain receptors x
extrinsic apoptotic signaling pathway via death domain receptors x x
cell-cell signaling involved in cardiac conduction x
Fas signaling pathway x x
glucocorticoid mediated signaling pathway x x
regulation of glucocorticoid mediated signaling pathway x x
regulation of Fas signaling pathway x x
multicellular organismal signaling x x
transmembrane receptor protein tyrosine kinase signaling pathway x x x
regulation of cardiac muscle contraction by calcium ion signaling x x x
regulation of glutamate receptor signaling pathway x x
negative regulation of transforming growth factor beta receptor signaling pathway x
enzyme linked receptor protein signaling pathway x x x
reelin-mediated signaling pathway x x
semaphorin-plexin signaling pathway involved in neuron projection guidance x
transmembrane receptor protein tyrosine phosphatase signaling pathway x x
interferon-gamma-mediated signaling pathway x x
interleukin-2-mediated signaling pathway x
calcineurin-NFAT signaling cascade x
regulation of calcineurin-NFAT signaling cascade x
type I interferon signaling pathway x
TRAM-dependent toll-like receptor signaling pathway x x x
TRAM-dependent toll-like receptor 4 signaling pathway x x x
semaphorin-plexin signaling pathway x x
positive regulation of transforming growth factor beta receptor signaling pathway x x
cytokine-mediated signaling pathway x x
negative regulation of stress-activated protein kinase signaling cascade x x x
regulation of interferon-gamma-mediated signaling pathway x x
regulation of type I interferon-mediated signaling pathway x
positive regulation of Wnt signaling pathway x
interleukin-15-mediated signaling pathway x
canonical Wnt signaling pathway involved in positive regulation of apoptotic process x
interleukin-12-mediated signaling pathway x
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Table 6.12 continued...
Pathways D1 D2 D3 D4
nerve growth factor signaling pathway x
G-protein coupled acetylcholine receptor signaling pathway x x
smoothened signaling pathway involved in regulation of cerebellar granule cell precursor
cell proliferation
x x
canonical Wnt signaling pathway involved in negative regulation of apoptotic process x
regulation of lipopolysaccharide-mediated signaling pathway x x x
lipopolysaccharide-mediated signaling pathway x x x
immune response-regulating cell surface receptor signaling pathway involved in
phagocytosis
x x x
Fc-gamma receptor signaling pathway involved in phagocytosis x x x
Fc-gamma receptor signaling pathway x x x
Fc receptor mediated stimulatory signaling pathway x x x
immune response-activating cell surface receptor signaling pathway x x x
Fc receptor signaling pathway x x x
regulation of signaling x x x
immune response-regulating cell surface receptor signaling pathway x
cell surface receptor signaling pathway x x x
regulation of stress-activated protein kinase signaling cascade x x x
immune response-regulating signaling pathway x
fibroblast growth factor receptor signaling pathway x x x
signaling x x x
single organism signaling x x x
epidermal growth factor receptor signaling pathway x x x
stress-activated protein kinase signaling cascade x x x
ERBB signaling pathway x x x
negative regulation of insulin receptor signaling pathway x x
regulation of insulin receptor signaling pathway x x
neurotrophin TRK receptor signaling pathway x x x
Tie signaling pathway x
negative regulation of epidermal growth factor receptor signaling pathway x x x
negative regulation of ERBB signaling pathway x x x
regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53
class mediator
x x x
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage
by p53 class mediator
x x x
regulation of epidermal growth factor receptor signaling pathway x x x
regulation of ERBB signaling pathway x x x
negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator x x x
regulation of intrinsic apoptotic signaling pathway by p53 class mediator x x x
phosphatidylinositol-mediated signaling x x
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Table 6.12 continued...
Pathways D1 D2 D3 D4
inositol lipid-mediated signaling x x
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator x x x
collagen-activated tyrosine kinase receptor signaling pathway x x
collagen-activated signaling pathway x x
leukemia inhibitory factor signaling pathway x
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage x x x
phosphatidylinositol 3-kinase signaling x x
cAMP-mediated signaling x x x
cyclic-nucleotide-mediated signaling x x
vascular endothelial growth factor receptor signaling pathway x
negative regulation of signaling x x x
regulation of nucleotide-binding oligomerization domain containing signaling pathway x x
regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway x
regulation of RIG-I signaling pathway x
positive regulation of protein kinase A signaling x x x x
BMP signaling pathway x
Ribosome biogenesis in eukaryotes x x x
Circadian rhythm - mammal x x
Phosphatidylinositol signaling system x x x
Ubiquitin mediated proteolysis x x x
Biotin metabolism x
Renal cell carcinoma x x x
Focal adhesion x x
VEGF signaling pathway x x
TGF-beta signaling pathway x x
Vascular smooth muscle contraction x x
Toxoplasmosis x x x
Axon guidance x x
Leukocyte transendothelial migration x
Huntington’s disease x x
RNA transport x x x
Endocytosis x
ABC transporters x
Gastric acid secretion x x
T cell receptor signaling pathway x x
Basal transcription factors x
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Table 6.12 continued...
Pathways D1 D2 D3 D4
Leishmaniasis x
Pancreatic cancer x x x
Adherens junction x x x x
Wnt signaling pathway x x
Basal cell carcinoma x x
Viral myocarditis x x
Complement and coagulation cascades x x
Hematopoietic cell lineage x x
Long-term potentiation x x x
Fc gamma R-mediated phagocytosis x x x
Calcium signaling pathway x x x
Pancreatic secretion x x
Oocyte meiosis x x
Jak-STAT signaling pathway x x
Glioma x x x
Melanoma x x x
Acute myeloid leukemia x x x
Prostate cancer x x x
Drug metabolism - cytochrome P450 x
Bladder cancer x
Chronic myeloid leukemia x x x
Staphylococcus aureus infection x x
Non-small cell lung cancer x x x
Cell cycle x x
Pathways in cancer x x x
Spliceosome x x
Regulation of actin cytoskeleton x x x
Bile secretion x x
Lysine biosynthesis x
Long-term depression x x x
Notch signaling pathway x x x x
Inositol phosphate metabolism x x x
Selenocompound metabolism x
Tyrosine metabolism x x
Phenylalanine metabolism x x x
Glycolysis / Gluconeogenesis x
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Table 6.12 continued...
Pathways D1 D2 D3 D4
Steroid hormone biosynthesis x x
Glycosphingolipid biosynthesis - globo series x
Lysosome x x
Chagas disease (American trypanosomiasis) x x
ErbB signaling pathway x x
Other glycan degradation x x
Glycosphingolipid biosynthesis - lacto and neolacto series x x
Endometrial cancer x x
Melanogenesis x x
Dilated cardiomyopathy x x
Olfactory transduction x
Hypertrophic cardiomyopathy (HCM) x
Type II diabetes mellitus x x
Gap junction x
Alanine, aspartate and glutamate metabolism x
mTOR signaling pathway x x
Neuroactive ligand-receptor interaction x
MAPK signaling pathway x x
Type I diabetes mellitus x
Mucin type O-Glycan biosynthesis x
osmosensory signaling pathway x
somatostatin receptor signaling pathway x
somatostatin signaling pathway x
canonical Wnt signaling pathway involved in regulation of type B pancreatic cell
proliferation
x x
stromal-epithelial cell signaling involved in prostate gland development x x
canonical Wnt signaling pathway involved in cardiac muscle cell fate commitment x
regulation of canonical Wnt signaling pathway involved in controlling type B pancreatic
cell proliferation
x x
negative regulation of canonical Wnt signaling pathway involved in controlling type B
pancreatic cell proliferation
x x
negative regulation of extrinsic apoptotic signaling pathway x x
negative regulation of apoptotic signaling pathway x x
canonical Wnt signaling pathway involved in neural crest cell differentiation x
negative regulation of Wnt signaling pathway involved in dorsal/ventral axis
specification
x x
intracellular receptor signaling pathway x
intracellular estrogen receptor signaling pathway x
positive regulation of retinoic acid receptor signaling pathway x
regulation of retinoic acid receptor signaling pathway x x
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Table 6.12 continued...
Pathways D1 D2 D3 D4
intracellular steroid hormone receptor signaling pathway x x x
second-messenger-mediated signaling x x
NIK/NF-kappaB signaling x
regulation of intracellular estrogen receptor signaling pathway x
positive regulation of intracellular steroid hormone receptor signaling pathway x
positive regulation of intracellular estrogen receptor signaling pathway x
retinoic acid receptor signaling pathway x x
cell-cell signaling x
purinergic receptor signaling pathway x
regulation of intracellular steroid hormone receptor signaling pathway x x
phospholipase C-activating G-protein coupled glutamate receptor signaling pathway x
bile acid signaling pathway x
extrinsic apoptotic signaling pathway in absence of ligand x x
purinergic nucleotide receptor signaling pathway x
steroid hormone mediated signaling pathway x x
gamma-aminobutyric acid signaling pathway x x
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress x x
positive regulation of TOR signaling x
neurotrophin signaling pathway x x
negative regulation of intracellular steroid hormone receptor signaling pathway x x
G-protein coupled glutamate receptor signaling pathway x
Fc-epsilon receptor signaling pathway x x
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex
development
x x
G-protein coupled receptor signaling pathway x x
insulin-like growth factor receptor signaling pathway x x
positive regulation of signaling x x
Base excision repair x
Mismatch repair x
Taste transduction x x
intrinsic apoptotic signaling pathway by p53 class mediator x x
intrinsic apoptotic signaling pathway in response to DNA damage x x
intrinsic apoptotic signaling pathway x x
platelet-derived growth factor receptor signaling pathway x
adiponectin-activated signaling pathway x x
adenylate cyclase-activating dopamine receptor signaling pathway x x
regulation of G-protein coupled receptor protein signaling pathway x
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Table 6.12 continued...
Pathways D1 D2 D3 D4
interleukin-6-mediated signaling pathway x
negative regulation of insulin-like growth factor receptor signaling pathway x x
regulation of insulin-like growth factor receptor signaling pathway x x
positive regulation of Notch signaling pathway x x
JAK-STAT cascade involved in growth hormone signaling pathway x
growth hormone receptor signaling pathway x
regulation of Notch signaling pathway x
Small cell lung cancer x x
Cell adhesion molecules (CAMs) x x
Citrate cycle (TCA cycle) x x
Neurotrophin signaling pathway x x
Proximal tubule bicarbonate reclamation x x
Apoptosis x x
Shigellosis x
Arrhythmogenic right ventricular cardiomyopathy (ARVC) x
Alzheimer’s disease x x
Cyanoamino acid metabolism x
regulation of smoothened signaling pathway involved in dorsal/ventral neural tube
patterning
x
negative regulation of smoothened signaling pathway involved in dorsal/ventral neural
tube patterning
x
positive regulation of I-kappaB kinase/NF-kappaB signaling x x
activation of signaling protein activity involved in unfolded protein response x
Roundabout signaling pathway x
regulation of adrenergic receptor signaling pathway x
ER-nucleus signaling pathway x
chemokine-mediated signaling pathway x x
calcium-mediated signaling x x
RNA polymerase x x
Glycerolipid metabolism x
Proteasome x x
positive regulation of hippo signaling x
activation of prostate induction by androgen receptor signaling pathway x
regulation of thrombin receptor signaling pathway x x
negative regulation of thrombin receptor signaling pathway x x
positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator x
negative regulation of smoothened signaling pathway x x
Pathogenic Escherichia coli infection x
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Table 6.12 continued...
Pathways D1 D2 D3 D4
Metabolic pathways x x
Fatty acid elongation in mitochondria x x
transforming growth factor beta receptor signaling pathway x x
regulation of protein insertion into mitochondrial membrane involved in apoptotic
signaling pathway
x x
positive regulation of protein insertion into mitochondrial membrane involved in
apoptotic signaling pathway
x x
protein insertion into mitochondrial membrane involved in apoptotic signaling pathway x x
hippo signaling x
regulation of mitochondrial outer membrane permeabilization involved in apoptotic
signaling pathway
x x
regulation of hippo signaling x
regulation of skeletal muscle contraction by calcium ion signaling x
negative regulation of chemokine-mediated signaling pathway x
positive regulation of lipopolysaccharide-mediated signaling pathway x x x
Protein processing in endoplasmic reticulum x x
Biosynthesis of unsaturated fatty acids x
alpha-Linolenic acid metabolism x
RNA degradation x
mRNA surveillance pathway x
Nucleotide excision repair x
Glycosaminoglycan degradation x
Carbohydrate digestion and absorption x
Colorectal cancer x
Adipocytokine signaling pathway x
B cell receptor signaling pathway x
Fc epsilon RI signaling pathway x
Progesterone-mediated oocyte maturation x
Toll-like receptor signaling pathway x
Osteoclast differentiation x
Tight junction x
Ether lipid metabolism x
Hedgehog signaling pathway x
DNA replication x
Cardiac muscle contraction x
Oxidative phosphorylation x
Parkinson’s disease x
Vibrio cholerae infection x
Epithelial cell signaling in Helicobacter pylori infection x
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Table 6.12 continued...
Pathways D1 D2 D3 D4
Rheumatoid arthritis x
Phagosome x
Protein digestion and absorption x
cGMP-mediated signaling x
G-protein coupled receptor signaling pathway coupled to cGMP nucleotide second
messenger
x
antigen receptor-mediated signaling pathway x
ionotropic glutamate receptor signaling pathway x
smoothened signaling pathway x
regulation of smoothened signaling pathway x
androgen receptor signaling pathway x x
mesodermal-endodermal cell signaling x
semaphorin-plexin signaling pathway involved in bone trabecula morphogenesis x
integrin-mediated signaling pathway x
negative regulation of transmembrane receptor protein serine/threonine kinase signaling
pathway
x
negative regulation of BMP signaling pathway x
canonical Wnt signaling pathway involved in regulation of cell proliferation x
regulation of Wnt signaling pathway involved in dorsal/ventral axis specification x
Wnt signaling pathway involved in dorsal/ventral axis specification x
Wnt signaling pathway involved in somitogenesis x
semaphorin-plexin signaling pathway involved in outflow tract morphogenesis x
positive regulation of semaphorin-plexin signaling pathway involved in outflow tract
morphogenesis
x
regulation of semaphorin-plexin signaling pathway x
positive regulation of semaphorin-plexin signaling pathway x
cholecystokinin signaling pathway x
negative regulation of retinoic acid receptor signaling pathway x
cell surface receptor signaling pathway involved in heart development x
positive regulation of chemokine-mediated signaling pathway x
regulation of chemokine-mediated signaling pathway x
negative regulation of intrinsic apoptotic signaling pathway in response to oxidative
stress
x
regulation of intrinsic apoptotic signaling pathway in response to oxidative stress x
regulation of TOR signaling x
intrinsic apoptotic signaling pathway in response to oxidative stress x
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand x
TOR signaling x
negative regulation of intrinsic apoptotic signaling pathway x
regulation of extrinsic apoptotic signaling pathway in absence of ligand x
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Table 6.12 continued...
Pathways D1 D2 D3 D4
regulation of intrinsic apoptotic signaling pathway x
adenylate cyclase-modulating G-protein coupled receptor signaling pathway x
protein kinase B signaling x
G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second
messenger
x
regulation of extrinsic apoptotic signaling pathway x
insulin receptor signaling pathway x x
extrinsic apoptotic signaling pathway x
mesenchymal smoothened signaling pathway involved in prostate gland development x
epithelial-mesenchymal signaling involved in prostate gland development x
regulation of nodal signaling pathway involved in determination of left/right asymmetry x
regulation of nodal signaling pathway involved in determination of lateral mesoderm
left/right asymmetry
x
nodal signaling pathway involved in determination of left/right asymmetry x
regulation of nodal signaling pathway x
nodal signaling pathway involved in determination of lateral mesoderm left/right
asymmetry
x
cerebellar Purkinje cell-granule cell precursor cell signaling involved in regulation of
granule cell precursor cell proliferation
x
epithelial-mesenchymal cell signaling x
regulation of transmembrane receptor protein serine/threonine kinase signaling pathway x
nodal signaling pathway x
regulation of activin receptor signaling pathway x
positive regulation of smoothened signaling pathway x
transmembrane receptor protein serine/threonine kinase signaling pathway x
activin receptor signaling pathway x
ciliary receptor clustering involved in smoothened signaling pathway x
smoothened signaling pathway involved in ventral spinal cord patterning x
thrombin receptor signaling pathway x
negative regulation of platelet-derived growth factor receptor signaling pathway x
regulation of platelet-derived growth factor receptor signaling pathway x
brain-derived neurotrophic factor receptor signaling pathway x
calcium-mediated signaling using intracellular calcium source x
Glycerophospholipid metabolism x
Natural killer cell mediated cytotoxicity x
ECM-receptor interaction x
regulation of fibroblast growth factor receptor signaling pathway x
positive regulation of insulin-like growth factor receptor signaling pathway x
apoptotic signaling pathway x
regulation of apoptotic signaling pathway x
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Table 6.12 continued...
Pathways D1 D2 D3 D4
positive regulation of G-protein coupled receptor protein signaling pathway x
positive regulation of phosphatidylinositol 3-kinase signaling x
regulation of phosphatidylinositol 3-kinase signaling x
regulation of protein kinase B signaling x
mesenchymal-epithelial cell signaling involved in prostate gland development x
mesenchymal-epithelial cell signaling x
Fatty acid metabolism x
PPAR signaling pathway x
RIG-I-like receptor signaling pathway x
Salivary secretion x
MyD88-independent toll-like receptor signaling pathway x
toll-like receptor 4 signaling pathway x
toll-like receptor signaling pathway x
pattern recognition receptor signaling pathway x
regulation of I-kappaB kinase/NF-kappaB signaling x
I-kappaB kinase/NF-kappaB signaling x
negative regulation of canonical Wnt signaling pathway x
negative regulation of Wnt signaling pathway x
regulation of canonical Wnt signaling pathway x
regulation of Wnt signaling pathway x
Glycosaminoglycan biosynthesis - keratan sulfate x
Glyoxylate and dicarboxylate metabolism x
Porphyrin and chlorophyll metabolism x
serotonin receptor signaling pathway x
Other types of O-glycan biosynthesis x
N-Glycan biosynthesis x x
Cytosolic DNA-sensing pathway x
Aminoacyl-tRNA biosynthesis x
Antigen processing and presentation x
Renin-angiotensin system x
African trypanosomiasis x
regulation of toll-like receptor 3 signaling pathway x
positive regulation of toll-like receptor 3 signaling pathway x
Toll signaling pathway x x
regulation of toll-like receptor 4 signaling pathway x
positive regulation of toll-like receptor 4 signaling pathway x
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Table 6.12 continued...
Pathways D1 D2 D3 D4
positive regulation of protein kinase B signaling x
Aldosterone-regulated sodium reabsorption x
Pyruvate metabolism x
activation of MAPK activity by adrenergic receptor signaling pathway x
epidermal growth factor-activated receptor transactivation by G-protein coupled
receptor signaling pathway
x
positive regulation of epidermal growth factor receptor signaling pathway x
positive regulation of ERBB signaling pathway x
adrenergic receptor signaling pathway x
adenylate cyclase-activating adrenergic receptor signaling pathway x
positive regulation of cAMP-mediated signaling x
regulation of cAMP-mediated signaling x
One carbon pool by folate x
protein kinase A signaling x x
regulation of protein kinase A signaling x x
regulation of intrinsic apoptotic signaling pathway in response to DNA damage x x
Collecting duct acid secretion x
fibroblast growth factor receptor signaling pathway involved in negative regulation of
apoptotic process in bone marrow
x
fibroblast growth factor receptor signaling pathway involved in hemopoiesis x
fibroblast growth factor receptor signaling pathway involved in positive regulation of
cell proliferation in bone marrow
x
fibroblast growth factor receptor signaling pathway involved in mammary gland
specification
x
nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway x
granzyme-mediated apoptotic signaling pathway x
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7 Elucidating the Importance of Clustering
Replicates in Three Dimensional
Microarray Gene Expression Data
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7.1 Introduction
The advancement of microarray technology facilitates monitoring the expression profiles
of thousands of genes not only over a set of replicates but also across a set of time points
or different doses of several chemical substances. Though the experimental set up remains
unchanged to measure the expression values of genes at each time point over a set of
replicates, the variations in the expression values over the replicates can still be present
due to abnormalities of the experimental protocol when taking the expression profiles
(technical replicates) or physiological variations in the population leading to heterogeneity
among the samples (biological replicates). Thus, equalizing the effects of the replicates by
forcing together those which exhibits dissimilar expression patters may not be beneficial
in mining three dimensional dataset to extract the biologically meaningful information. In
this chapter, we aim at unraveling the effects of non-clustered replicates on the quality
of the resultant triclusters obtained after applying the EMOA-δ-TRIMAX triclustering
algorithm to the gene expression datasets used in the previous chapters.
7.2 Materials and Methods
7.2.1 Dataset 1 (Accession no.- GSE11324)
The work of J.S. Carroll et al. aimed at elucidating the transcriptional regulation during
the exposure of a MCF-7 breast cancer cell to estrogen across 4 time points (0, 3, 6, and
12 hours) [1]. At each time point, the experiment was performed to monitor the expression
profiles of 54675 Affymetrix probe ids for three times keeping the experimental conditions
unchanged, thus the replicates can be referred to as biological ones.
7.2.2 Dataset 2 (Accession Number- GSE35671)
This work was carried out to reveal the regulatory mechanisms during the differentiation
of a human induced pluripotent stem cell (hiPSC) into cardiomyocytes [2]. This dataset
contains the expression profiles of 48803 Illumina probe ids across 12 time points (days 0,
3, 7, 10, 14, 20, 28, 35, 45, 60, 90 and 120) and at each time point the expression profiles
were measured for three biological replicates.
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7.2.3 Dataset 3 (Accession Number- GSE46280)
The purpose of the work carried out by M. Hecker et al. was to explore the expression
dynamics of 54675 Affymetrix probe ids during the exposure of peripheral blood mononu-
clear cells to subcutaneous IFN-beta-1b treatment across four time points (first, second,
third IFN-beta injection and after 1 month) and peripheral blood mononuclear cells were
collected from six patients [3]. Thus, in this dataset, the replicates can be considered as
biological ones.
7.2.4 Dataset 4 (Accession Number- GSE17693)
The dataset comprises expression profiles of 18675 probe ids across 5 time points (control,
day 1, day 2, day 3 and day 6) and 4 biological replicates. The experiment was done in
order to elucidate the potential key genes during the productive and unproductive repair
of mouse airway epithelial cells exposed to naphthalene [4, 5].
7.2.5 Dataset 5 (Accession Number- GSE17933)
This experiment was carried out by R.S. Thomas et al. to unravel the potential biomarkers
during the exposure of mouse lung tumors to naphthalene having five dose levels i.e. 0.5, 3,
10, 20 and 30 parts per million (ppm) [6]. For each of these dose levels, the experiment was
performed to monitor the expression profiles 45101 Affymetrix probe ids over four different
mice.
7.2.6 Dataset 6 (Accession Number- GSE18858)
The aim of this experiment was to provide insights into the potential biomarkers during
the exposure of five-week-old female B6C3F1 mouse liver tumors to the toxicants namely,
naphthalene and 1,2,3-trichloropropane having different dose levels i.e. (0.5, 3, 10, 20,
30 ppm for naphthalene and 2, 6, 20, 40, 60 mg/kg for 1,2,3-trichloropropane) [7]. For
each of the aforementioned dose levels, this dataset contains the expression profiles 45101
Affymetrix probe ids measured across four liver tumors taken from four different mice.
7.2.7 Dataset 7 (Accession Number- GSE38513)
The experiment was carried out by S.A. Gharib et al. in order to investigate the role of
matrix metalloproteinase 7 (MMP7) in governing the injured airway epithelial cell repair [8].
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To accomplish the goal, expression profiles of 45101 Affymetrix probe ids were measured
over four biological replicates during the exposure of Mmp7-null and wildtype mice airway
epithelial cells to naphthalene.
7.2.8 Workflow
Figure 7.1 shows the workflow applied in this chapter. After applying the proposed tri-
clustering algorithm EMOA-δ-TRIMAX to each of the datasets described in the previous
subsection, we have evaluated the mean of the pairwise Euclidean distances of the clus-
tered replicates for the triclusters which do not have all replicates. Afterwards, we have
calculated the mean of the pairwise Euclidean distances of all replicates for the triclusters
used in the previous step. Finally, we have computed the following metric for each of the
datasets.








, where dist non clust[k] and dist clust[k] represent the mean of the pairwise Euclidean
distances kth tricluster which does not have all replicates considering all and clustered
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replicates, respectively. n represents the total number of triclusters having at least one
replicate missing in case of dataset i. A higher value of divergencei corresponds to a
dataset having more divergent replicates.
7.3 Results and Discussion
From each of the Figures 7.2-7.8, we can observe the enhancement of the average intra-
cluster Euclidean distances between replicates if we include all non-clustered replicates in
the triclusters which do not have all replicates.
Figure 7.2: Average Euclidean distances between the expression profiles of each pair of
clustered (red) and all (blue, dashed line) replicates over the clustered genes
and time points for Dataset 1.
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Figure 7.3: Average Euclidean distances between the expression profiles of each pair of
clustered (red) and all (blue, dashed line) replicates over the clustered genes
and time points for Dataset 2.
Figure 7.4: Average Euclidean distances between the expression profiles of each pair of
clustered (red) and all (blue, dashed line) replicates over the clustered genes
and time points for Dataset 3.
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Figure 7.5: Average Euclidean distances between the expression profiles of each pair of
clustered (red) and all (blue, dashed line) replicates over the clustered genes
and different doses of toxicants for Dataset 4.
Figure 7.6: Average Euclidean distances between the expression profiles of each pair of
clustered (red) and all (blue, dashed line) replicates over the clustered genes
and different doses of toxicants for Dataset 5.
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Figure 7.7: Average Euclidean distances between the expression profiles of each pair of
clustered (red) and all (blue, dashed line) replicates over the clustered genes
and different doses of toxicants for Dataset 6.
Figure 7.8: Average Euclidean distances between the expression profiles of each pair of
clustered (red) and all (blue, dashed line) replicates over the clustered genes
and different doses of toxicants for Dataset 7.
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Additionally, Table 7.1 enlists the values of the metric divergencei for each of the
datasets described in the previous section. It is of interest to see a relatively small value
of divergencei in case of the datasets 1 and 2, whereas this value becomes higher for the
rest of the datasets.










Altogether, this chapter provides insights into the importance of clustering replicates in
the context of mining three dimensional microarray gene expression datasets in order to
extract biologically meaningful information. Moreover, our results indicate the fact that
if you move more from in vitro towards in vivo, the divergence between the biological
replicates increases significantly. For instance, we have found the lowest divergence in case
of dataset 1 (cells in culture), whereas the value becomes significantly higher in case of the
dataset 3 and dataset 5 where the biological replicates are of more complex nature such as
whole animals or patients.
7.5 Bibliography
[1] Carroll, J.S., Meyer, C.A., Song, J., Li, W., Geistlinger, T.R., Eeckhoute, J., Brodsky,
A.S., Keeton, E.K., Fertuck, K.C., Hall, G.F., Wang, Q., Bekiranov, S., Sementchenko,
V., Fox, E.A., Silver, P.A., Gingeras, T.R., Liu, X.S., Brown, M.: Genome-wide analysis
of estrogen receptor binding sites. Nature Genetics 38(11), 1289–1297 (2006)
[2] Babiarz, J.E., Ravon, M., Sridhar, S., Ravindran, P., Swanson, B., Bitter, H., Weiser,
T., Chiao, E., Certa, U., Kolaja, K.L.: Determination of the human cardiomyocyte
280
mRNA and miRNA differentiation network by fine-scale profiling. Stem Cells and De-
velopment 21(11), 1956–1965 (2012). doi:10.1089/scd.2011.0357
[3] Hecker, M., Thamilarasan, M., Koczan, D., Schroeder, I., Flechtner, K., Freiesleben,
S., Fuellen, G., Thiesen, H.J., Zettl, U.K.: MicroRNA expression changes dur-
ing interferon-beta treatment in the peripheral blood of multiple sclerosis pa-
tients. International Journal of Molecular Sciences 14(8), 16087–16110 (2013).
doi:10.3390/ijms140816087
[4] Snyder, J.C., Zemke, A.C., Stripp, B.R.: Reparative capacity of airway epithelium im-
pacts deposition and remodeling of extracellular matrix. American Journal of Respira-
tory Cell and Molecular Biology 40(6), 633–642 (2009). doi:10.1165/rcmb.2008-0334OC
[5] Zemke, A.C., Snyder, J.C., Brockway, B.L., Drake, J.A., Reynolds, S.D., Kaminski, N.,
Stripp, B.R.: Molecular staging of epithelial maturation using secretory cell-specific
genes as markers. American Journal of Respiratory Cell and Molecular Biology 40(3),
340–348 (2009). doi:10.1165/rcmb.2007-0380OC
[6] Thomas, R.S., Bao, W., Chu, T.M., Bessarabova, M., Nikolskaya, T., Nikolsky, Y.,
Andersen, M.E., Wolfinger, R.D.: Use of short-term transcriptional profiles to assess the
long-term cancer-related safety of environmental and industrial chemicals. Toxicological
Sciences 112(2), 311–321 (2009). doi:10.1093/toxsci/kfp233
[7] Thomas, R.S., Clewell, H.J.r., Allen, B.C., Wesselkamper, S.C., Wang, N.C., Lambert,
J.C., Hess-Wilson, J.K., Zhao, Q.J., Andersen, M.E.: Application of transcriptional
benchmark dose values in quantitative cancer and noncancer risk assessment. Toxico-
logical Sciences 120(1), 194–205 (2011). doi:10.1093/toxsci/kfq355
[8] Gharib, S.A., Altemeier, W.A., Van Winkle, L.S., Plopper, C.G., Schlesinger, S.Y.,
Buell, C.A., Brauer, R., Lee, V., Parks, W.C., Chen, P.: Matrix metalloproteinase-
7 coordinates airway epithelial injury response and differentiation of ciliated cells.





In this work, I have proposed a triclustering algorithm δ-TRIMAX by introducing a
novel coherence measure to mine three-dimensional gene expression datasets. This algo-
rithm has been applied to a time series dataset which monitors expression profiles upon
exposure of an MCF-7 breast cancer cell to estrogen. In this application, the algorithm
has been found to be useful in identifying the potential biological processes involved in the
progression of breast cancer. However, it had clear limitations such as the inability to ex-
tract overlapping triclusters and the possibility of getting stuck into local optima due to its
greedy search heuristic approach. I therefore developed an improved version of δ-TRIMAX
algorithm, EMOA-δ-TRIMAX which effectively remediated the pitfalls of the former one.
We have proven the merits of EMOA-δ-TRIMAX using one artificial dataset and three
real-life datasets where it outperforms the other algorithms for each of the aforementioned
datasets. Moreover, the improved version of δ-TRIMAX algorithm has been found to
be beneficial in analyzing a time series gene expression dataset which monitors gene ex-
pression profiles during stem cell differentiation into cardiomyocytes for revealing the key
genes play instrumental roles in driving the phenotypic changes of the cell and unveil the
regulatory mechanisms during different stages of cardiomyocytes development. Moreover,
EMOA-δ-TRIMAX has also been used not only to infer gene regulatory networks during
the exposure of a MCF-7 breast cancer cell to estrogen but also to elucidate the signaling
pathways that may be triggered by different chemical substances or toxicants. Altogether,
this work emphasizes the application of the proposed triclustering algorithms in the con-
text of analyzing three dimensional microarray gene expression dataset and provides new
insights in the context of transcriptional regulation, developmental biology, disease biology
and toxicology. One possible extension of the work would be incorporating the regulatory
information into the EMOA-δ-TRIMAX algorithm to ensure both co-expression and co-
regulation of the genes belonging to the resultant triclusters. Additionally, in the context
of mining time series gene expression data, EMOA-δ-TRIMAX algorithm yields triclusters
that may have nonconsecutive time points which may be treated as inconsequential from
a biological point of view. Thus representing time intervals instead of the time points in
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